Search Results For:

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [agreement-type] => Array
                (
                    [0] => research-development-agreement
                )

        )

    [filters] => Array
        (
            [agreement] => Array
                (
                    [agreement-type] => Array
                        (
                            [0] => research-development-agreement
                        )

                )

        )

    [child_filters] => Array
        (
        )

    [agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => agreement-type
                            [field] => slug
                            [terms] => Array
                                (
                                    [0] => research-development-agreement
                                )

                        )

                )

        )

    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [tax_query] => Array
                (
                )

            [meta_query] => Array
                (
                    [relation] => OR
                    [0] => Array
                        (
                            [key] => agreement
                            [value] => "11902"
                            [compare] => LIKE
                        )

                    [1] => Array
                        (
                            [key] => agreement
                            [value] => "5773"
                            [compare] => LIKE
                        )

                    [2] => Array
                        (
                            [key] => agreement
                            [value] => "2438"
                            [compare] => LIKE
                        )

                    [3] => Array
                        (
                            [key] => agreement
                            [value] => "1040"
                            [compare] => LIKE
                        )

                    [4] => Array
                        (
                            [key] => agreement
                            [value] => "3313"
                            [compare] => LIKE
                        )

                    [5] => Array
                        (
                            [key] => agreement
                            [value] => "2882"
                            [compare] => LIKE
                        )

                    [6] => Array
                        (
                            [key] => agreement
                            [value] => "11914"
                            [compare] => LIKE
                        )

                    [7] => Array
                        (
                            [key] => agreement
                            [value] => "3719"
                            [compare] => LIKE
                        )

                    [8] => Array
                        (
                            [key] => agreement
                            [value] => "8049"
                            [compare] => LIKE
                        )

                    [9] => Array
                        (
                            [key] => agreement
                            [value] => "994"
                            [compare] => LIKE
                        )

                    [10] => Array
                        (
                            [key] => agreement
                            [value] => "7560"
                            [compare] => LIKE
                        )

                    [11] => Array
                        (
                            [key] => agreement
                            [value] => "1101"
                            [compare] => LIKE
                        )

                    [12] => Array
                        (
                            [key] => agreement
                            [value] => "12042"
                            [compare] => LIKE
                        )

                    [13] => Array
                        (
                            [key] => agreement
                            [value] => "4678"
                            [compare] => LIKE
                        )

                    [14] => Array
                        (
                            [key] => agreement
                            [value] => "4692"
                            [compare] => LIKE
                        )

                    [15] => Array
                        (
                            [key] => agreement
                            [value] => "11819"
                            [compare] => LIKE
                        )

                    [16] => Array
                        (
                            [key] => agreement
                            [value] => "3373"
                            [compare] => LIKE
                        )

                    [17] => Array
                        (
                            [key] => agreement
                            [value] => "3333"
                            [compare] => LIKE
                        )

                    [18] => Array
                        (
                            [key] => agreement
                            [value] => "5586"
                            [compare] => LIKE
                        )

                    [19] => Array
                        (
                            [key] => agreement
                            [value] => "5589"
                            [compare] => LIKE
                        )

                    [20] => Array
                        (
                            [key] => agreement
                            [value] => "6626"
                            [compare] => LIKE
                        )

                    [21] => Array
                        (
                            [key] => agreement
                            [value] => "11261"
                            [compare] => LIKE
                        )

                    [22] => Array
                        (
                            [key] => agreement
                            [value] => "1392"
                            [compare] => LIKE
                        )

                    [23] => Array
                        (
                            [key] => agreement
                            [value] => "1075"
                            [compare] => LIKE
                        )

                    [24] => Array
                        (
                            [key] => agreement
                            [value] => "1077"
                            [compare] => LIKE
                        )

                    [25] => Array
                        (
                            [key] => agreement
                            [value] => "11692"
                            [compare] => LIKE
                        )

                    [26] => Array
                        (
                            [key] => agreement
                            [value] => "12092"
                            [compare] => LIKE
                        )

                    [27] => Array
                        (
                            [key] => agreement
                            [value] => "9058"
                            [compare] => LIKE
                        )

                    [28] => Array
                        (
                            [key] => agreement
                            [value] => "12405"
                            [compare] => LIKE
                        )

                    [29] => Array
                        (
                            [key] => agreement
                            [value] => "9074"
                            [compare] => LIKE
                        )

                    [30] => Array
                        (
                            [key] => agreement
                            [value] => "11016"
                            [compare] => LIKE
                        )

                    [31] => Array
                        (
                            [key] => agreement
                            [value] => "1104"
                            [compare] => LIKE
                        )

                    [32] => Array
                        (
                            [key] => agreement
                            [value] => "7440"
                            [compare] => LIKE
                        )

                    [33] => Array
                        (
                            [key] => agreement
                            [value] => "11109"
                            [compare] => LIKE
                        )

                    [34] => Array
                        (
                            [key] => agreement
                            [value] => "3776"
                            [compare] => LIKE
                        )

                    [35] => Array
                        (
                            [key] => agreement
                            [value] => "2732"
                            [compare] => LIKE
                        )

                    [36] => Array
                        (
                            [key] => agreement
                            [value] => "2455"
                            [compare] => LIKE
                        )

                    [37] => Array
                        (
                            [key] => agreement
                            [value] => "2817"
                            [compare] => LIKE
                        )

                    [38] => Array
                        (
                            [key] => agreement
                            [value] => "12076"
                            [compare] => LIKE
                        )

                    [39] => Array
                        (
                            [key] => agreement
                            [value] => "6274"
                            [compare] => LIKE
                        )

                    [40] => Array
                        (
                            [key] => agreement
                            [value] => "11632"
                            [compare] => LIKE
                        )

                )

        )

    [text_agreement_args] => 
    [text_provision_args] => 
    [agreement_ids] => Array
        (
            [0] => 11902
            [1] => 5773
            [2] => 2438
            [3] => 1040
            [4] => 3313
            [5] => 2882
            [6] => 11914
            [7] => 3719
            [8] => 8049
            [9] => 994
            [10] => 7560
            [11] => 1101
            [12] => 12042
            [13] => 4678
            [14] => 4692
            [15] => 11819
            [16] => 3373
            [17] => 3333
            [18] => 5586
            [19] => 5589
            [20] => 6626
            [21] => 11261
            [22] => 1392
            [23] => 1075
            [24] => 1077
            [25] => 11692
            [26] => 12092
            [27] => 9058
            [28] => 12405
            [29] => 9074
            [30] => 11016
            [31] => 1104
            [32] => 7440
            [33] => 11109
            [34] => 3776
            [35] => 2732
            [36] => 2455
            [37] => 2817
            [38] => 12076
            [39] => 6274
            [40] => 11632
        )

    [agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                )

                        )

                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                )

                        )

                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [ignore_sticky_posts] => 
                    [suppress_filters] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [taxonomy] => agreement-type
                    [term] => research-development-agreement
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                    [field] => slug
                                    [operator] => IN
                                    [include_children] => 1
                                )

                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_term_relationships
                        )

                    [queried_terms] => Array
                        (
                            [agreement-type] => Array
                                (
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                    [field] => slug
                                )

                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT   wpry_posts.*
					 FROM wpry_posts  LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
					 WHERE 1=1  AND ( 
  wpry_term_relationships.term_taxonomy_id IN (287)
) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 GROUP BY wpry_posts.ID
					 ORDER BY wpry_posts.post_title ASC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 11902
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:25:26
                            [post_date_gmt] => 2024-08-26 12:25:26
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:25:26
                            [post_modified_gmt] => 2024-08-26 12:25:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11902
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 5773
                            [post_author] => 5
                            [post_date] => 2022-09-13 11:54:12
                            [post_date_gmt] => 2022-09-13 11:54:12
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-inc-diagnostics-and-therapeutics-for-viral-infections-global-health-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-13 11:55:56
                            [post_modified_gmt] => 2022-09-13 11:55:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5773
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 2438
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:43:39
                            [post_date_gmt] => 2021-01-19 06:43:39
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:05:25
                            [post_modified_gmt] => 2021-09-15 12:05:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 1040
                            [post_author] => 6
                            [post_date] => 2020-05-20 21:11:05
                            [post_date_gmt] => 2020-05-20 21:11:05
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-for-profit
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:22:40
                            [post_modified_gmt] => 2024-07-16 14:22:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1040
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 3313
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:12:41
                            [post_date_gmt] => 2021-06-30 10:12:41
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:03
                            [post_modified_gmt] => 2021-09-15 11:58:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3313
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 2882
                            [post_author] => 6
                            [post_date] => 2021-05-14 14:03:29
                            [post_date_gmt] => 2021-05-14 14:03:29
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:31
                            [post_modified_gmt] => 2021-09-15 11:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 11914
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:19:40
                            [post_date_gmt] => 2024-09-02 09:19:40
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:19:40
                            [post_modified_gmt] => 2024-09-02 09:19:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11914
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3719
                            [post_author] => 5
                            [post_date] => 2021-08-23 11:02:40
                            [post_date_gmt] => 2021-08-23 11:02:40
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:51
                            [post_modified_gmt] => 2021-09-15 11:58:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3719
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 8049
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:37:47
                            [post_date_gmt] => 2022-12-12 08:37:47
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 08:37:47
                            [post_modified_gmt] => 2022-12-12 08:37:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=8049
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 994
                            [post_author] => 7
                            [post_date] => 2020-05-18 19:52:27
                            [post_date_gmt] => 2020-05-18 19:52:27
                            [post_content] => 
                            [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:59:18
                            [post_modified_gmt] => 2021-09-15 11:59:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=994
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 7560
                            [post_author] => 5
                            [post_date] => 2022-12-07 15:07:36
                            [post_date_gmt] => 2022-12-07 15:07:36
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 15:08:17
                            [post_modified_gmt] => 2022-12-07 15:08:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=7560
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 1101
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:41:03
                            [post_date_gmt] => 2020-05-21 20:41:03
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:23:44
                            [post_modified_gmt] => 2024-07-16 14:23:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1101
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 12042
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:36:02
                            [post_date_gmt] => 2024-09-12 12:36:02
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:36:02
                            [post_modified_gmt] => 2024-09-12 12:36:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12042
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 4678
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:00:45
                            [post_date_gmt] => 2022-04-25 11:00:45
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:35:48
                            [post_modified_gmt] => 2022-08-11 09:35:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4678
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 4692
                            [post_author] => 5
                            [post_date] => 2022-04-25 14:24:30
                            [post_date_gmt] => 2022-04-25 14:24:30
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:36:24
                            [post_modified_gmt] => 2022-08-11 09:36:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4692
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 11819
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:07:00
                            [post_date_gmt] => 2024-07-15 15:07:00
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:07:00
                            [post_modified_gmt] => 2024-07-15 15:07:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11819
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 3373
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:31:33
                            [post_date_gmt] => 2021-06-30 16:31:33
                            [post_content] => 
                            [post_title] => Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:17:38
                            [post_modified_gmt] => 2022-10-11 12:17:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3373
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 3333
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:11:59
                            [post_date_gmt] => 2021-06-30 12:11:59
                            [post_content] => 
                            [post_title] => Gates Foundation - CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:17:55
                            [post_modified_gmt] => 2022-10-11 12:17:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3333
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 5586
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:34:02
                            [post_date_gmt] => 2022-08-11 09:34:02
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:37:27
                            [post_modified_gmt] => 2022-08-11 09:37:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5586
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 5589
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:35:21
                            [post_date_gmt] => 2022-08-11 09:35:21
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:35:21
                            [post_modified_gmt] => 2022-08-11 09:35:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5589
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 6626
                            [post_author] => 5
                            [post_date] => 2022-11-08 11:48:23
                            [post_date_gmt] => 2022-11-08 11:48:23
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 11:48:23
                            [post_modified_gmt] => 2022-11-08 11:48:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=6626
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 11261
                            [post_author] => 5
                            [post_date] => 2023-09-19 08:31:45
                            [post_date_gmt] => 2023-09-19 08:31:45
                            [post_content] => 
                            [post_title] => Gates Foundation - Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-19 08:31:45
                            [post_modified_gmt] => 2023-09-19 08:31:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11261
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 1392
                            [post_author] => 7
                            [post_date] => 2020-05-30 20:09:57
                            [post_date_gmt] => 2020-05-30 20:09:57
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 11:07:43
                            [post_modified_gmt] => 2022-12-16 11:07:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1392
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 1075
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:13:25
                            [post_date_gmt] => 2020-05-21 20:13:25
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-07 11:54:17
                            [post_modified_gmt] => 2024-11-07 11:54:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1075
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 1077
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:15:15
                            [post_date_gmt] => 2020-05-21 20:15:15
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-07 11:54:35
                            [post_modified_gmt] => 2024-11-07 11:54:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1077
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 11692
                            [post_author] => 5
                            [post_date] => 2024-04-08 09:14:55
                            [post_date_gmt] => 2024-04-08 09:14:55
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 09:14:55
                            [post_modified_gmt] => 2024-04-08 09:14:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11692
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 12092
                            [post_author] => 5
                            [post_date] => 2024-10-08 10:45:15
                            [post_date_gmt] => 2024-10-08 10:45:15
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:56:39
                            [post_modified_gmt] => 2024-10-09 14:56:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12092
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 9058
                            [post_author] => 5
                            [post_date] => 2023-03-06 11:20:36
                            [post_date_gmt] => 2023-03-06 11:20:36
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:33:14
                            [post_modified_gmt] => 2023-03-08 11:33:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9058
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 12405
                            [post_author] => 5
                            [post_date] => 2024-12-03 12:07:06
                            [post_date_gmt] => 2024-12-03 12:07:06
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-03 12:07:06
                            [post_modified_gmt] => 2024-12-03 12:07:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12405
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 9074
                            [post_author] => 5
                            [post_date] => 2023-03-07 13:56:00
                            [post_date_gmt] => 2023-03-07 13:56:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:19:29
                            [post_modified_gmt] => 2024-07-16 14:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9074
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 11016
                            [post_author] => 5
                            [post_date] => 2023-08-23 06:56:23
                            [post_date_gmt] => 2023-08-23 06:56:23
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 11016
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 09:11:35
                            [post_modified_gmt] => 2023-08-24 09:11:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11016
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 1104
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:42:29
                            [post_date_gmt] => 2020-05-21 20:42:29
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:19
                            [post_modified_gmt] => 2022-10-11 12:21:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1104
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 7440
                            [post_author] => 5
                            [post_date] => 2022-12-01 11:18:22
                            [post_date_gmt] => 2022-12-01 11:18:22
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-01 11:18:22
                            [post_modified_gmt] => 2022-12-01 11:18:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=7440
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 11109
                            [post_author] => 5
                            [post_date] => 2023-09-01 06:30:03
                            [post_date_gmt] => 2023-09-01 06:30:03
                            [post_content] => 
                            [post_title] => US Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 15:45:40
                            [post_modified_gmt] => 2023-09-04 15:45:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11109
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 3776
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:24:04
                            [post_date_gmt] => 2021-09-09 11:24:04
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:12:55
                            [post_modified_gmt] => 2021-09-15 12:12:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3776
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 2732
                            [post_author] => 5
                            [post_date] => 2021-03-23 15:54:07
                            [post_date_gmt] => 2021-03-23 15:54:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:18:39
                            [post_modified_gmt] => 2021-09-15 12:18:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2732
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 2455
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:19:51
                            [post_date_gmt] => 2021-02-25 15:19:51
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:13:19
                            [post_modified_gmt] => 2021-09-15 12:13:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2455
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 2817
                            [post_author] => 5
                            [post_date] => 2021-04-16 11:58:45
                            [post_date_gmt] => 2021-04-16 11:58:45
                            [post_content] => 
                            [post_title] => US Department of Defense – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-05 07:58:47
                            [post_modified_gmt] => 2024-09-05 07:58:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 12076
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:24:25
                            [post_date_gmt] => 2024-10-07 14:24:25
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 15:06:03
                            [post_modified_gmt] => 2024-10-07 15:06:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12076
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 6274
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:10:40
                            [post_date_gmt] => 2022-10-25 07:10:40
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 07:11:03
                            [post_modified_gmt] => 2022-10-25 07:11:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=6274
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 11632
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:32:34
                            [post_date_gmt] => 2024-02-19 08:32:34
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:32:34
                            [post_modified_gmt] => 2024-02-19 08:32:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11632
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 41
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 11902
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:25:26
                    [post_date_gmt] => 2024-08-26 12:25:26
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:25:26
                    [post_modified_gmt] => 2024-08-26 12:25:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=11902
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 41
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 1
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 871908cedb317c9fc2fe54aa249c33d6
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                        )

                    [meta_query] => Array
                        (
                            [relation] => OR
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                )

                            [38] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                )

                            [39] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                )

                            [40] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                )

                        )

                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                        )

                    [meta_query] => Array
                        (
                            [relation] => OR
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                )

                            [38] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                )

                            [39] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                )

                            [40] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                )

                        )

                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [ignore_sticky_posts] => 
                    [suppress_filters] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                )

                            [38] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                )

                            [39] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                )

                            [40] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                )

                            [relation] => OR
                        )

                    [relation] => OR
                    [meta_table] => wpry_postmeta
                    [meta_id_column] => post_id
                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_postmeta
                        )

                    [clauses:protected] => Array
                        (
                            [wpry_postmeta] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-8] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-9] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-10] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-11] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-12] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-13] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-15] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-16] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-17] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-18] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-19] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-20] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-21] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-23] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-24] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-25] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-27] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-28] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-29] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-31] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-32] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-33] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-34] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-35] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-36] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-37] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-38] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-39] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-40] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                        )

                    [has_or_relation:protected] => 1
                )

            [date_query] => 
            [request] => SELECT   wpry_posts.*
					 FROM wpry_posts  INNER JOIN wpry_postmeta ON ( wpry_posts.ID = wpry_postmeta.post_id )
					 WHERE 1=1  AND ( 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11902\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"5773\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"2438\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"1040\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"3313\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"2882\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11914\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"3719\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"8049\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"994\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"7560\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"1101\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"12042\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"4678\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"4692\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11819\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"3373\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"3333\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"5586\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"5589\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"6626\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11261\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"1392\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"1075\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"1077\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11692\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"12092\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"9058\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"12405\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"9074\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11016\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"1104\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"7440\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11109\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"3776\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"2732\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"2455\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"2817\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"12076\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"6274\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}\"11632\"{961465077386ecb67f9f292839f8e27412edb75957e233b5d98a02e005e60eee}' )
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 GROUP BY wpry_posts.ID
					 ORDER BY wpry_posts.post_date DESC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 12421
                            [post_author] => 5
                            [post_date] => 2024-12-05 14:36:49
                            [post_date_gmt] => 2024-12-05 14:36:49
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:47:11
                            [post_modified_gmt] => 2024-12-05 15:47:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12421
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 12419
                            [post_author] => 5
                            [post_date] => 2024-12-05 14:18:35
                            [post_date_gmt] => 2024-12-05 14:18:35
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:48:01
                            [post_modified_gmt] => 2024-12-05 15:48:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12419
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 12418
                            [post_author] => 5
                            [post_date] => 2024-12-05 14:08:33
                            [post_date_gmt] => 2024-12-05 14:08:33
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:47:38
                            [post_modified_gmt] => 2024-12-05 15:47:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12418
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 12417
                            [post_author] => 5
                            [post_date] => 2024-12-05 14:01:34
                            [post_date_gmt] => 2024-12-05 14:01:34
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:46:51
                            [post_modified_gmt] => 2024-12-05 15:46:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12417
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 12416
                            [post_author] => 5
                            [post_date] => 2024-12-05 13:49:28
                            [post_date_gmt] => 2024-12-05 13:49:28
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:46:13
                            [post_modified_gmt] => 2024-12-05 15:46:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12416
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 12415
                            [post_author] => 5
                            [post_date] => 2024-12-05 13:41:10
                            [post_date_gmt] => 2024-12-05 13:41:10
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:45:57
                            [post_modified_gmt] => 2024-12-05 15:45:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12415
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 12414
                            [post_author] => 5
                            [post_date] => 2024-12-05 12:37:47
                            [post_date_gmt] => 2024-12-05 12:37:47
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:43:28
                            [post_modified_gmt] => 2024-12-05 15:43:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12414
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 12413
                            [post_author] => 5
                            [post_date] => 2024-12-03 14:43:59
                            [post_date_gmt] => 2024-12-03 14:43:59
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:39:32
                            [post_modified_gmt] => 2024-12-05 15:39:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12413
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 12412
                            [post_author] => 5
                            [post_date] => 2024-12-03 14:23:19
                            [post_date_gmt] => 2024-12-03 14:23:19
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:43:42
                            [post_modified_gmt] => 2024-12-05 15:43:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12412
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 12411
                            [post_author] => 5
                            [post_date] => 2024-12-03 13:47:40
                            [post_date_gmt] => 2024-12-03 13:47:40
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:44:08
                            [post_modified_gmt] => 2024-12-05 15:44:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12411
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 12410
                            [post_author] => 5
                            [post_date] => 2024-12-03 13:03:03
                            [post_date_gmt] => 2024-12-03 13:03:03
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:39:51
                            [post_modified_gmt] => 2024-12-05 15:39:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12410
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 12409
                            [post_author] => 5
                            [post_date] => 2024-12-03 12:48:11
                            [post_date_gmt] => 2024-12-03 12:48:11
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:45:41
                            [post_modified_gmt] => 2024-12-05 15:45:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12409
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 12408
                            [post_author] => 5
                            [post_date] => 2024-12-03 12:42:31
                            [post_date_gmt] => 2024-12-03 12:42:31
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:44:26
                            [post_modified_gmt] => 2024-12-05 15:44:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12408
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 12407
                            [post_author] => 5
                            [post_date] => 2024-12-03 12:24:37
                            [post_date_gmt] => 2024-12-03 12:24:37
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:45:12
                            [post_modified_gmt] => 2024-12-05 15:45:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12407
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 12096
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:59:43
                            [post_date_gmt] => 2024-10-09 14:59:43
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:59:43
                            [post_modified_gmt] => 2024-10-09 14:59:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12096
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 12097
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:59:36
                            [post_date_gmt] => 2024-10-09 14:59:36
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:59:36
                            [post_modified_gmt] => 2024-10-09 14:59:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12097
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 12098
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:59:30
                            [post_date_gmt] => 2024-10-09 14:59:30
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:59:30
                            [post_modified_gmt] => 2024-10-09 14:59:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12098
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 12099
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:59:23
                            [post_date_gmt] => 2024-10-09 14:59:23
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 15:32:53
                            [post_modified_gmt] => 2024-10-09 15:32:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12099
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 12095
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:59:18
                            [post_date_gmt] => 2024-10-09 14:59:18
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:59:18
                            [post_modified_gmt] => 2024-10-09 14:59:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12095
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 12094
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:59:12
                            [post_date_gmt] => 2024-10-09 14:59:12
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 15:27:38
                            [post_modified_gmt] => 2024-10-09 15:27:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12094
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 12102
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:59:05
                            [post_date_gmt] => 2024-10-09 14:59:05
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 15:25:48
                            [post_modified_gmt] => 2024-10-09 15:25:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12102
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 12103
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:58:59
                            [post_date_gmt] => 2024-10-09 14:58:59
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:58:59
                            [post_modified_gmt] => 2024-10-09 14:58:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12103
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 12104
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:58:53
                            [post_date_gmt] => 2024-10-09 14:58:53
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:58:53
                            [post_modified_gmt] => 2024-10-09 14:58:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12104
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 12105
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:58:47
                            [post_date_gmt] => 2024-10-09 14:58:47
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:58:47
                            [post_modified_gmt] => 2024-10-09 14:58:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12105
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 12106
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:58:42
                            [post_date_gmt] => 2024-10-09 14:58:42
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:58:42
                            [post_modified_gmt] => 2024-10-09 14:58:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12106
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 12107
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:53:55
                            [post_date_gmt] => 2024-10-09 14:53:55
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 15:31:13
                            [post_modified_gmt] => 2024-10-09 15:31:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12107
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 12080
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:24:07
                            [post_date_gmt] => 2024-10-07 14:24:07
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 14:19:53
                            [post_modified_gmt] => 2024-10-28 14:19:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12080
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 12081
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:22:43
                            [post_date_gmt] => 2024-10-07 14:22:43
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 15:10:33
                            [post_modified_gmt] => 2024-10-07 15:10:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12081
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 12082
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:22:13
                            [post_date_gmt] => 2024-10-07 14:22:13
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:52:13
                            [post_modified_gmt] => 2024-10-07 14:52:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12082
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 12083
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:21:50
                            [post_date_gmt] => 2024-10-07 14:21:50
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:55:48
                            [post_modified_gmt] => 2024-10-07 14:55:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12083
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 12084
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:20:13
                            [post_date_gmt] => 2024-10-07 14:20:13
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 15:08:36
                            [post_modified_gmt] => 2024-10-07 15:08:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12084
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 12085
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:18:25
                            [post_date_gmt] => 2024-10-07 14:18:25
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:41:33
                            [post_modified_gmt] => 2024-10-07 14:41:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12085
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 12086
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:09:43
                            [post_date_gmt] => 2024-10-07 14:09:43
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:35:44
                            [post_modified_gmt] => 2024-10-07 14:35:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 12088
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:09:23
                            [post_date_gmt] => 2024-10-07 14:09:23
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:57:21
                            [post_modified_gmt] => 2024-10-07 14:57:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12088
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 12089
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:09:08
                            [post_date_gmt] => 2024-10-07 14:09:08
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:57:53
                            [post_modified_gmt] => 2024-10-07 14:57:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12089
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 12087
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:08:53
                            [post_date_gmt] => 2024-10-07 14:08:53
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-21 11:40:34
                            [post_modified_gmt] => 2024-10-21 11:40:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12087
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 12090
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:08:40
                            [post_date_gmt] => 2024-10-07 14:08:40
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:58:45
                            [post_modified_gmt] => 2024-10-07 14:58:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12090
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 12079
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:08:23
                            [post_date_gmt] => 2024-10-07 14:08:23
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:56:47
                            [post_modified_gmt] => 2024-10-07 14:56:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12079
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 12078
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:07:56
                            [post_date_gmt] => 2024-10-07 14:07:56
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:56:20
                            [post_modified_gmt] => 2024-10-07 14:56:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12078
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 12091
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:07:21
                            [post_date_gmt] => 2024-10-07 14:07:21
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 15:03:46
                            [post_modified_gmt] => 2024-10-07 15:03:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12091
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 12056
                            [post_author] => 5
                            [post_date] => 2024-09-12 13:39:59
                            [post_date_gmt] => 2024-09-12 13:39:59
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 13:39:59
                            [post_modified_gmt] => 2024-09-12 13:39:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12056
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 12045
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:43
                            [post_date_gmt] => 2024-09-12 12:37:43
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 13:22:43
                            [post_modified_gmt] => 2024-09-12 13:22:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12045
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 12046
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:37
                            [post_date_gmt] => 2024-09-12 12:37:37
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 13:12:39
                            [post_modified_gmt] => 2024-09-12 13:12:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12046
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 12047
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:30
                            [post_date_gmt] => 2024-09-12 12:37:30
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:37:30
                            [post_modified_gmt] => 2024-09-12 12:37:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12047
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 12049
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:22
                            [post_date_gmt] => 2024-09-12 12:37:22
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 13:03:05
                            [post_modified_gmt] => 2024-09-12 13:03:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12049
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 12050
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:17
                            [post_date_gmt] => 2024-09-12 12:37:17
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:53:21
                            [post_modified_gmt] => 2024-09-12 12:53:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12050
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 12051
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:11
                            [post_date_gmt] => 2024-09-12 12:37:11
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:37:11
                            [post_modified_gmt] => 2024-09-12 12:37:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 12048
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:05
                            [post_date_gmt] => 2024-09-12 12:37:05
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:37:05
                            [post_modified_gmt] => 2024-09-12 12:37:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12048
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 12044
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:36:59
                            [post_date_gmt] => 2024-09-12 12:36:59
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 13:22:04
                            [post_modified_gmt] => 2024-09-12 13:22:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12044
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 12053
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:36:46
                            [post_date_gmt] => 2024-09-12 12:36:46
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:36:46
                            [post_modified_gmt] => 2024-09-12 12:36:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12053
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 12054
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:35:33
                            [post_date_gmt] => 2024-09-12 12:35:33
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 13:08:46
                            [post_modified_gmt] => 2024-09-12 13:08:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12054
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 12052
                            [post_author] => 5
                            [post_date] => 2024-09-12 09:31:55
                            [post_date_gmt] => 2024-09-12 09:31:55
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:36:53
                            [post_modified_gmt] => 2024-09-12 12:36:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12052
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 12021
                            [post_author] => 5
                            [post_date] => 2024-09-04 10:40:57
                            [post_date_gmt] => 2024-09-04 10:40:57
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:40:57
                            [post_modified_gmt] => 2024-09-04 10:40:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 12020
                            [post_author] => 5
                            [post_date] => 2024-09-04 10:35:24
                            [post_date_gmt] => 2024-09-04 10:35:24
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-portfolio-company-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:35:24
                            [post_modified_gmt] => 2024-09-04 10:35:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12020
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 12007
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:27
                            [post_date_gmt] => 2024-09-02 09:18:27
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:35:51
                            [post_modified_gmt] => 2024-09-02 14:35:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12007
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 12006
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:21
                            [post_date_gmt] => 2024-09-02 09:18:21
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:18:21
                            [post_modified_gmt] => 2024-09-02 09:18:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12006
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 12005
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:16
                            [post_date_gmt] => 2024-09-02 09:18:16
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:25:19
                            [post_modified_gmt] => 2024-09-02 14:25:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12005
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 12004
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:10
                            [post_date_gmt] => 2024-09-02 09:18:10
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:23:39
                            [post_modified_gmt] => 2024-09-02 14:23:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12004
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 11999
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:02
                            [post_date_gmt] => 2024-09-02 09:18:02
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 10:40:18
                            [post_modified_gmt] => 2024-09-02 10:40:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11999
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 11998
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:54
                            [post_date_gmt] => 2024-09-02 09:17:54
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 10:48:33
                            [post_modified_gmt] => 2024-09-02 10:48:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11998
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 11931
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:37
                            [post_date_gmt] => 2024-09-02 09:17:37
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:58:41
                            [post_modified_gmt] => 2024-09-03 08:58:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11931
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 11930
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:27
                            [post_date_gmt] => 2024-09-02 09:17:27
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 10:33:23
                            [post_modified_gmt] => 2024-09-02 10:33:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11930
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 11928
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:18
                            [post_date_gmt] => 2024-09-02 09:17:18
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:17:04
                            [post_modified_gmt] => 2024-09-03 08:17:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11928
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 11927
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:09
                            [post_date_gmt] => 2024-09-02 09:17:09
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:44:21
                            [post_modified_gmt] => 2024-09-03 08:44:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11927
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 11926
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:03
                            [post_date_gmt] => 2024-09-02 09:17:03
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:17:03
                            [post_modified_gmt] => 2024-09-02 09:17:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11926
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 11925
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:39
                            [post_date_gmt] => 2024-09-02 09:16:39
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 11:06:24
                            [post_modified_gmt] => 2024-09-02 11:06:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11925
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 11924
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:32
                            [post_date_gmt] => 2024-09-02 09:16:32
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:16:44
                            [post_modified_gmt] => 2024-09-03 08:16:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11924
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 11920
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:23
                            [post_date_gmt] => 2024-09-02 09:16:23
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:39:42
                            [post_modified_gmt] => 2024-10-28 12:39:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11920
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 11923
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:17
                            [post_date_gmt] => 2024-09-02 09:16:17
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:12:38
                            [post_modified_gmt] => 2024-09-03 08:12:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11923
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 11917
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:04
                            [post_date_gmt] => 2024-09-02 09:16:04
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:21:48
                            [post_modified_gmt] => 2024-09-02 14:21:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11917
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 12009
                            [post_author] => 5
                            [post_date] => 2024-09-02 08:24:39
                            [post_date_gmt] => 2024-09-02 08:24:39
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:30:38
                            [post_modified_gmt] => 2024-09-02 14:30:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12009
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 11918
                            [post_author] => 5
                            [post_date] => 2024-08-26 15:05:16
                            [post_date_gmt] => 2024-08-26 15:05:16
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:43:25
                            [post_modified_gmt] => 2024-09-02 09:43:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11918
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 11905
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:28:27
                            [post_date_gmt] => 2024-08-26 12:28:27
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:28:27
                            [post_modified_gmt] => 2024-08-26 12:28:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11905
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 11906
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:27:58
                            [post_date_gmt] => 2024-08-26 12:27:58
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:27:58
                            [post_modified_gmt] => 2024-08-26 12:27:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11906
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 11907
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:27:45
                            [post_date_gmt] => 2024-08-26 12:27:45
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:27:45
                            [post_modified_gmt] => 2024-08-26 12:27:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 11908
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:27:36
                            [post_date_gmt] => 2024-08-26 12:27:36
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:45:32
                            [post_modified_gmt] => 2024-08-26 12:45:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 11909
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:26:58
                            [post_date_gmt] => 2024-08-26 12:26:58
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:46:05
                            [post_modified_gmt] => 2024-08-26 12:46:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 11912
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:22:24
                            [post_date_gmt] => 2024-08-26 12:22:24
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:22:24
                            [post_modified_gmt] => 2024-08-26 12:22:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11912
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 11911
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:19:52
                            [post_date_gmt] => 2024-08-26 12:19:52
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:19:52
                            [post_modified_gmt] => 2024-08-26 12:19:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11911
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 11904
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:16:25
                            [post_date_gmt] => 2024-08-26 12:16:25
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:42:32
                            [post_modified_gmt] => 2024-08-26 12:42:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11904
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 11910
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:14:56
                            [post_date_gmt] => 2024-08-26 12:14:56
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:27:23
                            [post_modified_gmt] => 2024-08-26 12:27:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11910
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 12008
                            [post_author] => 5
                            [post_date] => 2024-08-02 08:14:31
                            [post_date_gmt] => 2024-08-02 08:14:31
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:38:35
                            [post_modified_gmt] => 2024-09-02 14:38:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12008
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 11821
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:15:45
                            [post_date_gmt] => 2024-07-15 15:15:45
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:17:49
                            [post_modified_gmt] => 2024-07-15 15:17:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11821
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 11825
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:14:50
                            [post_date_gmt] => 2024-07-15 15:14:50
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:15:29
                            [post_modified_gmt] => 2024-07-15 15:15:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11825
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 11827
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:14:27
                            [post_date_gmt] => 2024-07-15 15:14:27
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:14:27
                            [post_modified_gmt] => 2024-07-15 15:14:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11827
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 11828
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:13:11
                            [post_date_gmt] => 2024-07-15 15:13:11
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:13:11
                            [post_modified_gmt] => 2024-07-15 15:13:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11828
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 11831
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:11:29
                            [post_date_gmt] => 2024-07-15 15:11:29
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:14:10
                            [post_modified_gmt] => 2024-07-15 15:14:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11831
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 11834
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:09:41
                            [post_date_gmt] => 2024-07-15 15:09:41
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:10:44
                            [post_modified_gmt] => 2024-07-15 15:10:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11834
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 11835
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:09:17
                            [post_date_gmt] => 2024-07-15 15:09:17
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:09:17
                            [post_modified_gmt] => 2024-07-15 15:09:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11835
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 11836
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:08:25
                            [post_date_gmt] => 2024-07-15 15:08:25
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:08:25
                            [post_modified_gmt] => 2024-07-15 15:08:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11836
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 11837
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:06:07
                            [post_date_gmt] => 2024-07-15 15:06:07
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:08:00
                            [post_modified_gmt] => 2024-07-15 15:08:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11837
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 11824
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:05:21
                            [post_date_gmt] => 2024-07-15 15:05:21
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:05:21
                            [post_modified_gmt] => 2024-07-15 15:05:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11824
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 11829
                            [post_author] => 5
                            [post_date] => 2024-07-12 12:56:46
                            [post_date_gmt] => 2024-07-12 12:56:46
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:12:47
                            [post_modified_gmt] => 2024-07-15 15:12:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11829
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 11703
                            [post_author] => 5
                            [post_date] => 2024-04-08 11:11:54
                            [post_date_gmt] => 2024-04-08 11:11:54
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:22:20
                            [post_modified_gmt] => 2024-04-08 11:22:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11703
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 11702
                            [post_author] => 5
                            [post_date] => 2024-04-08 11:08:16
                            [post_date_gmt] => 2024-04-08 11:08:16
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:22:36
                            [post_modified_gmt] => 2024-04-08 11:22:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11702
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 11701
                            [post_author] => 5
                            [post_date] => 2024-04-08 10:08:21
                            [post_date_gmt] => 2024-04-08 10:08:21
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:21:00
                            [post_modified_gmt] => 2024-04-08 11:21:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11701
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 11700
                            [post_author] => 5
                            [post_date] => 2024-04-08 10:00:51
                            [post_date_gmt] => 2024-04-08 10:00:51
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:21:15
                            [post_modified_gmt] => 2024-04-08 11:21:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11700
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 11699
                            [post_author] => 5
                            [post_date] => 2024-04-08 09:57:53
                            [post_date_gmt] => 2024-04-08 09:57:53
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:21:33
                            [post_modified_gmt] => 2024-04-08 11:21:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11699
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 11698
                            [post_author] => 5
                            [post_date] => 2024-04-08 09:50:58
                            [post_date_gmt] => 2024-04-08 09:50:58
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:21:51
                            [post_modified_gmt] => 2024-04-08 11:21:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11698
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 11696
                            [post_author] => 5
                            [post_date] => 2024-04-08 09:37:34
                            [post_date_gmt] => 2024-04-08 09:37:34
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:20:42
                            [post_modified_gmt] => 2024-04-08 11:20:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 11694
                            [post_author] => 5
                            [post_date] => 2024-04-08 09:23:51
                            [post_date_gmt] => 2024-04-08 09:23:51
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:22:05
                            [post_modified_gmt] => 2024-04-08 11:22:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11694
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 11649
                            [post_author] => 5
                            [post_date] => 2024-02-19 16:43:58
                            [post_date_gmt] => 2024-02-19 16:43:58
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 16:43:58
                            [post_modified_gmt] => 2024-02-19 16:43:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11649
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 11648
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:48:32
                            [post_date_gmt] => 2024-02-19 08:48:32
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:48:32
                            [post_modified_gmt] => 2024-02-19 08:48:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11648
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 11647
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:47:07
                            [post_date_gmt] => 2024-02-19 08:47:07
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:47:07
                            [post_modified_gmt] => 2024-02-19 08:47:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11647
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 11646
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:45:09
                            [post_date_gmt] => 2024-02-19 08:45:09
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:51:59
                            [post_modified_gmt] => 2024-02-19 08:51:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11646
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 11645
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:43:50
                            [post_date_gmt] => 2024-02-19 08:43:50
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:51:41
                            [post_modified_gmt] => 2024-02-19 08:51:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11645
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 11644
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:40:46
                            [post_date_gmt] => 2024-02-19 08:40:46
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:51:24
                            [post_modified_gmt] => 2024-02-19 08:51:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11644
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 11643
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:38:10
                            [post_date_gmt] => 2024-02-19 08:38:10
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:50:57
                            [post_modified_gmt] => 2024-02-19 08:50:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11643
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 11642
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:37:11
                            [post_date_gmt] => 2024-02-19 08:37:11
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:50:41
                            [post_modified_gmt] => 2024-02-19 08:50:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11642
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 11641
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:35:54
                            [post_date_gmt] => 2024-02-19 08:35:54
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:50:26
                            [post_modified_gmt] => 2024-02-19 08:50:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11641
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 11637
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:35:21
                            [post_date_gmt] => 2024-02-19 08:35:21
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:50:11
                            [post_modified_gmt] => 2024-02-19 08:50:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11637
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 11635
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:34:34
                            [post_date_gmt] => 2024-02-19 08:34:34
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:49:53
                            [post_modified_gmt] => 2024-02-19 08:49:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11635
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 11634
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:31:58
                            [post_date_gmt] => 2024-02-19 08:31:58
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:46:26
                            [post_modified_gmt] => 2024-02-19 08:46:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11634
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 11339
                            [post_author] => 5
                            [post_date] => 2023-09-26 14:15:18
                            [post_date_gmt] => 2023-09-26 14:15:18
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 14:15:18
                            [post_modified_gmt] => 2023-09-26 14:15:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11339
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 11274
                            [post_author] => 5
                            [post_date] => 2023-09-26 14:05:33
                            [post_date_gmt] => 2023-09-26 14:05:33
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 14:07:54
                            [post_modified_gmt] => 2023-09-26 14:07:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11274
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 11273
                            [post_author] => 5
                            [post_date] => 2023-09-19 15:52:21
                            [post_date_gmt] => 2023-09-19 15:52:21
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-19 15:52:52
                            [post_modified_gmt] => 2023-09-19 15:52:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11273
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 11272
                            [post_author] => 5
                            [post_date] => 2023-09-19 15:44:02
                            [post_date_gmt] => 2023-09-19 15:44:02
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-19 15:45:41
                            [post_modified_gmt] => 2023-09-19 15:45:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11272
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 11271
                            [post_author] => 5
                            [post_date] => 2023-09-19 15:15:58
                            [post_date_gmt] => 2023-09-19 15:15:58
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:30:25
                            [post_modified_gmt] => 2023-11-10 14:30:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11271
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 11270
                            [post_author] => 5
                            [post_date] => 2023-09-19 14:27:13
                            [post_date_gmt] => 2023-09-19 14:27:13
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-19 15:31:17
                            [post_modified_gmt] => 2023-09-19 15:31:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11270
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 11269
                            [post_author] => 5
                            [post_date] => 2023-09-19 13:24:11
                            [post_date_gmt] => 2023-09-19 13:24:11
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-19 15:48:20
                            [post_modified_gmt] => 2023-09-19 15:48:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11269
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 11268
                            [post_author] => 5
                            [post_date] => 2023-09-19 09:49:33
                            [post_date_gmt] => 2023-09-19 09:49:33
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-19 14:29:09
                            [post_modified_gmt] => 2023-09-19 14:29:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11268
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 11145
                            [post_author] => 5
                            [post_date] => 2023-09-05 12:25:49
                            [post_date_gmt] => 2023-09-05 12:25:49
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 12:25:49
                            [post_modified_gmt] => 2023-09-05 12:25:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11145
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 11144
                            [post_author] => 5
                            [post_date] => 2023-09-05 11:51:22
                            [post_date_gmt] => 2023-09-05 11:51:22
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 11:51:22
                            [post_modified_gmt] => 2023-09-05 11:51:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11144
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 11143
                            [post_author] => 5
                            [post_date] => 2023-09-05 11:36:20
                            [post_date_gmt] => 2023-09-05 11:36:20
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 11:36:20
                            [post_modified_gmt] => 2023-09-05 11:36:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 11142
                            [post_author] => 5
                            [post_date] => 2023-09-05 11:23:35
                            [post_date_gmt] => 2023-09-05 11:23:35
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 12:14:59
                            [post_modified_gmt] => 2023-09-05 12:14:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11142
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 11141
                            [post_author] => 5
                            [post_date] => 2023-09-05 10:28:18
                            [post_date_gmt] => 2023-09-05 10:28:18
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 12:20:34
                            [post_modified_gmt] => 2023-09-05 12:20:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 11140
                            [post_author] => 5
                            [post_date] => 2023-09-05 09:30:03
                            [post_date_gmt] => 2023-09-05 09:30:03
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 09:30:03
                            [post_modified_gmt] => 2023-09-05 09:30:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 11139
                            [post_author] => 5
                            [post_date] => 2023-09-05 08:13:21
                            [post_date_gmt] => 2023-09-05 08:13:21
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:54:38
                            [post_modified_gmt] => 2024-09-04 10:54:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 11138
                            [post_author] => 5
                            [post_date] => 2023-09-05 07:25:41
                            [post_date_gmt] => 2023-09-05 07:25:41
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 09:27:47
                            [post_modified_gmt] => 2023-09-05 09:27:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11138
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 11137
                            [post_author] => 5
                            [post_date] => 2023-09-05 06:29:43
                            [post_date_gmt] => 2023-09-05 06:29:43
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 06:29:43
                            [post_modified_gmt] => 2023-09-05 06:29:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 11136
                            [post_author] => 5
                            [post_date] => 2023-09-04 15:29:56
                            [post_date_gmt] => 2023-09-04 15:29:56
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 09:24:14
                            [post_modified_gmt] => 2024-01-11 09:24:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11136
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 11135
                            [post_author] => 5
                            [post_date] => 2023-09-04 14:52:10
                            [post_date_gmt] => 2023-09-04 14:52:10
                            [post_content] => 
                            [post_title] => U.S. Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 15:30:23
                            [post_modified_gmt] => 2023-09-04 15:30:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 11111
                            [post_author] => 5
                            [post_date] => 2023-09-01 07:10:42
                            [post_date_gmt] => 2023-09-01 07:10:42
                            [post_content] => 
                            [post_title] => U.S. Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 11:07:45
                            [post_modified_gmt] => 2024-10-30 11:07:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 11019
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:13:46
                            [post_date_gmt] => 2023-08-24 08:13:46
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 14:05:38
                            [post_modified_gmt] => 2024-09-03 14:05:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11019
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 11021
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:11:05
                            [post_date_gmt] => 2023-08-24 08:11:05
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:11:05
                            [post_modified_gmt] => 2023-08-24 08:11:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 11023
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:10:08
                            [post_date_gmt] => 2023-08-24 08:10:08
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:10:08
                            [post_modified_gmt] => 2023-08-24 08:10:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11023
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 11028
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:08:50
                            [post_date_gmt] => 2023-08-24 08:08:50
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:08:50
                            [post_modified_gmt] => 2023-08-24 08:08:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11028
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 11029
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:07:41
                            [post_date_gmt] => 2023-08-24 08:07:41
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:07:41
                            [post_modified_gmt] => 2023-08-24 08:07:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11029
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 11018
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:05:11
                            [post_date_gmt] => 2023-08-24 08:05:11
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:05:11
                            [post_modified_gmt] => 2023-08-24 08:05:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11018
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 11031
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:04:36
                            [post_date_gmt] => 2023-08-24 08:04:36
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:06:55
                            [post_modified_gmt] => 2023-08-24 08:06:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11031
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 11020
                            [post_author] => 5
                            [post_date] => 2023-08-24 07:56:53
                            [post_date_gmt] => 2023-08-24 07:56:53
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 07:56:53
                            [post_modified_gmt] => 2023-08-24 07:56:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11020
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 11032
                            [post_author] => 5
                            [post_date] => 2023-08-23 13:27:36
                            [post_date_gmt] => 2023-08-23 13:27:36
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 07:55:09
                            [post_modified_gmt] => 2023-08-24 07:55:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11032
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 11026
                            [post_author] => 5
                            [post_date] => 2023-08-23 13:17:51
                            [post_date_gmt] => 2023-08-23 13:17:51
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 07:50:49
                            [post_modified_gmt] => 2023-08-24 07:50:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11026
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 11030
                            [post_author] => 5
                            [post_date] => 2023-08-23 13:10:30
                            [post_date_gmt] => 2023-08-23 13:10:30
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-23 13:32:24
                            [post_modified_gmt] => 2023-08-23 13:32:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11030
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 11022
                            [post_author] => 5
                            [post_date] => 2023-08-23 12:45:06
                            [post_date_gmt] => 2023-08-23 12:45:06
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 09:16:00
                            [post_modified_gmt] => 2023-08-24 09:16:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11022
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 10998
                            [post_author] => 5
                            [post_date] => 2023-08-11 08:59:40
                            [post_date_gmt] => 2023-08-11 08:59:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 15:06:00
                            [post_modified_gmt] => 2023-08-14 15:06:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=10998
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 10997
                            [post_author] => 5
                            [post_date] => 2023-08-11 08:41:21
                            [post_date_gmt] => 2023-08-11 08:41:21
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-army-contracting-command-via-ati-regeneron-covid-19-antibodies-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 15:00:44
                            [post_modified_gmt] => 2023-08-14 15:00:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=10997
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 9090
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:46:30
                            [post_date_gmt] => 2023-03-08 10:46:30
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 13:05:09
                            [post_modified_gmt] => 2024-09-20 13:05:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9090
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 9089
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:34:53
                            [post_date_gmt] => 2023-03-08 10:34:53
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:24:52
                            [post_modified_gmt] => 2023-03-08 11:24:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9089
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 9088
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:31:00
                            [post_date_gmt] => 2023-03-08 10:31:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 13:02:47
                            [post_modified_gmt] => 2024-09-20 13:02:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9088
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 9087
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:15:07
                            [post_date_gmt] => 2023-03-08 10:15:07
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 13:02:08
                            [post_modified_gmt] => 2024-09-20 13:02:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9087
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 9086
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:59:11
                            [post_date_gmt] => 2023-03-08 09:59:11
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 13:01:50
                            [post_modified_gmt] => 2024-09-20 13:01:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 9083
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:45:42
                            [post_date_gmt] => 2023-03-08 09:45:42
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:41:43
                            [post_modified_gmt] => 2024-09-20 12:41:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9083
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 9082
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:34:23
                            [post_date_gmt] => 2023-03-08 09:34:23
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:48:03
                            [post_modified_gmt] => 2024-09-20 12:48:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9082
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 9081
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:59:57
                            [post_date_gmt] => 2023-03-07 14:59:57
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 13:05:48
                            [post_modified_gmt] => 2024-09-20 13:05:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9081
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 9080
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:44:45
                            [post_date_gmt] => 2023-03-07 14:44:45
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:56:26
                            [post_modified_gmt] => 2024-09-20 12:56:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9080
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 9079
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:40:00
                            [post_date_gmt] => 2023-03-07 14:40:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:50:02
                            [post_modified_gmt] => 2024-09-20 12:50:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9079
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 9078
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:31:51
                            [post_date_gmt] => 2023-03-07 14:31:51
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:58:14
                            [post_modified_gmt] => 2024-09-20 12:58:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9078
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 9077
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:28:57
                            [post_date_gmt] => 2023-03-07 14:28:57
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:40:52
                            [post_modified_gmt] => 2024-09-20 12:40:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9077
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 9076
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:09:37
                            [post_date_gmt] => 2023-03-07 14:09:37
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:57:32
                            [post_modified_gmt] => 2024-09-20 12:57:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9076
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 9073
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:46:52
                            [post_date_gmt] => 2023-03-07 12:46:52
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:36:43
                            [post_modified_gmt] => 2024-09-20 12:36:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9073
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 9072
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:24:17
                            [post_date_gmt] => 2023-03-07 12:24:17
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:37:58
                            [post_modified_gmt] => 2024-09-20 12:37:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9072
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 9071
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:09:50
                            [post_date_gmt] => 2023-03-07 12:09:50
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:34:19
                            [post_modified_gmt] => 2024-09-20 12:34:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9071
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 9070
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:39:51
                            [post_date_gmt] => 2023-03-06 18:39:51
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:33:26
                            [post_modified_gmt] => 2024-09-20 12:33:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9070
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 9069
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:34:47
                            [post_date_gmt] => 2023-03-06 18:34:47
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:33:02
                            [post_modified_gmt] => 2024-09-20 12:33:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9069
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 9068
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:20:18
                            [post_date_gmt] => 2023-03-06 18:20:18
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:19:36
                            [post_modified_gmt] => 2024-09-20 12:19:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9068
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 9067
                            [post_author] => 5
                            [post_date] => 2023-03-06 16:40:37
                            [post_date_gmt] => 2023-03-06 16:40:37
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:21:00
                            [post_modified_gmt] => 2024-09-20 12:21:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9067
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 9066
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:55:39
                            [post_date_gmt] => 2023-03-06 15:55:39
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:37:20
                            [post_modified_gmt] => 2024-09-20 12:37:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9066
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 9065
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:36:15
                            [post_date_gmt] => 2023-03-06 15:36:15
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:27:54
                            [post_modified_gmt] => 2024-09-20 12:27:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9065
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 9064
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:24:23
                            [post_date_gmt] => 2023-03-06 15:24:23
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:21:33
                            [post_modified_gmt] => 2024-09-20 12:21:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9064
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 9063
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:10:08
                            [post_date_gmt] => 2023-03-06 15:10:08
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:32:33
                            [post_modified_gmt] => 2024-09-20 12:32:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9063
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 9062
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:05:13
                            [post_date_gmt] => 2023-03-06 15:05:13
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:18:42
                            [post_modified_gmt] => 2024-09-20 12:18:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9062
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 9061
                            [post_author] => 5
                            [post_date] => 2023-03-06 13:14:19
                            [post_date_gmt] => 2023-03-06 13:14:19
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:32:02
                            [post_modified_gmt] => 2024-09-20 12:32:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9061
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 8491
                            [post_author] => 5
                            [post_date] => 2023-01-19 11:34:54
                            [post_date_gmt] => 2023-01-19 11:34:54
                            [post_content] => 
                            [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-vaccine-funding-agreement-template
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 15:32:38
                            [post_modified_gmt] => 2023-09-26 15:32:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8491
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [174] => WP_Post Object
                        (
                            [ID] => 8490
                            [post_author] => 5
                            [post_date] => 2023-01-19 11:11:46
                            [post_date_gmt] => 2023-01-19 11:11:46
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:44:48
                            [post_modified_gmt] => 2023-09-27 09:44:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8490
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [175] => WP_Post Object
                        (
                            [ID] => 8489
                            [post_author] => 5
                            [post_date] => 2023-01-19 10:44:52
                            [post_date_gmt] => 2023-01-19 10:44:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:46:11
                            [post_modified_gmt] => 2023-09-27 09:46:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8489
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [176] => WP_Post Object
                        (
                            [ID] => 8488
                            [post_author] => 5
                            [post_date] => 2023-01-19 10:15:15
                            [post_date_gmt] => 2023-01-19 10:15:15
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:40:32
                            [post_modified_gmt] => 2023-09-27 09:40:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8488
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [177] => WP_Post Object
                        (
                            [ID] => 8487
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:59:54
                            [post_date_gmt] => 2023-01-19 09:59:54
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:34:06
                            [post_modified_gmt] => 2023-09-27 09:34:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8487
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [178] => WP_Post Object
                        (
                            [ID] => 8486
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:46:36
                            [post_date_gmt] => 2023-01-19 09:46:36
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:41:21
                            [post_modified_gmt] => 2023-09-27 09:41:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8486
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [179] => WP_Post Object
                        (
                            [ID] => 8485
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:39:38
                            [post_date_gmt] => 2023-01-19 09:39:38
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:30:16
                            [post_modified_gmt] => 2023-09-27 09:30:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8485
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [180] => WP_Post Object
                        (
                            [ID] => 8484
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:17:50
                            [post_date_gmt] => 2023-01-19 09:17:50
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:47:03
                            [post_modified_gmt] => 2024-09-04 10:47:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8484
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [181] => WP_Post Object
                        (
                            [ID] => 8482
                            [post_author] => 5
                            [post_date] => 2023-01-18 16:32:52
                            [post_date_gmt] => 2023-01-18 16:32:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:47:48
                            [post_modified_gmt] => 2024-09-04 10:47:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [182] => WP_Post Object
                        (
                            [ID] => 8481
                            [post_author] => 5
                            [post_date] => 2023-01-18 15:49:38
                            [post_date_gmt] => 2023-01-18 15:49:38
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 14:29:39
                            [post_modified_gmt] => 2023-09-26 14:29:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [183] => WP_Post Object
                        (
                            [ID] => 8480
                            [post_author] => 5
                            [post_date] => 2023-01-17 17:53:00
                            [post_date_gmt] => 2023-01-17 17:53:00
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:57:32
                            [post_modified_gmt] => 2023-11-10 13:57:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8480
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [184] => WP_Post Object
                        (
                            [ID] => 8479
                            [post_author] => 5
                            [post_date] => 2023-01-17 17:35:45
                            [post_date_gmt] => 2023-01-17 17:35:45
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:22:09
                            [post_modified_gmt] => 2023-07-11 09:22:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [185] => WP_Post Object
                        (
                            [ID] => 8469
                            [post_author] => 5
                            [post_date] => 2023-01-13 13:35:47
                            [post_date_gmt] => 2023-01-13 13:35:47
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:54:14
                            [post_modified_gmt] => 2023-06-26 13:54:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8469
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [186] => WP_Post Object
                        (
                            [ID] => 8468
                            [post_author] => 5
                            [post_date] => 2023-01-11 14:35:38
                            [post_date_gmt] => 2023-01-11 14:35:38
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:55:43
                            [post_modified_gmt] => 2023-06-22 14:55:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8468
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [187] => WP_Post Object
                        (
                            [ID] => 8467
                            [post_author] => 5
                            [post_date] => 2023-01-11 14:29:13
                            [post_date_gmt] => 2023-01-11 14:29:13
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:52:17
                            [post_modified_gmt] => 2023-06-22 14:52:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [188] => WP_Post Object
                        (
                            [ID] => 8462
                            [post_author] => 5
                            [post_date] => 2023-01-10 12:12:52
                            [post_date_gmt] => 2023-01-10 12:12:52
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:43:22
                            [post_modified_gmt] => 2023-11-10 14:43:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [189] => WP_Post Object
                        (
                            [ID] => 8461
                            [post_author] => 5
                            [post_date] => 2023-01-10 09:08:41
                            [post_date_gmt] => 2023-01-10 09:08:41
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:53:03
                            [post_modified_gmt] => 2023-06-21 09:53:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [190] => WP_Post Object
                        (
                            [ID] => 5625
                            [post_author] => 5
                            [post_date] => 2022-12-15 09:51:55
                            [post_date_gmt] => 2022-12-15 09:51:55
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:36:42
                            [post_modified_gmt] => 2024-09-04 10:36:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5625
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [191] => WP_Post Object
                        (
                            [ID] => 8314
                            [post_author] => 5
                            [post_date] => 2022-12-13 11:46:36
                            [post_date_gmt] => 2022-12-13 11:46:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:07:37
                            [post_modified_gmt] => 2024-11-18 15:07:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [192] => WP_Post Object
                        (
                            [ID] => 8313
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:48:56
                            [post_date_gmt] => 2022-12-13 10:48:56
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:08:00
                            [post_modified_gmt] => 2024-11-18 15:08:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [193] => WP_Post Object
                        (
                            [ID] => 8312
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:35:08
                            [post_date_gmt] => 2022-12-13 10:35:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:08:20
                            [post_modified_gmt] => 2024-11-18 15:08:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [194] => WP_Post Object
                        (
                            [ID] => 8311
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:09:44
                            [post_date_gmt] => 2022-12-13 10:09:44
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:08:44
                            [post_modified_gmt] => 2024-11-18 15:08:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [195] => WP_Post Object
                        (
                            [ID] => 8192
                            [post_author] => 5
                            [post_date] => 2022-12-13 09:04:26
                            [post_date_gmt] => 2022-12-13 09:04:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:09:09
                            [post_modified_gmt] => 2024-11-18 15:09:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [196] => WP_Post Object
                        (
                            [ID] => 8191
                            [post_author] => 5
                            [post_date] => 2022-12-12 16:19:19
                            [post_date_gmt] => 2022-12-12 16:19:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:09:36
                            [post_modified_gmt] => 2024-11-18 15:09:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [197] => WP_Post Object
                        (
                            [ID] => 8190
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:29:46
                            [post_date_gmt] => 2022-12-12 15:29:46
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:10:02
                            [post_modified_gmt] => 2024-11-18 15:10:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [198] => WP_Post Object
                        (
                            [ID] => 8157
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:23:50
                            [post_date_gmt] => 2022-12-12 15:23:50
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:10:21
                            [post_modified_gmt] => 2024-11-18 15:10:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [199] => WP_Post Object
                        (
                            [ID] => 8152
                            [post_author] => 5
                            [post_date] => 2022-12-12 12:04:21
                            [post_date_gmt] => 2022-12-12 12:04:21
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:10:51
                            [post_modified_gmt] => 2024-11-18 15:10:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [200] => WP_Post Object
                        (
                            [ID] => 8151
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:56:08
                            [post_date_gmt] => 2022-12-12 11:56:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:11:13
                            [post_modified_gmt] => 2024-11-18 15:11:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [201] => WP_Post Object
                        (
                            [ID] => 8150
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:21:26
                            [post_date_gmt] => 2022-12-12 11:21:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:11:37
                            [post_modified_gmt] => 2024-11-18 15:11:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [202] => WP_Post Object
                        (
                            [ID] => 8143
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:10:19
                            [post_date_gmt] => 2022-12-12 11:10:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:12:03
                            [post_modified_gmt] => 2024-11-18 15:12:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [203] => WP_Post Object
                        (
                            [ID] => 8142
                            [post_author] => 5
                            [post_date] => 2022-12-12 10:40:31
                            [post_date_gmt] => 2022-12-12 10:40:31
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:12:47
                            [post_modified_gmt] => 2024-11-18 15:12:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [204] => WP_Post Object
                        (
                            [ID] => 8131
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:57:36
                            [post_date_gmt] => 2022-12-12 09:57:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:13:14
                            [post_modified_gmt] => 2024-11-18 15:13:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [205] => WP_Post Object
                        (
                            [ID] => 8130
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:34:49
                            [post_date_gmt] => 2022-12-12 09:34:49
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:13:39
                            [post_modified_gmt] => 2024-11-18 15:13:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [206] => WP_Post Object
                        (
                            [ID] => 8129
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:55:53
                            [post_date_gmt] => 2022-12-12 08:55:53
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 13:36:21
                            [post_modified_gmt] => 2024-11-18 13:36:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [207] => WP_Post Object
                        (
                            [ID] => 8051
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:39:19
                            [post_date_gmt] => 2022-12-12 08:39:19
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:14:21
                            [post_modified_gmt] => 2024-11-18 15:14:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [208] => WP_Post Object
                        (
                            [ID] => 7582
                            [post_author] => 5
                            [post_date] => 2022-12-08 08:48:17
                            [post_date_gmt] => 2022-12-08 08:48:17
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:15:27
                            [post_modified_gmt] => 2024-04-09 08:15:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7582
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [209] => WP_Post Object
                        (
                            [ID] => 7581
                            [post_author] => 5
                            [post_date] => 2022-12-08 08:20:09
                            [post_date_gmt] => 2022-12-08 08:20:09
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:14:59
                            [post_modified_gmt] => 2024-04-09 08:14:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7581
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [210] => WP_Post Object
                        (
                            [ID] => 7580
                            [post_author] => 5
                            [post_date] => 2022-12-08 08:14:21
                            [post_date_gmt] => 2022-12-08 08:14:21
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:50:41
                            [post_modified_gmt] => 2024-09-04 10:50:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7580
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [211] => WP_Post Object
                        (
                            [ID] => 7570
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:44:09
                            [post_date_gmt] => 2022-12-07 16:44:09
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:04:49
                            [post_modified_gmt] => 2024-04-09 08:04:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7570
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [212] => WP_Post Object
                        (
                            [ID] => 7569
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:39:11
                            [post_date_gmt] => 2022-12-07 16:39:11
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:14:16
                            [post_modified_gmt] => 2024-04-09 08:14:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7569
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [213] => WP_Post Object
                        (
                            [ID] => 7568
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:18:53
                            [post_date_gmt] => 2022-12-07 16:18:53
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:12:01
                            [post_modified_gmt] => 2024-04-09 08:12:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7568
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [214] => WP_Post Object
                        (
                            [ID] => 7567
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:14:54
                            [post_date_gmt] => 2022-12-07 16:14:54
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:24:35
                            [post_modified_gmt] => 2023-11-10 14:24:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7567
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [215] => WP_Post Object
                        (
                            [ID] => 7563
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:00:00
                            [post_date_gmt] => 2022-12-07 16:00:00
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 11:11:31
                            [post_modified_gmt] => 2024-09-20 11:11:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7563
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [216] => WP_Post Object
                        (
                            [ID] => 7562
                            [post_author] => 5
                            [post_date] => 2022-12-07 15:26:44
                            [post_date_gmt] => 2022-12-07 15:26:44
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:01:28
                            [post_modified_gmt] => 2024-04-09 08:01:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7562
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [217] => WP_Post Object
                        (
                            [ID] => 7468
                            [post_author] => 5
                            [post_date] => 2022-12-05 12:56:35
                            [post_date_gmt] => 2022-12-05 12:56:35
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:23:05
                            [post_modified_gmt] => 2024-10-30 09:23:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7468
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [218] => WP_Post Object
                        (
                            [ID] => 7467
                            [post_author] => 5
                            [post_date] => 2022-12-05 12:50:39
                            [post_date_gmt] => 2022-12-05 12:50:39
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:24:10
                            [post_modified_gmt] => 2024-10-30 09:24:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [219] => WP_Post Object
                        (
                            [ID] => 7466
                            [post_author] => 5
                            [post_date] => 2022-12-05 12:39:45
                            [post_date_gmt] => 2022-12-05 12:39:45
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:26:06
                            [post_modified_gmt] => 2024-10-30 09:26:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [220] => WP_Post Object
                        (
                            [ID] => 7464
                            [post_author] => 5
                            [post_date] => 2022-12-05 11:38:57
                            [post_date_gmt] => 2022-12-05 11:38:57
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:28:25
                            [post_modified_gmt] => 2024-10-30 09:28:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [221] => WP_Post Object
                        (
                            [ID] => 7445
                            [post_author] => 5
                            [post_date] => 2022-12-05 11:10:08
                            [post_date_gmt] => 2022-12-05 11:10:08
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:21:08
                            [post_modified_gmt] => 2024-10-30 09:21:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7445
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [222] => WP_Post Object
                        (
                            [ID] => 7463
                            [post_author] => 5
                            [post_date] => 2022-12-05 10:28:51
                            [post_date_gmt] => 2022-12-05 10:28:51
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:26:30
                            [post_modified_gmt] => 2024-10-30 09:26:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [223] => WP_Post Object
                        (
                            [ID] => 7462
                            [post_author] => 5
                            [post_date] => 2022-12-05 10:15:17
                            [post_date_gmt] => 2022-12-05 10:15:17
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:25:27
                            [post_modified_gmt] => 2024-10-30 09:25:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [224] => WP_Post Object
                        (
                            [ID] => 7444
                            [post_author] => 5
                            [post_date] => 2022-12-01 14:17:31
                            [post_date_gmt] => 2022-12-01 14:17:31
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:21:53
                            [post_modified_gmt] => 2024-10-30 09:21:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [225] => WP_Post Object
                        (
                            [ID] => 7443
                            [post_author] => 5
                            [post_date] => 2022-12-01 11:47:54
                            [post_date_gmt] => 2022-12-01 11:47:54
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:27:35
                            [post_modified_gmt] => 2024-10-30 09:27:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [226] => WP_Post Object
                        (
                            [ID] => 7442
                            [post_author] => 5
                            [post_date] => 2022-12-01 11:26:45
                            [post_date_gmt] => 2022-12-01 11:26:45
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:23:48
                            [post_modified_gmt] => 2024-10-30 09:23:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [227] => WP_Post Object
                        (
                            [ID] => 6638
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:48:21
                            [post_date_gmt] => 2022-11-09 13:48:21
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:31:29
                            [post_modified_gmt] => 2023-07-11 09:31:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6638
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [228] => WP_Post Object
                        (
                            [ID] => 6637
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:40:00
                            [post_date_gmt] => 2022-11-09 13:40:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:37:34
                            [post_modified_gmt] => 2023-07-11 09:37:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6637
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [229] => WP_Post Object
                        (
                            [ID] => 6636
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:21:22
                            [post_date_gmt] => 2022-11-09 13:21:22
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:35:07
                            [post_modified_gmt] => 2023-07-11 09:35:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6636
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [230] => WP_Post Object
                        (
                            [ID] => 6635
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:05:41
                            [post_date_gmt] => 2022-11-09 13:05:41
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:11:40
                            [post_modified_gmt] => 2024-08-19 15:11:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6635
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [231] => WP_Post Object
                        (
                            [ID] => 6634
                            [post_author] => 5
                            [post_date] => 2022-11-08 19:23:52
                            [post_date_gmt] => 2022-11-08 19:23:52
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:43:33
                            [post_modified_gmt] => 2023-07-11 09:43:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6634
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [232] => WP_Post Object
                        (
                            [ID] => 6633
                            [post_author] => 5
                            [post_date] => 2022-11-08 19:03:56
                            [post_date_gmt] => 2022-11-08 19:03:56
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:40:28
                            [post_modified_gmt] => 2023-07-11 09:40:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6633
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [233] => WP_Post Object
                        (
                            [ID] => 6632
                            [post_author] => 5
                            [post_date] => 2022-11-08 18:14:54
                            [post_date_gmt] => 2022-11-08 18:14:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 08:47:59
                            [post_modified_gmt] => 2023-07-11 08:47:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6632
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [234] => WP_Post Object
                        (
                            [ID] => 6631
                            [post_author] => 5
                            [post_date] => 2022-11-08 16:07:28
                            [post_date_gmt] => 2022-11-08 16:07:28
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-24 13:00:28
                            [post_modified_gmt] => 2023-11-24 13:00:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6631
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [235] => WP_Post Object
                        (
                            [ID] => 6630
                            [post_author] => 5
                            [post_date] => 2022-11-08 15:22:11
                            [post_date_gmt] => 2022-11-08 15:22:11
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 08:56:26
                            [post_modified_gmt] => 2023-07-11 08:56:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6630
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [236] => WP_Post Object
                        (
                            [ID] => 6629
                            [post_author] => 5
                            [post_date] => 2022-11-08 14:54:13
                            [post_date_gmt] => 2022-11-08 14:54:13
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:32:36
                            [post_modified_gmt] => 2023-07-11 09:32:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6629
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [237] => WP_Post Object
                        (
                            [ID] => 6628
                            [post_author] => 5
                            [post_date] => 2022-11-08 13:12:06
                            [post_date_gmt] => 2022-11-08 13:12:06
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:13:38
                            [post_modified_gmt] => 2024-08-19 15:13:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6628
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [238] => WP_Post Object
                        (
                            [ID] => 6289
                            [post_author] => 5
                            [post_date] => 2022-10-26 07:36:18
                            [post_date_gmt] => 2022-10-26 07:36:18
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:39:39
                            [post_modified_gmt] => 2023-10-17 13:39:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6289
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [239] => WP_Post Object
                        (
                            [ID] => 6288
                            [post_author] => 5
                            [post_date] => 2022-10-26 06:46:06
                            [post_date_gmt] => 2022-10-26 06:46:06
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:51:09
                            [post_modified_gmt] => 2023-10-17 13:51:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6288
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [240] => WP_Post Object
                        (
                            [ID] => 6287
                            [post_author] => 5
                            [post_date] => 2022-10-25 15:22:03
                            [post_date_gmt] => 2022-10-25 15:22:03
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:48:09
                            [post_modified_gmt] => 2023-10-17 13:48:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6287
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [241] => WP_Post Object
                        (
                            [ID] => 6286
                            [post_author] => 5
                            [post_date] => 2022-10-25 15:16:07
                            [post_date_gmt] => 2022-10-25 15:16:07
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:35:35
                            [post_modified_gmt] => 2023-10-17 13:35:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6286
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [242] => WP_Post Object
                        (
                            [ID] => 6285
                            [post_author] => 5
                            [post_date] => 2022-10-25 15:01:54
                            [post_date_gmt] => 2022-10-25 15:01:54
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:33:38
                            [post_modified_gmt] => 2023-10-17 13:33:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6285
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [243] => WP_Post Object
                        (
                            [ID] => 6284
                            [post_author] => 5
                            [post_date] => 2022-10-25 14:47:20
                            [post_date_gmt] => 2022-10-25 14:47:20
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:12:49
                            [post_modified_gmt] => 2024-09-04 10:12:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6284
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [244] => WP_Post Object
                        (
                            [ID] => 6283
                            [post_author] => 5
                            [post_date] => 2022-10-25 14:33:12
                            [post_date_gmt] => 2022-10-25 14:33:12
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:09:22
                            [post_modified_gmt] => 2023-10-17 13:09:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [245] => WP_Post Object
                        (
                            [ID] => 6282
                            [post_author] => 5
                            [post_date] => 2022-10-25 09:24:40
                            [post_date_gmt] => 2022-10-25 09:24:40
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:14:05
                            [post_modified_gmt] => 2023-10-17 13:14:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6282
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [246] => WP_Post Object
                        (
                            [ID] => 6281
                            [post_author] => 5
                            [post_date] => 2022-10-25 08:56:46
                            [post_date_gmt] => 2022-10-25 08:56:46
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:21:12
                            [post_modified_gmt] => 2023-10-17 13:21:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6281
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [247] => WP_Post Object
                        (
                            [ID] => 6279
                            [post_author] => 5
                            [post_date] => 2022-10-25 08:07:31
                            [post_date_gmt] => 2022-10-25 08:07:31
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:22:08
                            [post_modified_gmt] => 2023-10-17 13:22:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6279
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [248] => WP_Post Object
                        (
                            [ID] => 6278
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:59:13
                            [post_date_gmt] => 2022-10-25 07:59:13
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:18:28
                            [post_modified_gmt] => 2023-10-17 13:18:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6278
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [249] => WP_Post Object
                        (
                            [ID] => 6277
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:51:55
                            [post_date_gmt] => 2022-10-25 07:51:55
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-14 10:55:31
                            [post_modified_gmt] => 2023-07-14 10:55:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6277
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [250] => WP_Post Object
                        (
                            [ID] => 6280
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:42:19
                            [post_date_gmt] => 2022-10-25 07:42:19
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:26:53
                            [post_modified_gmt] => 2023-10-17 13:26:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6280
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [251] => WP_Post Object
                        (
                            [ID] => 6276
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:37:13
                            [post_date_gmt] => 2022-10-25 07:37:13
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:24:43
                            [post_modified_gmt] => 2023-10-17 13:24:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6276
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [252] => WP_Post Object
                        (
                            [ID] => 5829
                            [post_author] => 5
                            [post_date] => 2022-10-11 12:04:17
                            [post_date_gmt] => 2022-10-11 12:04:17
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 09:23:23
                            [post_modified_gmt] => 2024-07-17 09:23:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5829
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [253] => WP_Post Object
                        (
                            [ID] => 5828
                            [post_author] => 5
                            [post_date] => 2022-10-11 11:14:22
                            [post_date_gmt] => 2022-10-11 11:14:22
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 09:29:41
                            [post_modified_gmt] => 2024-07-17 09:29:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5828
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [254] => WP_Post Object
                        (
                            [ID] => 5827
                            [post_author] => 5
                            [post_date] => 2022-10-11 10:21:39
                            [post_date_gmt] => 2022-10-11 10:21:39
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 09:05:28
                            [post_modified_gmt] => 2024-07-17 09:05:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5827
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [255] => WP_Post Object
                        (
                            [ID] => 5814
                            [post_author] => 5
                            [post_date] => 2022-10-05 16:01:43
                            [post_date_gmt] => 2022-10-05 16:01:43
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 09:19:24
                            [post_modified_gmt] => 2024-07-17 09:19:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5814
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [256] => WP_Post Object
                        (
                            [ID] => 5813
                            [post_author] => 5
                            [post_date] => 2022-10-05 15:37:35
                            [post_date_gmt] => 2022-10-05 15:37:35
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:56:45
                            [post_modified_gmt] => 2024-07-16 14:56:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5813
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [257] => WP_Post Object
                        (
                            [ID] => 5812
                            [post_author] => 5
                            [post_date] => 2022-10-05 14:34:35
                            [post_date_gmt] => 2022-10-05 14:34:35
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 09:45:00
                            [post_modified_gmt] => 2024-01-11 09:45:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [258] => WP_Post Object
                        (
                            [ID] => 5811
                            [post_author] => 5
                            [post_date] => 2022-10-05 13:31:14
                            [post_date_gmt] => 2022-10-05 13:31:14
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 08:55:31
                            [post_modified_gmt] => 2024-07-17 08:55:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5811
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [259] => WP_Post Object
                        (
                            [ID] => 5810
                            [post_author] => 5
                            [post_date] => 2022-10-05 12:10:58
                            [post_date_gmt] => 2022-10-05 12:10:58
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:48:42
                            [post_modified_gmt] => 2024-07-16 14:48:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [260] => WP_Post Object
                        (
                            [ID] => 5807
                            [post_author] => 5
                            [post_date] => 2022-10-05 10:53:32
                            [post_date_gmt] => 2022-10-05 10:53:32
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 08:52:06
                            [post_modified_gmt] => 2024-07-17 08:52:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [261] => WP_Post Object
                        (
                            [ID] => 5809
                            [post_author] => 5
                            [post_date] => 2022-10-05 07:50:36
                            [post_date_gmt] => 2022-10-05 07:50:36
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:22:58
                            [post_modified_gmt] => 2024-09-23 10:22:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [262] => WP_Post Object
                        (
                            [ID] => 5782
                            [post_author] => 5
                            [post_date] => 2022-09-16 07:28:56
                            [post_date_gmt] => 2022-09-16 07:28:56
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:43:22
                            [post_modified_gmt] => 2023-06-22 13:43:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [263] => WP_Post Object
                        (
                            [ID] => 5781
                            [post_author] => 5
                            [post_date] => 2022-09-14 13:33:43
                            [post_date_gmt] => 2022-09-14 13:33:43
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:39:31
                            [post_modified_gmt] => 2023-06-20 10:39:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5781
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [264] => WP_Post Object
                        (
                            [ID] => 5779
                            [post_author] => 5
                            [post_date] => 2022-09-14 13:01:55
                            [post_date_gmt] => 2022-09-14 13:01:55
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:37:55
                            [post_modified_gmt] => 2023-06-20 10:37:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5779
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [265] => WP_Post Object
                        (
                            [ID] => 5778
                            [post_author] => 5
                            [post_date] => 2022-09-14 11:49:49
                            [post_date_gmt] => 2022-09-14 11:49:49
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:49:46
                            [post_modified_gmt] => 2023-11-10 13:49:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5778
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [266] => WP_Post Object
                        (
                            [ID] => 5777
                            [post_author] => 5
                            [post_date] => 2022-09-14 11:30:25
                            [post_date_gmt] => 2022-09-14 11:30:25
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:32:58
                            [post_modified_gmt] => 2023-06-20 10:32:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5777
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [267] => WP_Post Object
                        (
                            [ID] => 5776
                            [post_author] => 5
                            [post_date] => 2022-09-14 11:17:28
                            [post_date_gmt] => 2022-09-14 11:17:28
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:33:48
                            [post_modified_gmt] => 2024-10-28 12:33:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5776
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [268] => WP_Post Object
                        (
                            [ID] => 5775
                            [post_author] => 5
                            [post_date] => 2022-09-13 13:17:53
                            [post_date_gmt] => 2022-09-13 13:17:53
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:32:11
                            [post_modified_gmt] => 2023-06-20 10:32:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5775
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [269] => WP_Post Object
                        (
                            [ID] => 5653
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:56:30
                            [post_date_gmt] => 2022-08-25 12:56:30
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:00:47
                            [post_modified_gmt] => 2023-06-22 14:00:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [270] => WP_Post Object
                        (
                            [ID] => 5652
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:26:53
                            [post_date_gmt] => 2022-08-25 12:26:53
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:48:11
                            [post_modified_gmt] => 2023-06-22 13:48:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [271] => WP_Post Object
                        (
                            [ID] => 5634
                            [post_author] => 5
                            [post_date] => 2022-08-22 13:18:41
                            [post_date_gmt] => 2022-08-22 13:18:41
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 07:28:32
                            [post_modified_gmt] => 2024-04-10 07:28:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5634
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [272] => WP_Post Object
                        (
                            [ID] => 5633
                            [post_author] => 5
                            [post_date] => 2022-08-22 13:15:31
                            [post_date_gmt] => 2022-08-22 13:15:31
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 07:32:31
                            [post_modified_gmt] => 2024-04-10 07:32:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5633
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [273] => WP_Post Object
                        (
                            [ID] => 5632
                            [post_author] => 5
                            [post_date] => 2022-08-22 13:03:54
                            [post_date_gmt] => 2022-08-22 13:03:54
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 08:43:51
                            [post_modified_gmt] => 2024-04-10 08:43:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5632
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [274] => WP_Post Object
                        (
                            [ID] => 5631
                            [post_author] => 5
                            [post_date] => 2022-08-22 12:52:49
                            [post_date_gmt] => 2022-08-22 12:52:49
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 08:50:09
                            [post_modified_gmt] => 2024-04-10 08:50:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5631
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [275] => WP_Post Object
                        (
                            [ID] => 5629
                            [post_author] => 5
                            [post_date] => 2022-08-22 12:19:52
                            [post_date_gmt] => 2022-08-22 12:19:52
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 09:39:05
                            [post_modified_gmt] => 2024-04-10 09:39:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5629
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [276] => WP_Post Object
                        (
                            [ID] => 5627
                            [post_author] => 5
                            [post_date] => 2022-08-22 11:56:36
                            [post_date_gmt] => 2022-08-22 11:56:36
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 10:16:53
                            [post_modified_gmt] => 2024-04-10 10:16:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5627
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [277] => WP_Post Object
                        (
                            [ID] => 5626
                            [post_author] => 5
                            [post_date] => 2022-08-22 11:12:04
                            [post_date_gmt] => 2022-08-22 11:12:04
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 11:27:24
                            [post_modified_gmt] => 2024-04-10 11:27:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5626
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [278] => WP_Post Object
                        (
                            [ID] => 5624
                            [post_author] => 5
                            [post_date] => 2022-08-17 08:56:52
                            [post_date_gmt] => 2022-08-17 08:56:52
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 13:47:22
                            [post_modified_gmt] => 2024-04-10 13:47:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5624
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [279] => WP_Post Object
                        (
                            [ID] => 5623
                            [post_author] => 5
                            [post_date] => 2022-08-16 15:29:11
                            [post_date_gmt] => 2022-08-16 15:29:11
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 12:55:01
                            [post_modified_gmt] => 2024-04-10 12:55:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5623
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [280] => WP_Post Object
                        (
                            [ID] => 5622
                            [post_author] => 5
                            [post_date] => 2022-08-16 14:49:36
                            [post_date_gmt] => 2022-08-16 14:49:36
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 12:24:34
                            [post_modified_gmt] => 2024-04-10 12:24:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5622
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [281] => WP_Post Object
                        (
                            [ID] => 5620
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:05:12
                            [post_date_gmt] => 2022-08-12 12:05:12
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 12:05:12
                            [post_modified_gmt] => 2022-08-12 12:05:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5620
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [282] => WP_Post Object
                        (
                            [ID] => 5619
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:02:21
                            [post_date_gmt] => 2022-08-12 12:02:21
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:01
                            [post_modified_gmt] => 2022-10-12 12:48:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5619
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [283] => WP_Post Object
                        (
                            [ID] => 5618
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:52:17
                            [post_date_gmt] => 2022-08-12 11:52:17
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:52:17
                            [post_modified_gmt] => 2022-08-12 11:52:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5618
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [284] => WP_Post Object
                        (
                            [ID] => 5617
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:49:46
                            [post_date_gmt] => 2022-08-12 11:49:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:49:46
                            [post_modified_gmt] => 2022-08-12 11:49:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5617
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [285] => WP_Post Object
                        (
                            [ID] => 5616
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:45:22
                            [post_date_gmt] => 2022-08-12 11:45:22
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:45:22
                            [post_modified_gmt] => 2022-08-12 11:45:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5616
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [286] => WP_Post Object
                        (
                            [ID] => 5615
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:40:08
                            [post_date_gmt] => 2022-08-12 11:40:08
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:40:08
                            [post_modified_gmt] => 2022-08-12 11:40:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5615
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [287] => WP_Post Object
                        (
                            [ID] => 5614
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:34:41
                            [post_date_gmt] => 2022-08-12 11:34:41
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:28:05
                            [post_modified_gmt] => 2022-09-29 11:28:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5614
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [288] => WP_Post Object
                        (
                            [ID] => 5612
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:14:31
                            [post_date_gmt] => 2022-08-12 10:14:31
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:07:37
                            [post_modified_gmt] => 2024-08-19 15:07:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5612
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [289] => WP_Post Object
                        (
                            [ID] => 5611
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:05:33
                            [post_date_gmt] => 2022-08-12 10:05:33
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 10:05:33
                            [post_modified_gmt] => 2022-08-12 10:05:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5611
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [290] => WP_Post Object
                        (
                            [ID] => 5610
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:31:00
                            [post_date_gmt] => 2022-08-12 09:31:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:09:01
                            [post_modified_gmt] => 2024-08-19 15:09:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5610
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [291] => WP_Post Object
                        (
                            [ID] => 5609
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:24:43
                            [post_date_gmt] => 2022-08-12 09:24:43
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:50:42
                            [post_modified_gmt] => 2024-10-28 12:50:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5609
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [292] => WP_Post Object
                        (
                            [ID] => 5608
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:09:54
                            [post_date_gmt] => 2022-08-12 09:09:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:05:22
                            [post_modified_gmt] => 2024-08-19 15:05:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5608
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [293] => WP_Post Object
                        (
                            [ID] => 5599
                            [post_author] => 5
                            [post_date] => 2022-08-11 14:17:45
                            [post_date_gmt] => 2022-08-11 14:17:45
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:38:13
                            [post_modified_gmt] => 2024-10-28 12:38:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5599
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [294] => WP_Post Object
                        (
                            [ID] => 5596
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:52:07
                            [post_date_gmt] => 2022-08-11 12:52:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:03:44
                            [post_modified_gmt] => 2024-08-19 15:03:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5596
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [295] => WP_Post Object
                        (
                            [ID] => 5595
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:36:15
                            [post_date_gmt] => 2022-08-11 12:36:15
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:01:10
                            [post_modified_gmt] => 2024-08-19 15:01:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5595
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [296] => WP_Post Object
                        (
                            [ID] => 5594
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:13:32
                            [post_date_gmt] => 2022-08-11 12:13:32
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:00:34
                            [post_modified_gmt] => 2024-08-19 15:00:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5594
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [297] => WP_Post Object
                        (
                            [ID] => 5593
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:48:52
                            [post_date_gmt] => 2022-08-11 11:48:52
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 14:59:00
                            [post_modified_gmt] => 2024-08-19 14:59:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5593
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [298] => WP_Post Object
                        (
                            [ID] => 5592
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:16:19
                            [post_date_gmt] => 2022-08-11 11:16:19
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-24 13:15:35
                            [post_modified_gmt] => 2024-07-24 13:15:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5592
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [299] => WP_Post Object
                        (
                            [ID] => 5591
                            [post_author] => 5
                            [post_date] => 2022-08-11 10:18:46
                            [post_date_gmt] => 2022-08-11 10:18:46
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:04:27
                            [post_modified_gmt] => 2024-08-19 15:04:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5591
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [300] => WP_Post Object
                        (
                            [ID] => 5427
                            [post_author] => 5
                            [post_date] => 2022-07-22 15:20:29
                            [post_date_gmt] => 2022-07-22 15:20:29
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:57:36
                            [post_modified_gmt] => 2023-06-21 09:57:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [301] => WP_Post Object
                        (
                            [ID] => 4857
                            [post_author] => 5
                            [post_date] => 2022-06-02 10:16:52
                            [post_date_gmt] => 2022-06-02 10:16:52
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:09:51
                            [post_modified_gmt] => 2023-11-10 15:09:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4857
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [302] => WP_Post Object
                        (
                            [ID] => 4855
                            [post_author] => 5
                            [post_date] => 2022-06-01 11:59:15
                            [post_date_gmt] => 2022-06-01 11:59:15
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-24 13:07:11
                            [post_modified_gmt] => 2024-07-24 13:07:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4855
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [303] => WP_Post Object
                        (
                            [ID] => 4853
                            [post_author] => 5
                            [post_date] => 2022-06-01 11:47:22
                            [post_date_gmt] => 2022-06-01 11:47:22
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-24 13:05:57
                            [post_modified_gmt] => 2024-07-24 13:05:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4853
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [304] => WP_Post Object
                        (
                            [ID] => 4704
                            [post_author] => 5
                            [post_date] => 2022-04-26 15:08:03
                            [post_date_gmt] => 2022-04-26 15:08:03
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:25:04
                            [post_modified_gmt] => 2024-07-23 14:25:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4704
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [305] => WP_Post Object
                        (
                            [ID] => 4703
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:56:55
                            [post_date_gmt] => 2022-04-26 14:56:55
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:29:54
                            [post_modified_gmt] => 2024-07-23 14:29:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4703
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [306] => WP_Post Object
                        (
                            [ID] => 4702
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:46:00
                            [post_date_gmt] => 2022-04-26 14:46:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:30:58
                            [post_modified_gmt] => 2024-07-23 14:30:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4702
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [307] => WP_Post Object
                        (
                            [ID] => 4701
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:30:45
                            [post_date_gmt] => 2022-04-26 14:30:45
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:29:12
                            [post_modified_gmt] => 2024-07-23 14:29:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4701
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [308] => WP_Post Object
                        (
                            [ID] => 4700
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:23:46
                            [post_date_gmt] => 2022-04-26 14:23:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:28:37
                            [post_modified_gmt] => 2024-07-23 14:28:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4700
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [309] => WP_Post Object
                        (
                            [ID] => 4699
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:06:18
                            [post_date_gmt] => 2022-04-26 14:06:18
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:27:46
                            [post_modified_gmt] => 2024-07-23 14:27:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4699
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [310] => WP_Post Object
                        (
                            [ID] => 4698
                            [post_author] => 5
                            [post_date] => 2022-04-26 12:27:58
                            [post_date_gmt] => 2022-04-26 12:27:58
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:26:02
                            [post_modified_gmt] => 2024-07-23 14:26:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4698
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [311] => WP_Post Object
                        (
                            [ID] => 4697
                            [post_author] => 5
                            [post_date] => 2022-04-26 12:05:54
                            [post_date_gmt] => 2022-04-26 12:05:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:51:07
                            [post_modified_gmt] => 2023-11-10 13:51:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4697
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [312] => WP_Post Object
                        (
                            [ID] => 4696
                            [post_author] => 5
                            [post_date] => 2022-04-26 11:05:38
                            [post_date_gmt] => 2022-04-26 11:05:38
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-11 12:45:04
                            [post_modified_gmt] => 2024-07-11 12:45:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [313] => WP_Post Object
                        (
                            [ID] => 4695
                            [post_author] => 5
                            [post_date] => 2022-04-26 09:54:07
                            [post_date_gmt] => 2022-04-26 09:54:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-24 12:48:56
                            [post_modified_gmt] => 2023-11-24 12:48:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4695
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [314] => WP_Post Object
                        (
                            [ID] => 4691
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:59:51
                            [post_date_gmt] => 2022-04-25 12:59:51
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:37:35
                            [post_modified_gmt] => 2022-09-26 14:37:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4691
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [315] => WP_Post Object
                        (
                            [ID] => 4690
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:53:48
                            [post_date_gmt] => 2022-04-25 12:53:48
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:46:23
                            [post_modified_gmt] => 2022-08-11 09:46:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4690
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [316] => WP_Post Object
                        (
                            [ID] => 4689
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:48:26
                            [post_date_gmt] => 2022-04-25 12:48:26
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:46:36
                            [post_modified_gmt] => 2022-08-11 09:46:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4689
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [317] => WP_Post Object
                        (
                            [ID] => 4688
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:44:13
                            [post_date_gmt] => 2022-04-25 12:44:13
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:46:53
                            [post_modified_gmt] => 2022-08-11 09:46:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4688
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [318] => WP_Post Object
                        (
                            [ID] => 4687
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:41:22
                            [post_date_gmt] => 2022-04-25 12:41:22
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:47:22
                            [post_modified_gmt] => 2022-08-11 09:47:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4687
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [319] => WP_Post Object
                        (
                            [ID] => 4686
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:37:16
                            [post_date_gmt] => 2022-04-25 12:37:16
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:47:39
                            [post_modified_gmt] => 2022-08-11 09:47:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4686
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [320] => WP_Post Object
                        (
                            [ID] => 4685
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:29:54
                            [post_date_gmt] => 2022-04-25 12:29:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:26:17
                            [post_modified_gmt] => 2022-09-29 11:26:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4685
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [321] => WP_Post Object
                        (
                            [ID] => 4684
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:25:07
                            [post_date_gmt] => 2022-04-25 12:25:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:17:01
                            [post_modified_gmt] => 2024-07-23 14:17:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4684
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [322] => WP_Post Object
                        (
                            [ID] => 4683
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:03:48
                            [post_date_gmt] => 2022-04-25 12:03:48
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:19:16
                            [post_modified_gmt] => 2024-07-23 14:19:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4683
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [323] => WP_Post Object
                        (
                            [ID] => 4682
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:56:46
                            [post_date_gmt] => 2022-04-25 11:56:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:18:05
                            [post_modified_gmt] => 2024-07-23 14:18:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4682
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [324] => WP_Post Object
                        (
                            [ID] => 4681
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:39:24
                            [post_date_gmt] => 2022-04-25 11:39:24
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:21:29
                            [post_modified_gmt] => 2024-07-23 14:21:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4681
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [325] => WP_Post Object
                        (
                            [ID] => 4680
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:17:54
                            [post_date_gmt] => 2022-04-25 11:17:54
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:34:18
                            [post_modified_gmt] => 2024-10-28 12:34:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4680
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [326] => WP_Post Object
                        (
                            [ID] => 4580
                            [post_author] => 5
                            [post_date] => 2022-03-31 14:34:38
                            [post_date_gmt] => 2022-03-31 14:34:38
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:58:04
                            [post_modified_gmt] => 2023-11-10 13:58:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4580
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [327] => WP_Post Object
                        (
                            [ID] => 4519
                            [post_author] => 5
                            [post_date] => 2022-03-25 12:48:09
                            [post_date_gmt] => 2022-03-25 12:48:09
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-grant-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:17:34
                            [post_modified_gmt] => 2024-08-19 15:17:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4519
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [328] => WP_Post Object
                        (
                            [ID] => 4516
                            [post_author] => 5
                            [post_date] => 2022-03-23 09:07:57
                            [post_date_gmt] => 2022-03-23 09:07:57
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:38:44
                            [post_modified_gmt] => 2024-10-28 12:38:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4516
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [329] => WP_Post Object
                        (
                            [ID] => 4205
                            [post_author] => 5
                            [post_date] => 2022-02-28 15:24:19
                            [post_date_gmt] => 2022-02-28 15:24:19
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:01:27
                            [post_modified_gmt] => 2023-06-22 14:01:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [330] => WP_Post Object
                        (
                            [ID] => 4204
                            [post_author] => 5
                            [post_date] => 2022-02-28 14:53:11
                            [post_date_gmt] => 2022-02-28 14:53:11
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:52:02
                            [post_modified_gmt] => 2023-06-22 13:52:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [331] => WP_Post Object
                        (
                            [ID] => 4201
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:33:22
                            [post_date_gmt] => 2022-02-28 13:33:22
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:02:58
                            [post_modified_gmt] => 2023-06-22 14:02:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [332] => WP_Post Object
                        (
                            [ID] => 4200
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:13:29
                            [post_date_gmt] => 2022-02-28 13:13:29
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:54:49
                            [post_modified_gmt] => 2023-06-22 13:54:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [333] => WP_Post Object
                        (
                            [ID] => 4066
                            [post_author] => 5
                            [post_date] => 2022-01-07 11:35:15
                            [post_date_gmt] => 2022-01-07 11:35:15
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:31:50
                            [post_modified_gmt] => 2024-09-23 10:31:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4066
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [334] => WP_Post Object
                        (
                            [ID] => 4065
                            [post_author] => 5
                            [post_date] => 2022-01-07 11:21:06
                            [post_date_gmt] => 2022-01-07 11:21:06
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:33:48
                            [post_modified_gmt] => 2024-09-23 10:33:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4065
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [335] => WP_Post Object
                        (
                            [ID] => 4064
                            [post_author] => 5
                            [post_date] => 2022-01-07 10:57:29
                            [post_date_gmt] => 2022-01-07 10:57:29
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:34:53
                            [post_modified_gmt] => 2024-09-23 10:34:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4064
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [336] => WP_Post Object
                        (
                            [ID] => 4063
                            [post_author] => 5
                            [post_date] => 2022-01-07 10:34:51
                            [post_date_gmt] => 2022-01-07 10:34:51
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:25:43
                            [post_modified_gmt] => 2024-09-23 10:25:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4063
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [337] => WP_Post Object
                        (
                            [ID] => 4062
                            [post_author] => 5
                            [post_date] => 2022-01-07 10:03:12
                            [post_date_gmt] => 2022-01-07 10:03:12
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:30:50
                            [post_modified_gmt] => 2024-09-23 10:30:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4062
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [338] => WP_Post Object
                        (
                            [ID] => 4061
                            [post_author] => 5
                            [post_date] => 2022-01-07 09:46:42
                            [post_date_gmt] => 2022-01-07 09:46:42
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:24:42
                            [post_modified_gmt] => 2024-09-23 10:24:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4061
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [339] => WP_Post Object
                        (
                            [ID] => 4060
                            [post_author] => 5
                            [post_date] => 2022-01-07 09:40:49
                            [post_date_gmt] => 2022-01-07 09:40:49
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 10:21:47
                            [post_modified_gmt] => 2023-10-17 10:21:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4060
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [340] => WP_Post Object
                        (
                            [ID] => 3792
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:23:13
                            [post_date_gmt] => 2021-09-09 14:23:13
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:07:03
                            [post_modified_gmt] => 2024-10-30 10:07:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3792
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [341] => WP_Post Object
                        (
                            [ID] => 3791
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:18:44
                            [post_date_gmt] => 2021-09-09 14:18:44
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:14:00
                            [post_modified_gmt] => 2024-10-30 10:14:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3791
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [342] => WP_Post Object
                        (
                            [ID] => 3789
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:07:30
                            [post_date_gmt] => 2021-09-09 14:07:30
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:12:17
                            [post_modified_gmt] => 2024-10-30 10:12:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3789
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [343] => WP_Post Object
                        (
                            [ID] => 3788
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:00:40
                            [post_date_gmt] => 2021-09-09 14:00:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:12:47
                            [post_modified_gmt] => 2024-10-30 10:12:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3788
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [344] => WP_Post Object
                        (
                            [ID] => 3786
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:20:21
                            [post_date_gmt] => 2021-09-09 13:20:21
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:50:25
                            [post_modified_gmt] => 2024-10-30 09:50:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3786
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [345] => WP_Post Object
                        (
                            [ID] => 3784
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:03:52
                            [post_date_gmt] => 2021-09-09 13:03:52
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:07:55
                            [post_modified_gmt] => 2024-10-30 10:07:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3784
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [346] => WP_Post Object
                        (
                            [ID] => 3783
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:41:47
                            [post_date_gmt] => 2021-09-09 12:41:47
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 09:17:03
                            [post_modified_gmt] => 2023-08-11 09:17:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3783
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [347] => WP_Post Object
                        (
                            [ID] => 3782
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:36:36
                            [post_date_gmt] => 2021-09-09 12:36:36
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:49:10
                            [post_modified_gmt] => 2024-01-09 13:49:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [348] => WP_Post Object
                        (
                            [ID] => 3781
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:29:54
                            [post_date_gmt] => 2021-09-09 12:29:54
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:51:56
                            [post_modified_gmt] => 2024-10-30 09:51:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3781
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [349] => WP_Post Object
                        (
                            [ID] => 3778
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:52:53
                            [post_date_gmt] => 2021-09-09 11:52:53
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 09:16:10
                            [post_modified_gmt] => 2023-08-11 09:16:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3778
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [350] => WP_Post Object
                        (
                            [ID] => 3765
                            [post_author] => 5
                            [post_date] => 2021-09-01 14:09:03
                            [post_date_gmt] => 2021-09-01 14:09:03
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:59:35
                            [post_modified_gmt] => 2023-08-02 15:59:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3765
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [351] => WP_Post Object
                        (
                            [ID] => 3764
                            [post_author] => 5
                            [post_date] => 2021-09-01 12:17:32
                            [post_date_gmt] => 2021-09-01 12:17:32
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 14:25:34
                            [post_modified_gmt] => 2023-08-14 14:25:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3764
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [352] => WP_Post Object
                        (
                            [ID] => 3758
                            [post_author] => 5
                            [post_date] => 2021-08-26 12:04:03
                            [post_date_gmt] => 2021-08-26 12:04:03
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:50:07
                            [post_modified_gmt] => 2024-01-09 13:50:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3758
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [353] => WP_Post Object
                        (
                            [ID] => 3757
                            [post_author] => 5
                            [post_date] => 2021-08-25 08:42:34
                            [post_date_gmt] => 2021-08-25 08:42:34
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:48:41
                            [post_modified_gmt] => 2023-06-26 13:48:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3757
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [354] => WP_Post Object
                        (
                            [ID] => 3756
                            [post_author] => 5
                            [post_date] => 2021-08-25 08:10:37
                            [post_date_gmt] => 2021-08-25 08:10:37
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:23:27
                            [post_modified_gmt] => 2023-06-26 12:23:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [355] => WP_Post Object
                        (
                            [ID] => 3755
                            [post_author] => 5
                            [post_date] => 2021-08-25 07:55:51
                            [post_date_gmt] => 2021-08-25 07:55:51
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:26:18
                            [post_modified_gmt] => 2024-01-10 16:26:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [356] => WP_Post Object
                        (
                            [ID] => 3754
                            [post_author] => 5
                            [post_date] => 2021-08-24 13:43:37
                            [post_date_gmt] => 2021-08-24 13:43:37
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:40:49
                            [post_modified_gmt] => 2023-06-27 11:40:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3754
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [357] => WP_Post Object
                        (
                            [ID] => 3753
                            [post_author] => 5
                            [post_date] => 2021-08-24 13:14:41
                            [post_date_gmt] => 2021-08-24 13:14:41
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 14:08:59
                            [post_modified_gmt] => 2023-06-26 14:08:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3753
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [358] => WP_Post Object
                        (
                            [ID] => 3751
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:54:56
                            [post_date_gmt] => 2021-08-24 12:54:56
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 14:08:20
                            [post_modified_gmt] => 2023-06-26 14:08:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3751
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [359] => WP_Post Object
                        (
                            [ID] => 3749
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:40:53
                            [post_date_gmt] => 2021-08-24 12:40:53
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:35:25
                            [post_modified_gmt] => 2023-06-27 11:35:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [360] => WP_Post Object
                        (
                            [ID] => 3748
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:31:07
                            [post_date_gmt] => 2021-08-24 12:31:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:19:34
                            [post_modified_gmt] => 2023-10-16 14:19:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [361] => WP_Post Object
                        (
                            [ID] => 3747
                            [post_author] => 5
                            [post_date] => 2021-08-24 11:12:07
                            [post_date_gmt] => 2021-08-24 11:12:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:19:26
                            [post_modified_gmt] => 2023-06-26 12:19:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3747
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [362] => WP_Post Object
                        (
                            [ID] => 3746
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:45:05
                            [post_date_gmt] => 2021-08-24 10:45:05
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:56:28
                            [post_modified_gmt] => 2023-06-26 13:56:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3746
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [363] => WP_Post Object
                        (
                            [ID] => 3744
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:32:54
                            [post_date_gmt] => 2021-08-24 10:32:54
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:23:55
                            [post_modified_gmt] => 2024-01-10 16:23:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [364] => WP_Post Object
                        (
                            [ID] => 3743
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:19:00
                            [post_date_gmt] => 2021-08-24 10:19:00
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:25:37
                            [post_modified_gmt] => 2024-01-10 16:25:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [365] => WP_Post Object
                        (
                            [ID] => 3736
                            [post_author] => 5
                            [post_date] => 2021-08-24 07:47:09
                            [post_date_gmt] => 2021-08-24 07:47:09
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:32:46
                            [post_modified_gmt] => 2024-01-10 16:32:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [366] => WP_Post Object
                        (
                            [ID] => 3726
                            [post_author] => 5
                            [post_date] => 2021-08-23 16:13:39
                            [post_date_gmt] => 2021-08-23 16:13:39
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:58:56
                            [post_modified_gmt] => 2023-11-10 13:58:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3726
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [367] => WP_Post Object
                        (
                            [ID] => 3725
                            [post_author] => 5
                            [post_date] => 2021-08-23 13:56:41
                            [post_date_gmt] => 2021-08-23 13:56:41
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:50:49
                            [post_modified_gmt] => 2023-06-26 13:50:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3725
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [368] => WP_Post Object
                        (
                            [ID] => 3724
                            [post_author] => 5
                            [post_date] => 2021-08-23 13:11:07
                            [post_date_gmt] => 2021-08-23 13:11:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:11:11
                            [post_modified_gmt] => 2023-08-02 15:11:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3724
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [369] => WP_Post Object
                        (
                            [ID] => 3722
                            [post_author] => 5
                            [post_date] => 2021-08-23 12:12:50
                            [post_date_gmt] => 2021-08-23 12:12:50
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:24:33
                            [post_modified_gmt] => 2023-06-26 12:24:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3722
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [370] => WP_Post Object
                        (
                            [ID] => 3696
                            [post_author] => 5
                            [post_date] => 2021-08-19 14:23:22
                            [post_date_gmt] => 2021-08-19 14:23:22
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 16:03:12
                            [post_modified_gmt] => 2023-08-02 16:03:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [371] => WP_Post Object
                        (
                            [ID] => 3493
                            [post_author] => 5
                            [post_date] => 2021-08-10 11:15:39
                            [post_date_gmt] => 2021-08-10 11:15:39
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:58:36
                            [post_modified_gmt] => 2023-06-22 13:58:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [372] => WP_Post Object
                        (
                            [ID] => 3379
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:56:54
                            [post_date_gmt] => 2021-06-30 17:56:54
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:39:06
                            [post_modified_gmt] => 2022-10-12 13:39:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3379
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [373] => WP_Post Object
                        (
                            [ID] => 3378
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:55:17
                            [post_date_gmt] => 2021-06-30 17:55:17
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-24 12:55:37
                            [post_modified_gmt] => 2024-07-24 12:55:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3378
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [374] => WP_Post Object
                        (
                            [ID] => 3377
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:20:14
                            [post_date_gmt] => 2021-06-30 17:20:14
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-24 13:03:56
                            [post_modified_gmt] => 2024-07-24 13:03:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3377
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [375] => WP_Post Object
                        (
                            [ID] => 3376
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:38:25
                            [post_date_gmt] => 2021-06-30 16:38:25
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-24 13:09:14
                            [post_modified_gmt] => 2024-07-24 13:09:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3376
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [376] => WP_Post Object
                        (
                            [ID] => 3375
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:36:27
                            [post_date_gmt] => 2021-06-30 16:36:27
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-24 12:55:34
                            [post_modified_gmt] => 2023-11-24 12:55:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3375
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [377] => WP_Post Object
                        (
                            [ID] => 3369
                            [post_author] => 6
                            [post_date] => 2021-06-30 15:09:50
                            [post_date_gmt] => 2021-06-30 15:09:50
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:17:00
                            [post_modified_gmt] => 2023-11-10 15:17:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3369
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [378] => WP_Post Object
                        (
                            [ID] => 3367
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:55:06
                            [post_date_gmt] => 2021-06-30 14:55:06
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:14:23
                            [post_modified_gmt] => 2023-11-10 15:14:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3367
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [379] => WP_Post Object
                        (
                            [ID] => 3365
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:51:27
                            [post_date_gmt] => 2021-06-30 14:51:27
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:10:53
                            [post_modified_gmt] => 2023-11-10 15:10:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3365
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [380] => WP_Post Object
                        (
                            [ID] => 3362
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:47:24
                            [post_date_gmt] => 2021-06-30 14:47:24
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:14:42
                            [post_modified_gmt] => 2023-11-10 15:14:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3362
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [381] => WP_Post Object
                        (
                            [ID] => 3359
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:38:46
                            [post_date_gmt] => 2021-06-30 14:38:46
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:16:07
                            [post_modified_gmt] => 2023-11-10 15:16:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3359
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [382] => WP_Post Object
                        (
                            [ID] => 3358
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:47:23
                            [post_date_gmt] => 2021-06-30 13:47:23
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:16:29
                            [post_modified_gmt] => 2023-11-10 15:16:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3358
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [383] => WP_Post Object
                        (
                            [ID] => 3357
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:41:11
                            [post_date_gmt] => 2021-06-30 13:41:11
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:05:19
                            [post_modified_gmt] => 2023-11-10 15:05:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3357
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [384] => WP_Post Object
                        (
                            [ID] => 3355
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:30:36
                            [post_date_gmt] => 2021-06-30 13:30:36
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:09:10
                            [post_modified_gmt] => 2023-11-10 15:09:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3355
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [385] => WP_Post Object
                        (
                            [ID] => 3353
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:25:17
                            [post_date_gmt] => 2021-06-30 13:25:17
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:12:34
                            [post_modified_gmt] => 2023-11-10 15:12:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3353
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [386] => WP_Post Object
                        (
                            [ID] => 3350
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:18:18
                            [post_date_gmt] => 2021-06-30 13:18:18
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:13:14
                            [post_modified_gmt] => 2023-11-10 15:13:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3350
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [387] => WP_Post Object
                        (
                            [ID] => 3347
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:12:31
                            [post_date_gmt] => 2021-06-30 13:12:31
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:13:45
                            [post_modified_gmt] => 2023-11-10 15:13:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3347
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [388] => WP_Post Object
                        (
                            [ID] => 3346
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:07:59
                            [post_date_gmt] => 2021-06-30 13:07:59
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:10:13
                            [post_modified_gmt] => 2023-11-10 15:10:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3346
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [389] => WP_Post Object
                        (
                            [ID] => 3345
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:04:52
                            [post_date_gmt] => 2021-06-30 13:04:52
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:08:39
                            [post_modified_gmt] => 2023-11-10 15:08:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3345
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [390] => WP_Post Object
                        (
                            [ID] => 3344
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:02:36
                            [post_date_gmt] => 2021-06-30 13:02:36
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:10:07
                            [post_modified_gmt] => 2023-06-21 12:10:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [391] => WP_Post Object
                        (
                            [ID] => 3343
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:57:07
                            [post_date_gmt] => 2021-06-30 12:57:07
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-21
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:11:24
                            [post_modified_gmt] => 2023-06-21 12:11:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3343
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [392] => WP_Post Object
                        (
                            [ID] => 3342
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:50:17
                            [post_date_gmt] => 2021-06-30 12:50:17
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:07:11
                            [post_modified_gmt] => 2023-06-21 12:07:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3342
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [393] => WP_Post Object
                        (
                            [ID] => 3341
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:44:43
                            [post_date_gmt] => 2021-06-30 12:44:43
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:06:00
                            [post_modified_gmt] => 2023-06-21 12:06:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3341
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [394] => WP_Post Object
                        (
                            [ID] => 3339
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:37:28
                            [post_date_gmt] => 2021-06-30 12:37:28
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:08:28
                            [post_modified_gmt] => 2023-06-21 12:08:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3339
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [395] => WP_Post Object
                        (
                            [ID] => 3338
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:27:08
                            [post_date_gmt] => 2021-06-30 12:27:08
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:08:16
                            [post_modified_gmt] => 2024-01-11 10:08:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3338
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [396] => WP_Post Object
                        (
                            [ID] => 3335
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:20:18
                            [post_date_gmt] => 2021-06-30 12:20:18
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:07:38
                            [post_modified_gmt] => 2023-11-10 15:07:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3335
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [397] => WP_Post Object
                        (
                            [ID] => 3336
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:18:57
                            [post_date_gmt] => 2021-06-30 12:18:57
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:05:22
                            [post_modified_gmt] => 2023-06-21 12:05:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3336
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [398] => WP_Post Object
                        (
                            [ID] => 3331
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:09:31
                            [post_date_gmt] => 2021-06-30 12:09:31
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:04:36
                            [post_modified_gmt] => 2023-06-21 12:04:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3331
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [399] => WP_Post Object
                        (
                            [ID] => 3329
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:04:02
                            [post_date_gmt] => 2021-06-30 12:04:02
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:10:20
                            [post_modified_gmt] => 2024-01-11 10:10:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3329
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [400] => WP_Post Object
                        (
                            [ID] => 3327
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:47:34
                            [post_date_gmt] => 2021-06-30 11:47:34
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:57:10
                            [post_modified_gmt] => 2023-08-02 14:57:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3327
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [401] => WP_Post Object
                        (
                            [ID] => 3326
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:35:26
                            [post_date_gmt] => 2021-06-30 11:35:26
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:00:27
                            [post_modified_gmt] => 2023-06-21 12:00:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3326
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [402] => WP_Post Object
                        (
                            [ID] => 3323
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:15:16
                            [post_date_gmt] => 2021-06-30 11:15:16
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:10:57
                            [post_modified_gmt] => 2024-01-11 10:10:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [403] => WP_Post Object
                        (
                            [ID] => 3321
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:12:36
                            [post_date_gmt] => 2021-06-30 11:12:36
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-13-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 10:02:31
                            [post_modified_gmt] => 2023-06-21 10:02:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3321
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [404] => WP_Post Object
                        (
                            [ID] => 3318
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:46:25
                            [post_date_gmt] => 2021-06-30 10:46:25
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:45:02
                            [post_modified_gmt] => 2024-09-04 10:45:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3318
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [405] => WP_Post Object
                        (
                            [ID] => 3316
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:25:45
                            [post_date_gmt] => 2021-06-30 10:25:45
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 11:58:34
                            [post_modified_gmt] => 2023-06-21 11:58:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3316
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [406] => WP_Post Object
                        (
                            [ID] => 3315
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:19:01
                            [post_date_gmt] => 2021-06-30 10:19:01
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 11:52:22
                            [post_modified_gmt] => 2023-06-21 11:52:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3315
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [407] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:45:09
                            [post_modified_gmt] => 2023-06-22 14:45:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [408] => WP_Post Object
                        (
                            [ID] => 2908
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:08:05
                            [post_date_gmt] => 2021-05-19 15:08:05
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:37:32
                            [post_modified_gmt] => 2023-06-22 14:37:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [409] => WP_Post Object
                        (
                            [ID] => 2907
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:46:20
                            [post_date_gmt] => 2021-05-19 14:46:20
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:40:14
                            [post_modified_gmt] => 2023-06-22 14:40:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [410] => WP_Post Object
                        (
                            [ID] => 2893
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:40:45
                            [post_date_gmt] => 2021-05-19 14:40:45
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:34:03
                            [post_modified_gmt] => 2023-06-22 14:34:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [411] => WP_Post Object
                        (
                            [ID] => 2892
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:30:23
                            [post_date_gmt] => 2021-05-14 19:30:23
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:57:50
                            [post_modified_gmt] => 2024-10-28 12:57:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [412] => WP_Post Object
                        (
                            [ID] => 2890
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:14:07
                            [post_date_gmt] => 2021-05-14 19:14:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:34:52
                            [post_modified_gmt] => 2023-06-22 14:34:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [413] => WP_Post Object
                        (
                            [ID] => 2889
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:09:07
                            [post_date_gmt] => 2021-05-14 19:09:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-21 11:28:56
                            [post_modified_gmt] => 2024-10-21 11:28:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [414] => WP_Post Object
                        (
                            [ID] => 2885
                            [post_author] => 5
                            [post_date] => 2021-05-14 18:17:37
                            [post_date_gmt] => 2021-05-14 18:17:37
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:36:43
                            [post_modified_gmt] => 2023-06-22 14:36:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [415] => WP_Post Object
                        (
                            [ID] => 2824
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:39:49
                            [post_date_gmt] => 2021-04-16 16:39:49
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 16:04:12
                            [post_modified_gmt] => 2023-08-02 16:04:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [416] => WP_Post Object
                        (
                            [ID] => 2822
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:09:31
                            [post_date_gmt] => 2021-04-16 16:09:31
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 09:04:12
                            [post_modified_gmt] => 2024-09-04 09:04:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [417] => WP_Post Object
                        (
                            [ID] => 2820
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:44:14
                            [post_date_gmt] => 2021-04-16 12:44:14
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 11:09:49
                            [post_modified_gmt] => 2024-10-30 11:09:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [418] => WP_Post Object
                        (
                            [ID] => 2744
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:12:35
                            [post_date_gmt] => 2021-03-30 15:12:35
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:25:08
                            [post_modified_gmt] => 2024-10-30 10:25:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [419] => WP_Post Object
                        (
                            [ID] => 2749
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:10:16
                            [post_date_gmt] => 2021-03-30 15:10:16
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:27:08
                            [post_modified_gmt] => 2024-10-30 10:27:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [420] => WP_Post Object
                        (
                            [ID] => 2748
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:05:46
                            [post_date_gmt] => 2021-03-30 15:05:46
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2748
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:25:33
                            [post_modified_gmt] => 2024-10-30 10:25:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [421] => WP_Post Object
                        (
                            [ID] => 2743
                            [post_author] => 5
                            [post_date] => 2021-03-24 15:11:40
                            [post_date_gmt] => 2021-03-24 15:11:40
                            [post_content] => 
                            [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:23:00
                            [post_modified_gmt] => 2024-10-30 10:23:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [422] => WP_Post Object
                        (
                            [ID] => 2742
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:37:07
                            [post_date_gmt] => 2021-03-24 13:37:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:23:42
                            [post_modified_gmt] => 2024-10-30 10:23:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [423] => WP_Post Object
                        (
                            [ID] => 2741
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:32:55
                            [post_date_gmt] => 2021-03-24 13:32:55
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:27:49
                            [post_modified_gmt] => 2024-10-30 10:27:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [424] => WP_Post Object
                        (
                            [ID] => 2739
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:12:14
                            [post_date_gmt] => 2021-03-24 13:12:14
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 10:34:52
                            [post_modified_gmt] => 2023-09-01 10:34:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [425] => WP_Post Object
                        (
                            [ID] => 2737
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:00:46
                            [post_date_gmt] => 2021-03-24 13:00:46
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:56:13
                            [post_modified_gmt] => 2024-09-04 10:56:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [426] => WP_Post Object
                        (
                            [ID] => 2736
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:15:15
                            [post_date_gmt] => 2021-03-23 18:15:15
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:28:15
                            [post_modified_gmt] => 2024-10-30 10:28:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [427] => WP_Post Object
                        (
                            [ID] => 2734
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:01:22
                            [post_date_gmt] => 2021-03-23 18:01:22
                            [post_content] => 
                            [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:22:17
                            [post_modified_gmt] => 2024-10-30 10:22:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [428] => WP_Post Object
                        (
                            [ID] => 2457
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:57
                            [post_date_gmt] => 2021-02-25 15:25:57
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 11:05:57
                            [post_modified_gmt] => 2024-10-30 11:05:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [429] => WP_Post Object
                        (
                            [ID] => 2461
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:35
                            [post_date_gmt] => 2021-02-25 15:23:35
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:34:20
                            [post_modified_gmt] => 2023-08-14 08:34:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [430] => WP_Post Object
                        (
                            [ID] => 2462
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:19
                            [post_date_gmt] => 2021-02-25 15:23:19
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:38:00
                            [post_modified_gmt] => 2023-08-14 08:38:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [431] => WP_Post Object
                        (
                            [ID] => 2463
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:22:52
                            [post_date_gmt] => 2021-02-25 15:22:52
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:56:24
                            [post_modified_gmt] => 2024-09-04 10:56:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [432] => WP_Post Object
                        (
                            [ID] => 2464
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:51
                            [post_date_gmt] => 2021-02-25 15:21:51
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:33:41
                            [post_modified_gmt] => 2023-08-14 08:33:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [433] => WP_Post Object
                        (
                            [ID] => 2465
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:32
                            [post_date_gmt] => 2021-02-25 15:21:32
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:39:58
                            [post_modified_gmt] => 2023-08-14 08:39:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [434] => WP_Post Object
                        (
                            [ID] => 2466
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:40
                            [post_date_gmt] => 2021-02-25 15:20:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:55:12
                            [post_modified_gmt] => 2024-01-09 13:55:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [435] => WP_Post Object
                        (
                            [ID] => 2467
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:15
                            [post_date_gmt] => 2021-02-25 15:20:15
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:32:07
                            [post_modified_gmt] => 2023-08-14 08:32:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [436] => WP_Post Object
                        (
                            [ID] => 2444
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:27:20
                            [post_date_gmt] => 2021-01-19 09:27:20
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:42:15
                            [post_modified_gmt] => 2023-06-20 10:42:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [437] => WP_Post Object
                        (
                            [ID] => 2443
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:14:03
                            [post_date_gmt] => 2021-01-19 09:14:03
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:46:42
                            [post_modified_gmt] => 2023-06-20 10:46:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [438] => WP_Post Object
                        (
                            [ID] => 2442
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:56:32
                            [post_date_gmt] => 2021-01-19 06:56:32
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:56:25
                            [post_modified_gmt] => 2024-01-09 13:56:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [439] => WP_Post Object
                        (
                            [ID] => 2441
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:48:04
                            [post_date_gmt] => 2021-01-19 06:48:04
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:51:31
                            [post_modified_gmt] => 2023-06-20 10:51:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [440] => WP_Post Object
                        (
                            [ID] => 1395
                            [post_author] => 7
                            [post_date] => 2020-05-30 21:25:33
                            [post_date_gmt] => 2020-05-30 21:25:33
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:18:12
                            [post_modified_gmt] => 2024-08-19 15:18:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [441] => WP_Post Object
                        (
                            [ID] => 1394
                            [post_author] => 7
                            [post_date] => 2020-05-30 21:22:44
                            [post_date_gmt] => 2020-05-30 21:22:44
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:19:03
                            [post_modified_gmt] => 2024-08-19 15:19:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [442] => WP_Post Object
                        (
                            [ID] => 1308
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:17:48
                            [post_date_gmt] => 2020-05-23 17:17:48
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 06:58:07
                            [post_modified_gmt] => 2024-09-20 06:58:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [443] => WP_Post Object
                        (
                            [ID] => 1283
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:57:44
                            [post_date_gmt] => 2020-05-22 22:57:44
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:36:58
                            [post_modified_gmt] => 2024-09-23 10:36:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [444] => WP_Post Object
                        (
                            [ID] => 1275
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:39:41
                            [post_date_gmt] => 2020-05-22 22:39:41
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:33:11
                            [post_modified_gmt] => 2024-09-23 10:33:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [445] => WP_Post Object
                        (
                            [ID] => 1274
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:38:47
                            [post_date_gmt] => 2020-05-22 22:38:47
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 09:04:22
                            [post_modified_gmt] => 2024-07-17 09:04:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [446] => WP_Post Object
                        (
                            [ID] => 1268
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:27:54
                            [post_date_gmt] => 2020-05-22 22:27:54
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 07:00:28
                            [post_modified_gmt] => 2024-09-20 07:00:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [447] => WP_Post Object
                        (
                            [ID] => 1253
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:42:28
                            [post_date_gmt] => 2020-05-22 21:42:28
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 06:51:10
                            [post_modified_gmt] => 2024-09-20 06:51:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [448] => WP_Post Object
                        (
                            [ID] => 1240
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:22:47
                            [post_date_gmt] => 2020-05-22 21:22:47
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:26:42
                            [post_modified_gmt] => 2024-09-23 10:26:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [449] => WP_Post Object
                        (
                            [ID] => 1221
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:09:53
                            [post_date_gmt] => 2020-05-22 20:09:53
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfpi3-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-29 12:09:52
                            [post_modified_gmt] => 2024-08-29 12:09:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [450] => WP_Post Object
                        (
                            [ID] => 1218
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:04:53
                            [post_date_gmt] => 2020-05-22 20:04:53
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 12:06:00
                            [post_modified_gmt] => 2024-04-10 12:06:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [451] => WP_Post Object
                        (
                            [ID] => 1211
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:50:22
                            [post_date_gmt] => 2020-05-22 19:50:22
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 06:52:24
                            [post_modified_gmt] => 2024-09-20 06:52:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [452] => WP_Post Object
                        (
                            [ID] => 1206
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:37:27
                            [post_date_gmt] => 2020-05-22 19:37:27
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-global-access-commitment-and-humanitarian-license
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-19 15:16:57
                            [post_modified_gmt] => 2024-08-19 15:16:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [453] => WP_Post Object
                        (
                            [ID] => 1200
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:35:05
                            [post_date_gmt] => 2020-05-22 19:35:05
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:46:00
                            [post_modified_gmt] => 2024-07-16 14:46:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [454] => WP_Post Object
                        (
                            [ID] => 1205
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:33:17
                            [post_date_gmt] => 2020-05-22 19:33:17
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:09:07
                            [post_modified_gmt] => 2023-06-29 13:09:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [455] => WP_Post Object
                        (
                            [ID] => 1204
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:31:46
                            [post_date_gmt] => 2020-05-22 19:31:46
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:56:09
                            [post_modified_gmt] => 2023-08-02 14:56:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [456] => WP_Post Object
                        (
                            [ID] => 1203
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:30:52
                            [post_date_gmt] => 2020-05-22 19:30:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:18:43
                            [post_modified_gmt] => 2023-06-29 13:18:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [457] => WP_Post Object
                        (
                            [ID] => 1202
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:28:49
                            [post_date_gmt] => 2020-05-22 19:28:49
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:12:39
                            [post_modified_gmt] => 2023-06-29 13:12:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [458] => WP_Post Object
                        (
                            [ID] => 1201
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:26:29
                            [post_date_gmt] => 2020-05-22 19:26:29
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 11:36:46
                            [post_modified_gmt] => 2024-01-11 11:36:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [459] => WP_Post Object
                        (
                            [ID] => 1199
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:21:57
                            [post_date_gmt] => 2020-05-22 19:21:57
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:47:24
                            [post_modified_gmt] => 2024-10-28 12:47:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [460] => WP_Post Object
                        (
                            [ID] => 1198
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:12:54
                            [post_date_gmt] => 2020-05-22 19:12:54
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:39:16
                            [post_modified_gmt] => 2024-07-16 14:39:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [461] => WP_Post Object
                        (
                            [ID] => 1190
                            [post_author] => 6
                            [post_date] => 2020-05-22 01:59:48
                            [post_date_gmt] => 2020-05-22 01:59:48
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:24:04
                            [post_modified_gmt] => 2024-09-23 10:24:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [462] => WP_Post Object
                        (
                            [ID] => 1187
                            [post_author] => 6
                            [post_date] => 2020-05-22 01:56:10
                            [post_date_gmt] => 2020-05-22 01:56:10
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 12:31:21
                            [post_modified_gmt] => 2024-04-10 12:31:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [463] => WP_Post Object
                        (
                            [ID] => 1184
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:08:17
                            [post_date_gmt] => 2020-05-22 00:08:17
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:50:58
                            [post_modified_gmt] => 2024-09-04 10:50:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [464] => WP_Post Object
                        (
                            [ID] => 1178
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:55:50
                            [post_date_gmt] => 2020-05-21 23:55:50
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 06:50:27
                            [post_modified_gmt] => 2024-09-20 06:50:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [465] => WP_Post Object
                        (
                            [ID] => 1176
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:52:12
                            [post_date_gmt] => 2020-05-21 23:52:12
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 10:30:44
                            [post_modified_gmt] => 2023-10-17 10:30:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [466] => WP_Post Object
                        (
                            [ID] => 1171
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:33:24
                            [post_date_gmt] => 2020-05-21 23:33:24
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-19 15:52:45
                            [post_modified_gmt] => 2024-09-19 15:52:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [467] => WP_Post Object
                        (
                            [ID] => 1165
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:23:57
                            [post_date_gmt] => 2020-05-21 23:23:57
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 06:59:18
                            [post_modified_gmt] => 2024-09-20 06:59:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [468] => WP_Post Object
                        (
                            [ID] => 1160
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:18:03
                            [post_date_gmt] => 2020-05-21 23:18:03
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:32:40
                            [post_modified_gmt] => 2024-09-23 10:32:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [469] => WP_Post Object
                        (
                            [ID] => 1159
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:14:15
                            [post_date_gmt] => 2020-05-21 23:14:15
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:33:10
                            [post_modified_gmt] => 2024-01-10 16:33:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [470] => WP_Post Object
                        (
                            [ID] => 1158
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:12:13
                            [post_date_gmt] => 2020-05-21 23:12:13
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 08:57:40
                            [post_modified_gmt] => 2024-07-17 08:57:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [471] => WP_Post Object
                        (
                            [ID] => 1139
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:35:04
                            [post_date_gmt] => 2020-05-21 22:35:04
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-17 09:00:46
                            [post_modified_gmt] => 2024-07-17 09:00:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [472] => WP_Post Object
                        (
                            [ID] => 1128
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:50:04
                            [post_date_gmt] => 2020-05-21 21:50:04
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 06:54:46
                            [post_modified_gmt] => 2024-09-20 06:54:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [473] => WP_Post Object
                        (
                            [ID] => 1111
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:03:23
                            [post_date_gmt] => 2020-05-21 21:03:23
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-19 15:53:40
                            [post_modified_gmt] => 2024-09-19 15:53:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [474] => WP_Post Object
                        (
                            [ID] => 996
                            [post_author] => 7
                            [post_date] => 2020-05-18 19:58:18
                            [post_date_gmt] => 2020-05-18 19:58:18
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:20:47
                            [post_modified_gmt] => 2023-10-16 14:20:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 475
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 12421
                    [post_author] => 5
                    [post_date] => 2024-12-05 14:36:49
                    [post_date_gmt] => 2024-12-05 14:36:49
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:47:11
                    [post_modified_gmt] => 2024-12-05 15:47:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12421
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 475
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => a49c345ce149eae40e82100918ec5471
            [query_vars_changed:WP_Query:private] => 
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_agreement_q_rslts] => 
    [text_provision_q_rslts] => 
    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 12421
                    [post_author] => 5
                    [post_date] => 2024-12-05 14:36:49
                    [post_date_gmt] => 2024-12-05 14:36:49
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:47:11
                    [post_modified_gmt] => 2024-12-05 15:47:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12421
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 12419
                    [post_author] => 5
                    [post_date] => 2024-12-05 14:18:35
                    [post_date_gmt] => 2024-12-05 14:18:35
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:48:01
                    [post_modified_gmt] => 2024-12-05 15:48:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12419
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 12418
                    [post_author] => 5
                    [post_date] => 2024-12-05 14:08:33
                    [post_date_gmt] => 2024-12-05 14:08:33
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:47:38
                    [post_modified_gmt] => 2024-12-05 15:47:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12418
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 12417
                    [post_author] => 5
                    [post_date] => 2024-12-05 14:01:34
                    [post_date_gmt] => 2024-12-05 14:01:34
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:46:51
                    [post_modified_gmt] => 2024-12-05 15:46:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12417
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 12416
                    [post_author] => 5
                    [post_date] => 2024-12-05 13:49:28
                    [post_date_gmt] => 2024-12-05 13:49:28
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:46:13
                    [post_modified_gmt] => 2024-12-05 15:46:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12416
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 12415
                    [post_author] => 5
                    [post_date] => 2024-12-05 13:41:10
                    [post_date_gmt] => 2024-12-05 13:41:10
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:45:57
                    [post_modified_gmt] => 2024-12-05 15:45:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12415
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 12414
                    [post_author] => 5
                    [post_date] => 2024-12-05 12:37:47
                    [post_date_gmt] => 2024-12-05 12:37:47
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:43:28
                    [post_modified_gmt] => 2024-12-05 15:43:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12414
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 12413
                    [post_author] => 5
                    [post_date] => 2024-12-03 14:43:59
                    [post_date_gmt] => 2024-12-03 14:43:59
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:39:32
                    [post_modified_gmt] => 2024-12-05 15:39:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12413
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 12412
                    [post_author] => 5
                    [post_date] => 2024-12-03 14:23:19
                    [post_date_gmt] => 2024-12-03 14:23:19
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:43:42
                    [post_modified_gmt] => 2024-12-05 15:43:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12412
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 12411
                    [post_author] => 5
                    [post_date] => 2024-12-03 13:47:40
                    [post_date_gmt] => 2024-12-03 13:47:40
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:44:08
                    [post_modified_gmt] => 2024-12-05 15:44:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12411
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 12410
                    [post_author] => 5
                    [post_date] => 2024-12-03 13:03:03
                    [post_date_gmt] => 2024-12-03 13:03:03
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:39:51
                    [post_modified_gmt] => 2024-12-05 15:39:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12410
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 12409
                    [post_author] => 5
                    [post_date] => 2024-12-03 12:48:11
                    [post_date_gmt] => 2024-12-03 12:48:11
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:45:41
                    [post_modified_gmt] => 2024-12-05 15:45:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12409
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 12408
                    [post_author] => 5
                    [post_date] => 2024-12-03 12:42:31
                    [post_date_gmt] => 2024-12-03 12:42:31
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:44:26
                    [post_modified_gmt] => 2024-12-05 15:44:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12408
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 12407
                    [post_author] => 5
                    [post_date] => 2024-12-03 12:24:37
                    [post_date_gmt] => 2024-12-03 12:24:37
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:45:12
                    [post_modified_gmt] => 2024-12-05 15:45:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12407
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 12096
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:59:43
                    [post_date_gmt] => 2024-10-09 14:59:43
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:59:43
                    [post_modified_gmt] => 2024-10-09 14:59:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12096
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 12097
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:59:36
                    [post_date_gmt] => 2024-10-09 14:59:36
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:59:36
                    [post_modified_gmt] => 2024-10-09 14:59:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12097
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 12098
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:59:30
                    [post_date_gmt] => 2024-10-09 14:59:30
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:59:30
                    [post_modified_gmt] => 2024-10-09 14:59:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12098
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 12099
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:59:23
                    [post_date_gmt] => 2024-10-09 14:59:23
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 15:32:53
                    [post_modified_gmt] => 2024-10-09 15:32:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12099
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 12095
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:59:18
                    [post_date_gmt] => 2024-10-09 14:59:18
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:59:18
                    [post_modified_gmt] => 2024-10-09 14:59:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12095
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 12094
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:59:12
                    [post_date_gmt] => 2024-10-09 14:59:12
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 15:27:38
                    [post_modified_gmt] => 2024-10-09 15:27:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12094
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 12102
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:59:05
                    [post_date_gmt] => 2024-10-09 14:59:05
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 15:25:48
                    [post_modified_gmt] => 2024-10-09 15:25:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12102
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 12103
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:58:59
                    [post_date_gmt] => 2024-10-09 14:58:59
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:58:59
                    [post_modified_gmt] => 2024-10-09 14:58:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12103
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 12104
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:58:53
                    [post_date_gmt] => 2024-10-09 14:58:53
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:58:53
                    [post_modified_gmt] => 2024-10-09 14:58:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12104
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 12105
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:58:47
                    [post_date_gmt] => 2024-10-09 14:58:47
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:58:47
                    [post_modified_gmt] => 2024-10-09 14:58:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12105
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 12106
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:58:42
                    [post_date_gmt] => 2024-10-09 14:58:42
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:58:42
                    [post_modified_gmt] => 2024-10-09 14:58:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12106
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 12107
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:53:55
                    [post_date_gmt] => 2024-10-09 14:53:55
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 15:31:13
                    [post_modified_gmt] => 2024-10-09 15:31:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12107
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 12080
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:24:07
                    [post_date_gmt] => 2024-10-07 14:24:07
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 14:19:53
                    [post_modified_gmt] => 2024-10-28 14:19:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12080
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 12081
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:22:43
                    [post_date_gmt] => 2024-10-07 14:22:43
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 15:10:33
                    [post_modified_gmt] => 2024-10-07 15:10:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12081
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 12082
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:22:13
                    [post_date_gmt] => 2024-10-07 14:22:13
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:52:13
                    [post_modified_gmt] => 2024-10-07 14:52:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12082
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 12083
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:21:50
                    [post_date_gmt] => 2024-10-07 14:21:50
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:55:48
                    [post_modified_gmt] => 2024-10-07 14:55:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12083
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 12084
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:20:13
                    [post_date_gmt] => 2024-10-07 14:20:13
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 15:08:36
                    [post_modified_gmt] => 2024-10-07 15:08:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12084
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 12085
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:18:25
                    [post_date_gmt] => 2024-10-07 14:18:25
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:41:33
                    [post_modified_gmt] => 2024-10-07 14:41:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12085
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 12086
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:09:43
                    [post_date_gmt] => 2024-10-07 14:09:43
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:35:44
                    [post_modified_gmt] => 2024-10-07 14:35:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12086
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 12088
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:09:23
                    [post_date_gmt] => 2024-10-07 14:09:23
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:57:21
                    [post_modified_gmt] => 2024-10-07 14:57:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12088
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 12089
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:09:08
                    [post_date_gmt] => 2024-10-07 14:09:08
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:57:53
                    [post_modified_gmt] => 2024-10-07 14:57:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12089
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 12087
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:08:53
                    [post_date_gmt] => 2024-10-07 14:08:53
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-21 11:40:34
                    [post_modified_gmt] => 2024-10-21 11:40:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12087
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 12090
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:08:40
                    [post_date_gmt] => 2024-10-07 14:08:40
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:58:45
                    [post_modified_gmt] => 2024-10-07 14:58:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12090
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 12079
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:08:23
                    [post_date_gmt] => 2024-10-07 14:08:23
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:56:47
                    [post_modified_gmt] => 2024-10-07 14:56:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12079
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 12078
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:07:56
                    [post_date_gmt] => 2024-10-07 14:07:56
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:56:20
                    [post_modified_gmt] => 2024-10-07 14:56:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12078
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 12091
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:07:21
                    [post_date_gmt] => 2024-10-07 14:07:21
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 15:03:46
                    [post_modified_gmt] => 2024-10-07 15:03:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12091
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 12056
                    [post_author] => 5
                    [post_date] => 2024-09-12 13:39:59
                    [post_date_gmt] => 2024-09-12 13:39:59
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 13:39:59
                    [post_modified_gmt] => 2024-09-12 13:39:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12056
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 12045
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:43
                    [post_date_gmt] => 2024-09-12 12:37:43
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 13:22:43
                    [post_modified_gmt] => 2024-09-12 13:22:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12045
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 12046
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:37
                    [post_date_gmt] => 2024-09-12 12:37:37
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 13:12:39
                    [post_modified_gmt] => 2024-09-12 13:12:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12046
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 12047
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:30
                    [post_date_gmt] => 2024-09-12 12:37:30
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 12:37:30
                    [post_modified_gmt] => 2024-09-12 12:37:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12047
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 12049
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:22
                    [post_date_gmt] => 2024-09-12 12:37:22
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 13:03:05
                    [post_modified_gmt] => 2024-09-12 13:03:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12049
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 12050
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:17
                    [post_date_gmt] => 2024-09-12 12:37:17
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 12:53:21
                    [post_modified_gmt] => 2024-09-12 12:53:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12050
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 12051
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:11
                    [post_date_gmt] => 2024-09-12 12:37:11
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 12:37:11
                    [post_modified_gmt] => 2024-09-12 12:37:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12051
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 12048
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:05
                    [post_date_gmt] => 2024-09-12 12:37:05
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 12:37:05
                    [post_modified_gmt] => 2024-09-12 12:37:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12048
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 12044
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:36:59
                    [post_date_gmt] => 2024-09-12 12:36:59
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 13:22:04
                    [post_modified_gmt] => 2024-09-12 13:22:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12044
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 12053
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:36:46
                    [post_date_gmt] => 2024-09-12 12:36:46
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 12:36:46
                    [post_modified_gmt] => 2024-09-12 12:36:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12053
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 12054
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:35:33
                    [post_date_gmt] => 2024-09-12 12:35:33
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 13:08:46
                    [post_modified_gmt] => 2024-09-12 13:08:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12054
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 12052
                    [post_author] => 5
                    [post_date] => 2024-09-12 09:31:55
                    [post_date_gmt] => 2024-09-12 09:31:55
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 12:36:53
                    [post_modified_gmt] => 2024-09-12 12:36:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12052
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 12021
                    [post_author] => 5
                    [post_date] => 2024-09-04 10:40:57
                    [post_date_gmt] => 2024-09-04 10:40:57
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:40:57
                    [post_modified_gmt] => 2024-09-04 10:40:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12021
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 12020
                    [post_author] => 5
                    [post_date] => 2024-09-04 10:35:24
                    [post_date_gmt] => 2024-09-04 10:35:24
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-portfolio-company-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:35:24
                    [post_modified_gmt] => 2024-09-04 10:35:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12020
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 12007
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:27
                    [post_date_gmt] => 2024-09-02 09:18:27
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:35:51
                    [post_modified_gmt] => 2024-09-02 14:35:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12007
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 12006
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:21
                    [post_date_gmt] => 2024-09-02 09:18:21
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 09:18:21
                    [post_modified_gmt] => 2024-09-02 09:18:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12006
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 12005
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:16
                    [post_date_gmt] => 2024-09-02 09:18:16
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:25:19
                    [post_modified_gmt] => 2024-09-02 14:25:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12005
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 12004
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:10
                    [post_date_gmt] => 2024-09-02 09:18:10
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:23:39
                    [post_modified_gmt] => 2024-09-02 14:23:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12004
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 11999
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:02
                    [post_date_gmt] => 2024-09-02 09:18:02
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 10:40:18
                    [post_modified_gmt] => 2024-09-02 10:40:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11999
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 11998
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:54
                    [post_date_gmt] => 2024-09-02 09:17:54
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 10:48:33
                    [post_modified_gmt] => 2024-09-02 10:48:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11998
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 11931
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:37
                    [post_date_gmt] => 2024-09-02 09:17:37
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:58:41
                    [post_modified_gmt] => 2024-09-03 08:58:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11931
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 11930
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:27
                    [post_date_gmt] => 2024-09-02 09:17:27
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 10:33:23
                    [post_modified_gmt] => 2024-09-02 10:33:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11930
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [62] => WP_Post Object
                (
                    [ID] => 11928
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:18
                    [post_date_gmt] => 2024-09-02 09:17:18
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:17:04
                    [post_modified_gmt] => 2024-09-03 08:17:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11928
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [63] => WP_Post Object
                (
                    [ID] => 11927
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:09
                    [post_date_gmt] => 2024-09-02 09:17:09
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:44:21
                    [post_modified_gmt] => 2024-09-03 08:44:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11927
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [64] => WP_Post Object
                (
                    [ID] => 11926
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:03
                    [post_date_gmt] => 2024-09-02 09:17:03
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 09:17:03
                    [post_modified_gmt] => 2024-09-02 09:17:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11926
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [65] => WP_Post Object
                (
                    [ID] => 11925
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:39
                    [post_date_gmt] => 2024-09-02 09:16:39
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 11:06:24
                    [post_modified_gmt] => 2024-09-02 11:06:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11925
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [66] => WP_Post Object
                (
                    [ID] => 11924
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:32
                    [post_date_gmt] => 2024-09-02 09:16:32
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:16:44
                    [post_modified_gmt] => 2024-09-03 08:16:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11924
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [67] => WP_Post Object
                (
                    [ID] => 11920
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:23
                    [post_date_gmt] => 2024-09-02 09:16:23
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:39:42
                    [post_modified_gmt] => 2024-10-28 12:39:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11920
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [68] => WP_Post Object
                (
                    [ID] => 11923
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:17
                    [post_date_gmt] => 2024-09-02 09:16:17
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:12:38
                    [post_modified_gmt] => 2024-09-03 08:12:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11923
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [69] => WP_Post Object
                (
                    [ID] => 11917
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:04
                    [post_date_gmt] => 2024-09-02 09:16:04
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:21:48
                    [post_modified_gmt] => 2024-09-02 14:21:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11917
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [70] => WP_Post Object
                (
                    [ID] => 12009
                    [post_author] => 5
                    [post_date] => 2024-09-02 08:24:39
                    [post_date_gmt] => 2024-09-02 08:24:39
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:30:38
                    [post_modified_gmt] => 2024-09-02 14:30:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12009
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [71] => WP_Post Object
                (
                    [ID] => 11918
                    [post_author] => 5
                    [post_date] => 2024-08-26 15:05:16
                    [post_date_gmt] => 2024-08-26 15:05:16
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 09:43:25
                    [post_modified_gmt] => 2024-09-02 09:43:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11918
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [72] => WP_Post Object
                (
                    [ID] => 11905
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:28:27
                    [post_date_gmt] => 2024-08-26 12:28:27
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:28:27
                    [post_modified_gmt] => 2024-08-26 12:28:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11905
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [73] => WP_Post Object
                (
                    [ID] => 11906
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:27:58
                    [post_date_gmt] => 2024-08-26 12:27:58
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:27:58
                    [post_modified_gmt] => 2024-08-26 12:27:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11906
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [74] => WP_Post Object
                (
                    [ID] => 11907
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:27:45
                    [post_date_gmt] => 2024-08-26 12:27:45
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:27:45
                    [post_modified_gmt] => 2024-08-26 12:27:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11907
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [75] => WP_Post Object
                (
                    [ID] => 11908
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:27:36
                    [post_date_gmt] => 2024-08-26 12:27:36
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:45:32
                    [post_modified_gmt] => 2024-08-26 12:45:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11908
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [76] => WP_Post Object
                (
                    [ID] => 11909
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:26:58
                    [post_date_gmt] => 2024-08-26 12:26:58
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:46:05
                    [post_modified_gmt] => 2024-08-26 12:46:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11909
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [77] => WP_Post Object
                (
                    [ID] => 11912
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:22:24
                    [post_date_gmt] => 2024-08-26 12:22:24
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:22:24
                    [post_modified_gmt] => 2024-08-26 12:22:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11912
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [78] => WP_Post Object
                (
                    [ID] => 11911
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:19:52
                    [post_date_gmt] => 2024-08-26 12:19:52
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:19:52
                    [post_modified_gmt] => 2024-08-26 12:19:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11911
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [79] => WP_Post Object
                (
                    [ID] => 11904
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:16:25
                    [post_date_gmt] => 2024-08-26 12:16:25
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:42:32
                    [post_modified_gmt] => 2024-08-26 12:42:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11904
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [80] => WP_Post Object
                (
                    [ID] => 11910
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:14:56
                    [post_date_gmt] => 2024-08-26 12:14:56
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:27:23
                    [post_modified_gmt] => 2024-08-26 12:27:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11910
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [81] => WP_Post Object
                (
                    [ID] => 12008
                    [post_author] => 5
                    [post_date] => 2024-08-02 08:14:31
                    [post_date_gmt] => 2024-08-02 08:14:31
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:38:35
                    [post_modified_gmt] => 2024-09-02 14:38:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12008
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [82] => WP_Post Object
                (
                    [ID] => 11821
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:15:45
                    [post_date_gmt] => 2024-07-15 15:15:45
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:17:49
                    [post_modified_gmt] => 2024-07-15 15:17:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11821
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [83] => WP_Post Object
                (
                    [ID] => 11825
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:14:50
                    [post_date_gmt] => 2024-07-15 15:14:50
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:15:29
                    [post_modified_gmt] => 2024-07-15 15:15:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11825
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [84] => WP_Post Object
                (
                    [ID] => 11827
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:14:27
                    [post_date_gmt] => 2024-07-15 15:14:27
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:14:27
                    [post_modified_gmt] => 2024-07-15 15:14:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11827
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [85] => WP_Post Object
                (
                    [ID] => 11828
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:13:11
                    [post_date_gmt] => 2024-07-15 15:13:11
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:13:11
                    [post_modified_gmt] => 2024-07-15 15:13:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11828
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [86] => WP_Post Object
                (
                    [ID] => 11831
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:11:29
                    [post_date_gmt] => 2024-07-15 15:11:29
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:14:10
                    [post_modified_gmt] => 2024-07-15 15:14:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11831
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [87] => WP_Post Object
                (
                    [ID] => 11834
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:09:41
                    [post_date_gmt] => 2024-07-15 15:09:41
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:10:44
                    [post_modified_gmt] => 2024-07-15 15:10:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11834
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [88] => WP_Post Object
                (
                    [ID] => 11835
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:09:17
                    [post_date_gmt] => 2024-07-15 15:09:17
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:09:17
                    [post_modified_gmt] => 2024-07-15 15:09:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11835
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [89] => WP_Post Object
                (
                    [ID] => 11836
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:08:25
                    [post_date_gmt] => 2024-07-15 15:08:25
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:08:25
                    [post_modified_gmt] => 2024-07-15 15:08:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11836
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [90] => WP_Post Object
                (
                    [ID] => 11837
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:06:07
                    [post_date_gmt] => 2024-07-15 15:06:07
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:08:00
                    [post_modified_gmt] => 2024-07-15 15:08:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11837
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [91] => WP_Post Object
                (
                    [ID] => 11824
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:05:21
                    [post_date_gmt] => 2024-07-15 15:05:21
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:05:21
                    [post_modified_gmt] => 2024-07-15 15:05:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11824
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [92] => WP_Post Object
                (
                    [ID] => 11829
                    [post_author] => 5
                    [post_date] => 2024-07-12 12:56:46
                    [post_date_gmt] => 2024-07-12 12:56:46
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:12:47
                    [post_modified_gmt] => 2024-07-15 15:12:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11829
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [93] => WP_Post Object
                (
                    [ID] => 11703
                    [post_author] => 5
                    [post_date] => 2024-04-08 11:11:54
                    [post_date_gmt] => 2024-04-08 11:11:54
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:22:20
                    [post_modified_gmt] => 2024-04-08 11:22:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11703
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [94] => WP_Post Object
                (
                    [ID] => 11702
                    [post_author] => 5
                    [post_date] => 2024-04-08 11:08:16
                    [post_date_gmt] => 2024-04-08 11:08:16
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:22:36
                    [post_modified_gmt] => 2024-04-08 11:22:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11702
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [95] => WP_Post Object
                (
                    [ID] => 11701
                    [post_author] => 5
                    [post_date] => 2024-04-08 10:08:21
                    [post_date_gmt] => 2024-04-08 10:08:21
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:21:00
                    [post_modified_gmt] => 2024-04-08 11:21:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11701
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [96] => WP_Post Object
                (
                    [ID] => 11700
                    [post_author] => 5
                    [post_date] => 2024-04-08 10:00:51
                    [post_date_gmt] => 2024-04-08 10:00:51
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:21:15
                    [post_modified_gmt] => 2024-04-08 11:21:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11700
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [97] => WP_Post Object
                (
                    [ID] => 11699
                    [post_author] => 5
                    [post_date] => 2024-04-08 09:57:53
                    [post_date_gmt] => 2024-04-08 09:57:53
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:21:33
                    [post_modified_gmt] => 2024-04-08 11:21:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11699
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [98] => WP_Post Object
                (
                    [ID] => 11698
                    [post_author] => 5
                    [post_date] => 2024-04-08 09:50:58
                    [post_date_gmt] => 2024-04-08 09:50:58
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:21:51
                    [post_modified_gmt] => 2024-04-08 11:21:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11698
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [99] => WP_Post Object
                (
                    [ID] => 11696
                    [post_author] => 5
                    [post_date] => 2024-04-08 09:37:34
                    [post_date_gmt] => 2024-04-08 09:37:34
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:20:42
                    [post_modified_gmt] => 2024-04-08 11:20:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11696
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [100] => WP_Post Object
                (
                    [ID] => 11694
                    [post_author] => 5
                    [post_date] => 2024-04-08 09:23:51
                    [post_date_gmt] => 2024-04-08 09:23:51
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:22:05
                    [post_modified_gmt] => 2024-04-08 11:22:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11694
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [101] => WP_Post Object
                (
                    [ID] => 11649
                    [post_author] => 5
                    [post_date] => 2024-02-19 16:43:58
                    [post_date_gmt] => 2024-02-19 16:43:58
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 16:43:58
                    [post_modified_gmt] => 2024-02-19 16:43:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11649
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [102] => WP_Post Object
                (
                    [ID] => 11648
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:48:32
                    [post_date_gmt] => 2024-02-19 08:48:32
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:48:32
                    [post_modified_gmt] => 2024-02-19 08:48:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11648
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [103] => WP_Post Object
                (
                    [ID] => 11647
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:47:07
                    [post_date_gmt] => 2024-02-19 08:47:07
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:47:07
                    [post_modified_gmt] => 2024-02-19 08:47:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11647
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [104] => WP_Post Object
                (
                    [ID] => 11646
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:45:09
                    [post_date_gmt] => 2024-02-19 08:45:09
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:51:59
                    [post_modified_gmt] => 2024-02-19 08:51:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11646
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [105] => WP_Post Object
                (
                    [ID] => 11645
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:43:50
                    [post_date_gmt] => 2024-02-19 08:43:50
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:51:41
                    [post_modified_gmt] => 2024-02-19 08:51:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11645
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [106] => WP_Post Object
                (
                    [ID] => 11644
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:40:46
                    [post_date_gmt] => 2024-02-19 08:40:46
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:51:24
                    [post_modified_gmt] => 2024-02-19 08:51:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11644
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [107] => WP_Post Object
                (
                    [ID] => 11643
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:38:10
                    [post_date_gmt] => 2024-02-19 08:38:10
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:50:57
                    [post_modified_gmt] => 2024-02-19 08:50:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11643
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [108] => WP_Post Object
                (
                    [ID] => 11642
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:37:11
                    [post_date_gmt] => 2024-02-19 08:37:11
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:50:41
                    [post_modified_gmt] => 2024-02-19 08:50:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11642
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [109] => WP_Post Object
                (
                    [ID] => 11641
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:35:54
                    [post_date_gmt] => 2024-02-19 08:35:54
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:50:26
                    [post_modified_gmt] => 2024-02-19 08:50:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11641
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [110] => WP_Post Object
                (
                    [ID] => 11637
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:35:21
                    [post_date_gmt] => 2024-02-19 08:35:21
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:50:11
                    [post_modified_gmt] => 2024-02-19 08:50:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11637
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [111] => WP_Post Object
                (
                    [ID] => 11635
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:34:34
                    [post_date_gmt] => 2024-02-19 08:34:34
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:49:53
                    [post_modified_gmt] => 2024-02-19 08:49:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11635
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [112] => WP_Post Object
                (
                    [ID] => 11634
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:31:58
                    [post_date_gmt] => 2024-02-19 08:31:58
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:46:26
                    [post_modified_gmt] => 2024-02-19 08:46:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11634
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [113] => WP_Post Object
                (
                    [ID] => 11339
                    [post_author] => 5
                    [post_date] => 2023-09-26 14:15:18
                    [post_date_gmt] => 2023-09-26 14:15:18
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-26 14:15:18
                    [post_modified_gmt] => 2023-09-26 14:15:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11339
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [114] => WP_Post Object
                (
                    [ID] => 11274
                    [post_author] => 5
                    [post_date] => 2023-09-26 14:05:33
                    [post_date_gmt] => 2023-09-26 14:05:33
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-26 14:07:54
                    [post_modified_gmt] => 2023-09-26 14:07:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11274
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [115] => WP_Post Object
                (
                    [ID] => 11273
                    [post_author] => 5
                    [post_date] => 2023-09-19 15:52:21
                    [post_date_gmt] => 2023-09-19 15:52:21
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-19 15:52:52
                    [post_modified_gmt] => 2023-09-19 15:52:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11273
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [116] => WP_Post Object
                (
                    [ID] => 11272
                    [post_author] => 5
                    [post_date] => 2023-09-19 15:44:02
                    [post_date_gmt] => 2023-09-19 15:44:02
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-19 15:45:41
                    [post_modified_gmt] => 2023-09-19 15:45:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11272
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [117] => WP_Post Object
                (
                    [ID] => 11271
                    [post_author] => 5
                    [post_date] => 2023-09-19 15:15:58
                    [post_date_gmt] => 2023-09-19 15:15:58
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:30:25
                    [post_modified_gmt] => 2023-11-10 14:30:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11271
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [118] => WP_Post Object
                (
                    [ID] => 11270
                    [post_author] => 5
                    [post_date] => 2023-09-19 14:27:13
                    [post_date_gmt] => 2023-09-19 14:27:13
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-19 15:31:17
                    [post_modified_gmt] => 2023-09-19 15:31:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11270
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [119] => WP_Post Object
                (
                    [ID] => 11269
                    [post_author] => 5
                    [post_date] => 2023-09-19 13:24:11
                    [post_date_gmt] => 2023-09-19 13:24:11
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-19 15:48:20
                    [post_modified_gmt] => 2023-09-19 15:48:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11269
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [120] => WP_Post Object
                (
                    [ID] => 11268
                    [post_author] => 5
                    [post_date] => 2023-09-19 09:49:33
                    [post_date_gmt] => 2023-09-19 09:49:33
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-19 14:29:09
                    [post_modified_gmt] => 2023-09-19 14:29:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11268
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [121] => WP_Post Object
                (
                    [ID] => 11145
                    [post_author] => 5
                    [post_date] => 2023-09-05 12:25:49
                    [post_date_gmt] => 2023-09-05 12:25:49
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 12:25:49
                    [post_modified_gmt] => 2023-09-05 12:25:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11145
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [122] => WP_Post Object
                (
                    [ID] => 11144
                    [post_author] => 5
                    [post_date] => 2023-09-05 11:51:22
                    [post_date_gmt] => 2023-09-05 11:51:22
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 11:51:22
                    [post_modified_gmt] => 2023-09-05 11:51:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11144
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [123] => WP_Post Object
                (
                    [ID] => 11143
                    [post_author] => 5
                    [post_date] => 2023-09-05 11:36:20
                    [post_date_gmt] => 2023-09-05 11:36:20
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 11:36:20
                    [post_modified_gmt] => 2023-09-05 11:36:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11143
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [124] => WP_Post Object
                (
                    [ID] => 11142
                    [post_author] => 5
                    [post_date] => 2023-09-05 11:23:35
                    [post_date_gmt] => 2023-09-05 11:23:35
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 12:14:59
                    [post_modified_gmt] => 2023-09-05 12:14:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11142
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [125] => WP_Post Object
                (
                    [ID] => 11141
                    [post_author] => 5
                    [post_date] => 2023-09-05 10:28:18
                    [post_date_gmt] => 2023-09-05 10:28:18
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 12:20:34
                    [post_modified_gmt] => 2023-09-05 12:20:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11141
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [126] => WP_Post Object
                (
                    [ID] => 11140
                    [post_author] => 5
                    [post_date] => 2023-09-05 09:30:03
                    [post_date_gmt] => 2023-09-05 09:30:03
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 09:30:03
                    [post_modified_gmt] => 2023-09-05 09:30:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11140
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [127] => WP_Post Object
                (
                    [ID] => 11139
                    [post_author] => 5
                    [post_date] => 2023-09-05 08:13:21
                    [post_date_gmt] => 2023-09-05 08:13:21
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:54:38
                    [post_modified_gmt] => 2024-09-04 10:54:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11139
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [128] => WP_Post Object
                (
                    [ID] => 11138
                    [post_author] => 5
                    [post_date] => 2023-09-05 07:25:41
                    [post_date_gmt] => 2023-09-05 07:25:41
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 09:27:47
                    [post_modified_gmt] => 2023-09-05 09:27:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11138
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [129] => WP_Post Object
                (
                    [ID] => 11137
                    [post_author] => 5
                    [post_date] => 2023-09-05 06:29:43
                    [post_date_gmt] => 2023-09-05 06:29:43
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 06:29:43
                    [post_modified_gmt] => 2023-09-05 06:29:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11137
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [130] => WP_Post Object
                (
                    [ID] => 11136
                    [post_author] => 5
                    [post_date] => 2023-09-04 15:29:56
                    [post_date_gmt] => 2023-09-04 15:29:56
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 09:24:14
                    [post_modified_gmt] => 2024-01-11 09:24:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11136
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [131] => WP_Post Object
                (
                    [ID] => 11135
                    [post_author] => 5
                    [post_date] => 2023-09-04 14:52:10
                    [post_date_gmt] => 2023-09-04 14:52:10
                    [post_content] => 
                    [post_title] => U.S. Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 15:30:23
                    [post_modified_gmt] => 2023-09-04 15:30:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11135
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [132] => WP_Post Object
                (
                    [ID] => 11111
                    [post_author] => 5
                    [post_date] => 2023-09-01 07:10:42
                    [post_date_gmt] => 2023-09-01 07:10:42
                    [post_content] => 
                    [post_title] => U.S. Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 11:07:45
                    [post_modified_gmt] => 2024-10-30 11:07:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11111
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [133] => WP_Post Object
                (
                    [ID] => 11019
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:13:46
                    [post_date_gmt] => 2023-08-24 08:13:46
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 14:05:38
                    [post_modified_gmt] => 2024-09-03 14:05:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11019
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [134] => WP_Post Object
                (
                    [ID] => 11021
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:11:05
                    [post_date_gmt] => 2023-08-24 08:11:05
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 08:11:05
                    [post_modified_gmt] => 2023-08-24 08:11:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11021
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [135] => WP_Post Object
                (
                    [ID] => 11023
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:10:08
                    [post_date_gmt] => 2023-08-24 08:10:08
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 08:10:08
                    [post_modified_gmt] => 2023-08-24 08:10:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11023
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [136] => WP_Post Object
                (
                    [ID] => 11028
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:08:50
                    [post_date_gmt] => 2023-08-24 08:08:50
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 08:08:50
                    [post_modified_gmt] => 2023-08-24 08:08:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11028
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [137] => WP_Post Object
                (
                    [ID] => 11029
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:07:41
                    [post_date_gmt] => 2023-08-24 08:07:41
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 08:07:41
                    [post_modified_gmt] => 2023-08-24 08:07:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11029
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [138] => WP_Post Object
                (
                    [ID] => 11018
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:05:11
                    [post_date_gmt] => 2023-08-24 08:05:11
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 08:05:11
                    [post_modified_gmt] => 2023-08-24 08:05:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11018
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [139] => WP_Post Object
                (
                    [ID] => 11031
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:04:36
                    [post_date_gmt] => 2023-08-24 08:04:36
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 08:06:55
                    [post_modified_gmt] => 2023-08-24 08:06:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11031
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [140] => WP_Post Object
                (
                    [ID] => 11020
                    [post_author] => 5
                    [post_date] => 2023-08-24 07:56:53
                    [post_date_gmt] => 2023-08-24 07:56:53
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 07:56:53
                    [post_modified_gmt] => 2023-08-24 07:56:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11020
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [141] => WP_Post Object
                (
                    [ID] => 11032
                    [post_author] => 5
                    [post_date] => 2023-08-23 13:27:36
                    [post_date_gmt] => 2023-08-23 13:27:36
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 07:55:09
                    [post_modified_gmt] => 2023-08-24 07:55:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11032
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [142] => WP_Post Object
                (
                    [ID] => 11026
                    [post_author] => 5
                    [post_date] => 2023-08-23 13:17:51
                    [post_date_gmt] => 2023-08-23 13:17:51
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 07:50:49
                    [post_modified_gmt] => 2023-08-24 07:50:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11026
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [143] => WP_Post Object
                (
                    [ID] => 11030
                    [post_author] => 5
                    [post_date] => 2023-08-23 13:10:30
                    [post_date_gmt] => 2023-08-23 13:10:30
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-23 13:32:24
                    [post_modified_gmt] => 2023-08-23 13:32:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11030
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [144] => WP_Post Object
                (
                    [ID] => 11022
                    [post_author] => 5
                    [post_date] => 2023-08-23 12:45:06
                    [post_date_gmt] => 2023-08-23 12:45:06
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 09:16:00
                    [post_modified_gmt] => 2023-08-24 09:16:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11022
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [145] => WP_Post Object
                (
                    [ID] => 10998
                    [post_author] => 5
                    [post_date] => 2023-08-11 08:59:40
                    [post_date_gmt] => 2023-08-11 08:59:40
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 15:06:00
                    [post_modified_gmt] => 2023-08-14 15:06:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=10998
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [146] => WP_Post Object
                (
                    [ID] => 10997
                    [post_author] => 5
                    [post_date] => 2023-08-11 08:41:21
                    [post_date_gmt] => 2023-08-11 08:41:21
                    [post_content] => 
                    [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-army-contracting-command-via-ati-regeneron-covid-19-antibodies-large-scale-manufacturing-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 15:00:44
                    [post_modified_gmt] => 2023-08-14 15:00:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=10997
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [147] => WP_Post Object
                (
                    [ID] => 9090
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:46:30
                    [post_date_gmt] => 2023-03-08 10:46:30
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 13:05:09
                    [post_modified_gmt] => 2024-09-20 13:05:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9090
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [148] => WP_Post Object
                (
                    [ID] => 9089
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:34:53
                    [post_date_gmt] => 2023-03-08 10:34:53
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:24:52
                    [post_modified_gmt] => 2023-03-08 11:24:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9089
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [149] => WP_Post Object
                (
                    [ID] => 9088
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:31:00
                    [post_date_gmt] => 2023-03-08 10:31:00
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 13:02:47
                    [post_modified_gmt] => 2024-09-20 13:02:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9088
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [150] => WP_Post Object
                (
                    [ID] => 9087
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:15:07
                    [post_date_gmt] => 2023-03-08 10:15:07
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 13:02:08
                    [post_modified_gmt] => 2024-09-20 13:02:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9087
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [151] => WP_Post Object
                (
                    [ID] => 9086
                    [post_author] => 5
                    [post_date] => 2023-03-08 09:59:11
                    [post_date_gmt] => 2023-03-08 09:59:11
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 13:01:50
                    [post_modified_gmt] => 2024-09-20 13:01:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9086
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [152] => WP_Post Object
                (
                    [ID] => 9083
                    [post_author] => 5
                    [post_date] => 2023-03-08 09:45:42
                    [post_date_gmt] => 2023-03-08 09:45:42
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:41:43
                    [post_modified_gmt] => 2024-09-20 12:41:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9083
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [153] => WP_Post Object
                (
                    [ID] => 9082
                    [post_author] => 5
                    [post_date] => 2023-03-08 09:34:23
                    [post_date_gmt] => 2023-03-08 09:34:23
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:48:03
                    [post_modified_gmt] => 2024-09-20 12:48:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9082
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [154] => WP_Post Object
                (
                    [ID] => 9081
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:59:57
                    [post_date_gmt] => 2023-03-07 14:59:57
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 13:05:48
                    [post_modified_gmt] => 2024-09-20 13:05:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9081
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [155] => WP_Post Object
                (
                    [ID] => 9080
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:44:45
                    [post_date_gmt] => 2023-03-07 14:44:45
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:56:26
                    [post_modified_gmt] => 2024-09-20 12:56:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9080
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [156] => WP_Post Object
                (
                    [ID] => 9079
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:40:00
                    [post_date_gmt] => 2023-03-07 14:40:00
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:50:02
                    [post_modified_gmt] => 2024-09-20 12:50:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9079
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [157] => WP_Post Object
                (
                    [ID] => 9078
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:31:51
                    [post_date_gmt] => 2023-03-07 14:31:51
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:58:14
                    [post_modified_gmt] => 2024-09-20 12:58:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9078
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [158] => WP_Post Object
                (
                    [ID] => 9077
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:28:57
                    [post_date_gmt] => 2023-03-07 14:28:57
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:40:52
                    [post_modified_gmt] => 2024-09-20 12:40:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9077
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [159] => WP_Post Object
                (
                    [ID] => 9076
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:09:37
                    [post_date_gmt] => 2023-03-07 14:09:37
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:57:32
                    [post_modified_gmt] => 2024-09-20 12:57:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9076
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [160] => WP_Post Object
                (
                    [ID] => 9073
                    [post_author] => 5
                    [post_date] => 2023-03-07 12:46:52
                    [post_date_gmt] => 2023-03-07 12:46:52
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:36:43
                    [post_modified_gmt] => 2024-09-20 12:36:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9073
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [161] => WP_Post Object
                (
                    [ID] => 9072
                    [post_author] => 5
                    [post_date] => 2023-03-07 12:24:17
                    [post_date_gmt] => 2023-03-07 12:24:17
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:37:58
                    [post_modified_gmt] => 2024-09-20 12:37:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9072
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [162] => WP_Post Object
                (
                    [ID] => 9071
                    [post_author] => 5
                    [post_date] => 2023-03-07 12:09:50
                    [post_date_gmt] => 2023-03-07 12:09:50
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:34:19
                    [post_modified_gmt] => 2024-09-20 12:34:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9071
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [163] => WP_Post Object
                (
                    [ID] => 9070
                    [post_author] => 5
                    [post_date] => 2023-03-06 18:39:51
                    [post_date_gmt] => 2023-03-06 18:39:51
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:33:26
                    [post_modified_gmt] => 2024-09-20 12:33:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9070
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [164] => WP_Post Object
                (
                    [ID] => 9069
                    [post_author] => 5
                    [post_date] => 2023-03-06 18:34:47
                    [post_date_gmt] => 2023-03-06 18:34:47
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:33:02
                    [post_modified_gmt] => 2024-09-20 12:33:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9069
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [165] => WP_Post Object
                (
                    [ID] => 9068
                    [post_author] => 5
                    [post_date] => 2023-03-06 18:20:18
                    [post_date_gmt] => 2023-03-06 18:20:18
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:19:36
                    [post_modified_gmt] => 2024-09-20 12:19:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9068
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [166] => WP_Post Object
                (
                    [ID] => 9067
                    [post_author] => 5
                    [post_date] => 2023-03-06 16:40:37
                    [post_date_gmt] => 2023-03-06 16:40:37
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:21:00
                    [post_modified_gmt] => 2024-09-20 12:21:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9067
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [167] => WP_Post Object
                (
                    [ID] => 9066
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:55:39
                    [post_date_gmt] => 2023-03-06 15:55:39
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:37:20
                    [post_modified_gmt] => 2024-09-20 12:37:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9066
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [168] => WP_Post Object
                (
                    [ID] => 9065
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:36:15
                    [post_date_gmt] => 2023-03-06 15:36:15
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:27:54
                    [post_modified_gmt] => 2024-09-20 12:27:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9065
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [169] => WP_Post Object
                (
                    [ID] => 9064
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:24:23
                    [post_date_gmt] => 2023-03-06 15:24:23
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:21:33
                    [post_modified_gmt] => 2024-09-20 12:21:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9064
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [170] => WP_Post Object
                (
                    [ID] => 9063
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:10:08
                    [post_date_gmt] => 2023-03-06 15:10:08
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:32:33
                    [post_modified_gmt] => 2024-09-20 12:32:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9063
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [171] => WP_Post Object
                (
                    [ID] => 9062
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:05:13
                    [post_date_gmt] => 2023-03-06 15:05:13
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:18:42
                    [post_modified_gmt] => 2024-09-20 12:18:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9062
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [172] => WP_Post Object
                (
                    [ID] => 9061
                    [post_author] => 5
                    [post_date] => 2023-03-06 13:14:19
                    [post_date_gmt] => 2023-03-06 13:14:19
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:32:02
                    [post_modified_gmt] => 2024-09-20 12:32:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9061
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [173] => WP_Post Object
                (
                    [ID] => 8491
                    [post_author] => 5
                    [post_date] => 2023-01-19 11:34:54
                    [post_date_gmt] => 2023-01-19 11:34:54
                    [post_content] => 
                    [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-vaccine-funding-agreement-template
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-26 15:32:38
                    [post_modified_gmt] => 2023-09-26 15:32:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8491
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [174] => WP_Post Object
                (
                    [ID] => 8490
                    [post_author] => 5
                    [post_date] => 2023-01-19 11:11:46
                    [post_date_gmt] => 2023-01-19 11:11:46
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:44:48
                    [post_modified_gmt] => 2023-09-27 09:44:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8490
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [175] => WP_Post Object
                (
                    [ID] => 8489
                    [post_author] => 5
                    [post_date] => 2023-01-19 10:44:52
                    [post_date_gmt] => 2023-01-19 10:44:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:46:11
                    [post_modified_gmt] => 2023-09-27 09:46:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8489
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [176] => WP_Post Object
                (
                    [ID] => 8488
                    [post_author] => 5
                    [post_date] => 2023-01-19 10:15:15
                    [post_date_gmt] => 2023-01-19 10:15:15
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:40:32
                    [post_modified_gmt] => 2023-09-27 09:40:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8488
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [177] => WP_Post Object
                (
                    [ID] => 8487
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:59:54
                    [post_date_gmt] => 2023-01-19 09:59:54
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:34:06
                    [post_modified_gmt] => 2023-09-27 09:34:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8487
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [178] => WP_Post Object
                (
                    [ID] => 8486
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:46:36
                    [post_date_gmt] => 2023-01-19 09:46:36
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:41:21
                    [post_modified_gmt] => 2023-09-27 09:41:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8486
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [179] => WP_Post Object
                (
                    [ID] => 8485
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:39:38
                    [post_date_gmt] => 2023-01-19 09:39:38
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:30:16
                    [post_modified_gmt] => 2023-09-27 09:30:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8485
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [180] => WP_Post Object
                (
                    [ID] => 8484
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:17:50
                    [post_date_gmt] => 2023-01-19 09:17:50
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:47:03
                    [post_modified_gmt] => 2024-09-04 10:47:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8484
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [181] => WP_Post Object
                (
                    [ID] => 8482
                    [post_author] => 5
                    [post_date] => 2023-01-18 16:32:52
                    [post_date_gmt] => 2023-01-18 16:32:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:47:48
                    [post_modified_gmt] => 2024-09-04 10:47:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8482
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [182] => WP_Post Object
                (
                    [ID] => 8481
                    [post_author] => 5
                    [post_date] => 2023-01-18 15:49:38
                    [post_date_gmt] => 2023-01-18 15:49:38
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-26 14:29:39
                    [post_modified_gmt] => 2023-09-26 14:29:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8481
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [183] => WP_Post Object
                (
                    [ID] => 8480
                    [post_author] => 5
                    [post_date] => 2023-01-17 17:53:00
                    [post_date_gmt] => 2023-01-17 17:53:00
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:57:32
                    [post_modified_gmt] => 2023-11-10 13:57:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8480
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [184] => WP_Post Object
                (
                    [ID] => 8479
                    [post_author] => 5
                    [post_date] => 2023-01-17 17:35:45
                    [post_date_gmt] => 2023-01-17 17:35:45
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:22:09
                    [post_modified_gmt] => 2023-07-11 09:22:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8479
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [185] => WP_Post Object
                (
                    [ID] => 8469
                    [post_author] => 5
                    [post_date] => 2023-01-13 13:35:47
                    [post_date_gmt] => 2023-01-13 13:35:47
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:54:14
                    [post_modified_gmt] => 2023-06-26 13:54:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8469
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [186] => WP_Post Object
                (
                    [ID] => 8468
                    [post_author] => 5
                    [post_date] => 2023-01-11 14:35:38
                    [post_date_gmt] => 2023-01-11 14:35:38
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:55:43
                    [post_modified_gmt] => 2023-06-22 14:55:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8468
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [187] => WP_Post Object
                (
                    [ID] => 8467
                    [post_author] => 5
                    [post_date] => 2023-01-11 14:29:13
                    [post_date_gmt] => 2023-01-11 14:29:13
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:52:17
                    [post_modified_gmt] => 2023-06-22 14:52:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [188] => WP_Post Object
                (
                    [ID] => 8462
                    [post_author] => 5
                    [post_date] => 2023-01-10 12:12:52
                    [post_date_gmt] => 2023-01-10 12:12:52
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:43:22
                    [post_modified_gmt] => 2023-11-10 14:43:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [189] => WP_Post Object
                (
                    [ID] => 8461
                    [post_author] => 5
                    [post_date] => 2023-01-10 09:08:41
                    [post_date_gmt] => 2023-01-10 09:08:41
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 09:53:03
                    [post_modified_gmt] => 2023-06-21 09:53:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8461
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [190] => WP_Post Object
                (
                    [ID] => 5625
                    [post_author] => 5
                    [post_date] => 2022-12-15 09:51:55
                    [post_date_gmt] => 2022-12-15 09:51:55
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:36:42
                    [post_modified_gmt] => 2024-09-04 10:36:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5625
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [191] => WP_Post Object
                (
                    [ID] => 8314
                    [post_author] => 5
                    [post_date] => 2022-12-13 11:46:36
                    [post_date_gmt] => 2022-12-13 11:46:36
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:07:37
                    [post_modified_gmt] => 2024-11-18 15:07:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [192] => WP_Post Object
                (
                    [ID] => 8313
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:48:56
                    [post_date_gmt] => 2022-12-13 10:48:56
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:08:00
                    [post_modified_gmt] => 2024-11-18 15:08:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [193] => WP_Post Object
                (
                    [ID] => 8312
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:35:08
                    [post_date_gmt] => 2022-12-13 10:35:08
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:08:20
                    [post_modified_gmt] => 2024-11-18 15:08:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [194] => WP_Post Object
                (
                    [ID] => 8311
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:09:44
                    [post_date_gmt] => 2022-12-13 10:09:44
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:08:44
                    [post_modified_gmt] => 2024-11-18 15:08:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [195] => WP_Post Object
                (
                    [ID] => 8192
                    [post_author] => 5
                    [post_date] => 2022-12-13 09:04:26
                    [post_date_gmt] => 2022-12-13 09:04:26
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:09:09
                    [post_modified_gmt] => 2024-11-18 15:09:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [196] => WP_Post Object
                (
                    [ID] => 8191
                    [post_author] => 5
                    [post_date] => 2022-12-12 16:19:19
                    [post_date_gmt] => 2022-12-12 16:19:19
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:09:36
                    [post_modified_gmt] => 2024-11-18 15:09:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [197] => WP_Post Object
                (
                    [ID] => 8190
                    [post_author] => 5
                    [post_date] => 2022-12-12 15:29:46
                    [post_date_gmt] => 2022-12-12 15:29:46
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:10:02
                    [post_modified_gmt] => 2024-11-18 15:10:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [198] => WP_Post Object
                (
                    [ID] => 8157
                    [post_author] => 5
                    [post_date] => 2022-12-12 15:23:50
                    [post_date_gmt] => 2022-12-12 15:23:50
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:10:21
                    [post_modified_gmt] => 2024-11-18 15:10:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [199] => WP_Post Object
                (
                    [ID] => 8152
                    [post_author] => 5
                    [post_date] => 2022-12-12 12:04:21
                    [post_date_gmt] => 2022-12-12 12:04:21
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:10:51
                    [post_modified_gmt] => 2024-11-18 15:10:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [200] => WP_Post Object
                (
                    [ID] => 8151
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:56:08
                    [post_date_gmt] => 2022-12-12 11:56:08
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:11:13
                    [post_modified_gmt] => 2024-11-18 15:11:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [201] => WP_Post Object
                (
                    [ID] => 8150
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:21:26
                    [post_date_gmt] => 2022-12-12 11:21:26
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:11:37
                    [post_modified_gmt] => 2024-11-18 15:11:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [202] => WP_Post Object
                (
                    [ID] => 8143
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:10:19
                    [post_date_gmt] => 2022-12-12 11:10:19
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:12:03
                    [post_modified_gmt] => 2024-11-18 15:12:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [203] => WP_Post Object
                (
                    [ID] => 8142
                    [post_author] => 5
                    [post_date] => 2022-12-12 10:40:31
                    [post_date_gmt] => 2022-12-12 10:40:31
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:12:47
                    [post_modified_gmt] => 2024-11-18 15:12:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [204] => WP_Post Object
                (
                    [ID] => 8131
                    [post_author] => 5
                    [post_date] => 2022-12-12 09:57:36
                    [post_date_gmt] => 2022-12-12 09:57:36
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:13:14
                    [post_modified_gmt] => 2024-11-18 15:13:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [205] => WP_Post Object
                (
                    [ID] => 8130
                    [post_author] => 5
                    [post_date] => 2022-12-12 09:34:49
                    [post_date_gmt] => 2022-12-12 09:34:49
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:13:39
                    [post_modified_gmt] => 2024-11-18 15:13:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [206] => WP_Post Object
                (
                    [ID] => 8129
                    [post_author] => 5
                    [post_date] => 2022-12-12 08:55:53
                    [post_date_gmt] => 2022-12-12 08:55:53
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 13:36:21
                    [post_modified_gmt] => 2024-11-18 13:36:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [207] => WP_Post Object
                (
                    [ID] => 8051
                    [post_author] => 5
                    [post_date] => 2022-12-12 08:39:19
                    [post_date_gmt] => 2022-12-12 08:39:19
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:14:21
                    [post_modified_gmt] => 2024-11-18 15:14:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [208] => WP_Post Object
                (
                    [ID] => 7582
                    [post_author] => 5
                    [post_date] => 2022-12-08 08:48:17
                    [post_date_gmt] => 2022-12-08 08:48:17
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-09 08:15:27
                    [post_modified_gmt] => 2024-04-09 08:15:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7582
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [209] => WP_Post Object
                (
                    [ID] => 7581
                    [post_author] => 5
                    [post_date] => 2022-12-08 08:20:09
                    [post_date_gmt] => 2022-12-08 08:20:09
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-09 08:14:59
                    [post_modified_gmt] => 2024-04-09 08:14:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7581
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [210] => WP_Post Object
                (
                    [ID] => 7580
                    [post_author] => 5
                    [post_date] => 2022-12-08 08:14:21
                    [post_date_gmt] => 2022-12-08 08:14:21
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:50:41
                    [post_modified_gmt] => 2024-09-04 10:50:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7580
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [211] => WP_Post Object
                (
                    [ID] => 7570
                    [post_author] => 5
                    [post_date] => 2022-12-07 16:44:09
                    [post_date_gmt] => 2022-12-07 16:44:09
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-09 08:04:49
                    [post_modified_gmt] => 2024-04-09 08:04:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7570
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [212] => WP_Post Object
                (
                    [ID] => 7569
                    [post_author] => 5
                    [post_date] => 2022-12-07 16:39:11
                    [post_date_gmt] => 2022-12-07 16:39:11
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-09 08:14:16
                    [post_modified_gmt] => 2024-04-09 08:14:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7569
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [213] => WP_Post Object
                (
                    [ID] => 7568
                    [post_author] => 5
                    [post_date] => 2022-12-07 16:18:53
                    [post_date_gmt] => 2022-12-07 16:18:53
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-09 08:12:01
                    [post_modified_gmt] => 2024-04-09 08:12:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7568
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [214] => WP_Post Object
                (
                    [ID] => 7567
                    [post_author] => 5
                    [post_date] => 2022-12-07 16:14:54
                    [post_date_gmt] => 2022-12-07 16:14:54
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:24:35
                    [post_modified_gmt] => 2023-11-10 14:24:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7567
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [215] => WP_Post Object
                (
                    [ID] => 7563
                    [post_author] => 5
                    [post_date] => 2022-12-07 16:00:00
                    [post_date_gmt] => 2022-12-07 16:00:00
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 11:11:31
                    [post_modified_gmt] => 2024-09-20 11:11:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7563
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [216] => WP_Post Object
                (
                    [ID] => 7562
                    [post_author] => 5
                    [post_date] => 2022-12-07 15:26:44
                    [post_date_gmt] => 2022-12-07 15:26:44
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-09 08:01:28
                    [post_modified_gmt] => 2024-04-09 08:01:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7562
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [217] => WP_Post Object
                (
                    [ID] => 7468
                    [post_author] => 5
                    [post_date] => 2022-12-05 12:56:35
                    [post_date_gmt] => 2022-12-05 12:56:35
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:23:05
                    [post_modified_gmt] => 2024-10-30 09:23:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7468
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [218] => WP_Post Object
                (
                    [ID] => 7467
                    [post_author] => 5
                    [post_date] => 2022-12-05 12:50:39
                    [post_date_gmt] => 2022-12-05 12:50:39
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:24:10
                    [post_modified_gmt] => 2024-10-30 09:24:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [219] => WP_Post Object
                (
                    [ID] => 7466
                    [post_author] => 5
                    [post_date] => 2022-12-05 12:39:45
                    [post_date_gmt] => 2022-12-05 12:39:45
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:26:06
                    [post_modified_gmt] => 2024-10-30 09:26:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7466
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [220] => WP_Post Object
                (
                    [ID] => 7464
                    [post_author] => 5
                    [post_date] => 2022-12-05 11:38:57
                    [post_date_gmt] => 2022-12-05 11:38:57
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:28:25
                    [post_modified_gmt] => 2024-10-30 09:28:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7464
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [221] => WP_Post Object
                (
                    [ID] => 7445
                    [post_author] => 5
                    [post_date] => 2022-12-05 11:10:08
                    [post_date_gmt] => 2022-12-05 11:10:08
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:21:08
                    [post_modified_gmt] => 2024-10-30 09:21:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7445
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [222] => WP_Post Object
                (
                    [ID] => 7463
                    [post_author] => 5
                    [post_date] => 2022-12-05 10:28:51
                    [post_date_gmt] => 2022-12-05 10:28:51
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:26:30
                    [post_modified_gmt] => 2024-10-30 09:26:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7463
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [223] => WP_Post Object
                (
                    [ID] => 7462
                    [post_author] => 5
                    [post_date] => 2022-12-05 10:15:17
                    [post_date_gmt] => 2022-12-05 10:15:17
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:25:27
                    [post_modified_gmt] => 2024-10-30 09:25:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [224] => WP_Post Object
                (
                    [ID] => 7444
                    [post_author] => 5
                    [post_date] => 2022-12-01 14:17:31
                    [post_date_gmt] => 2022-12-01 14:17:31
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:21:53
                    [post_modified_gmt] => 2024-10-30 09:21:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7444
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [225] => WP_Post Object
                (
                    [ID] => 7443
                    [post_author] => 5
                    [post_date] => 2022-12-01 11:47:54
                    [post_date_gmt] => 2022-12-01 11:47:54
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:27:35
                    [post_modified_gmt] => 2024-10-30 09:27:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7443
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [226] => WP_Post Object
                (
                    [ID] => 7442
                    [post_author] => 5
                    [post_date] => 2022-12-01 11:26:45
                    [post_date_gmt] => 2022-12-01 11:26:45
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:23:48
                    [post_modified_gmt] => 2024-10-30 09:23:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7442
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [227] => WP_Post Object
                (
                    [ID] => 6638
                    [post_author] => 5
                    [post_date] => 2022-11-09 13:48:21
                    [post_date_gmt] => 2022-11-09 13:48:21
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:31:29
                    [post_modified_gmt] => 2023-07-11 09:31:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6638
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [228] => WP_Post Object
                (
                    [ID] => 6637
                    [post_author] => 5
                    [post_date] => 2022-11-09 13:40:00
                    [post_date_gmt] => 2022-11-09 13:40:00
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:37:34
                    [post_modified_gmt] => 2023-07-11 09:37:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6637
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [229] => WP_Post Object
                (
                    [ID] => 6636
                    [post_author] => 5
                    [post_date] => 2022-11-09 13:21:22
                    [post_date_gmt] => 2022-11-09 13:21:22
                    [post_content] => 
                    [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:35:07
                    [post_modified_gmt] => 2023-07-11 09:35:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6636
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [230] => WP_Post Object
                (
                    [ID] => 6635
                    [post_author] => 5
                    [post_date] => 2022-11-09 13:05:41
                    [post_date_gmt] => 2022-11-09 13:05:41
                    [post_content] => 
                    [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:11:40
                    [post_modified_gmt] => 2024-08-19 15:11:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6635
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [231] => WP_Post Object
                (
                    [ID] => 6634
                    [post_author] => 5
                    [post_date] => 2022-11-08 19:23:52
                    [post_date_gmt] => 2022-11-08 19:23:52
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:43:33
                    [post_modified_gmt] => 2023-07-11 09:43:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6634
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [232] => WP_Post Object
                (
                    [ID] => 6633
                    [post_author] => 5
                    [post_date] => 2022-11-08 19:03:56
                    [post_date_gmt] => 2022-11-08 19:03:56
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:40:28
                    [post_modified_gmt] => 2023-07-11 09:40:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6633
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [233] => WP_Post Object
                (
                    [ID] => 6632
                    [post_author] => 5
                    [post_date] => 2022-11-08 18:14:54
                    [post_date_gmt] => 2022-11-08 18:14:54
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 08:47:59
                    [post_modified_gmt] => 2023-07-11 08:47:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6632
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [234] => WP_Post Object
                (
                    [ID] => 6631
                    [post_author] => 5
                    [post_date] => 2022-11-08 16:07:28
                    [post_date_gmt] => 2022-11-08 16:07:28
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-24 13:00:28
                    [post_modified_gmt] => 2023-11-24 13:00:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6631
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [235] => WP_Post Object
                (
                    [ID] => 6630
                    [post_author] => 5
                    [post_date] => 2022-11-08 15:22:11
                    [post_date_gmt] => 2022-11-08 15:22:11
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 08:56:26
                    [post_modified_gmt] => 2023-07-11 08:56:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6630
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [236] => WP_Post Object
                (
                    [ID] => 6629
                    [post_author] => 5
                    [post_date] => 2022-11-08 14:54:13
                    [post_date_gmt] => 2022-11-08 14:54:13
                    [post_content] => 
                    [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:32:36
                    [post_modified_gmt] => 2023-07-11 09:32:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6629
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [237] => WP_Post Object
                (
                    [ID] => 6628
                    [post_author] => 5
                    [post_date] => 2022-11-08 13:12:06
                    [post_date_gmt] => 2022-11-08 13:12:06
                    [post_content] => 
                    [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:13:38
                    [post_modified_gmt] => 2024-08-19 15:13:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6628
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [238] => WP_Post Object
                (
                    [ID] => 6289
                    [post_author] => 5
                    [post_date] => 2022-10-26 07:36:18
                    [post_date_gmt] => 2022-10-26 07:36:18
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:39:39
                    [post_modified_gmt] => 2023-10-17 13:39:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6289
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [239] => WP_Post Object
                (
                    [ID] => 6288
                    [post_author] => 5
                    [post_date] => 2022-10-26 06:46:06
                    [post_date_gmt] => 2022-10-26 06:46:06
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:51:09
                    [post_modified_gmt] => 2023-10-17 13:51:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6288
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [240] => WP_Post Object
                (
                    [ID] => 6287
                    [post_author] => 5
                    [post_date] => 2022-10-25 15:22:03
                    [post_date_gmt] => 2022-10-25 15:22:03
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:48:09
                    [post_modified_gmt] => 2023-10-17 13:48:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6287
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [241] => WP_Post Object
                (
                    [ID] => 6286
                    [post_author] => 5
                    [post_date] => 2022-10-25 15:16:07
                    [post_date_gmt] => 2022-10-25 15:16:07
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:35:35
                    [post_modified_gmt] => 2023-10-17 13:35:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6286
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [242] => WP_Post Object
                (
                    [ID] => 6285
                    [post_author] => 5
                    [post_date] => 2022-10-25 15:01:54
                    [post_date_gmt] => 2022-10-25 15:01:54
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:33:38
                    [post_modified_gmt] => 2023-10-17 13:33:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6285
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [243] => WP_Post Object
                (
                    [ID] => 6284
                    [post_author] => 5
                    [post_date] => 2022-10-25 14:47:20
                    [post_date_gmt] => 2022-10-25 14:47:20
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:12:49
                    [post_modified_gmt] => 2024-09-04 10:12:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6284
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [244] => WP_Post Object
                (
                    [ID] => 6283
                    [post_author] => 5
                    [post_date] => 2022-10-25 14:33:12
                    [post_date_gmt] => 2022-10-25 14:33:12
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:09:22
                    [post_modified_gmt] => 2023-10-17 13:09:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6283
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [245] => WP_Post Object
                (
                    [ID] => 6282
                    [post_author] => 5
                    [post_date] => 2022-10-25 09:24:40
                    [post_date_gmt] => 2022-10-25 09:24:40
                    [post_content] => 
                    [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:14:05
                    [post_modified_gmt] => 2023-10-17 13:14:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6282
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [246] => WP_Post Object
                (
                    [ID] => 6281
                    [post_author] => 5
                    [post_date] => 2022-10-25 08:56:46
                    [post_date_gmt] => 2022-10-25 08:56:46
                    [post_content] => 
                    [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:21:12
                    [post_modified_gmt] => 2023-10-17 13:21:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6281
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [247] => WP_Post Object
                (
                    [ID] => 6279
                    [post_author] => 5
                    [post_date] => 2022-10-25 08:07:31
                    [post_date_gmt] => 2022-10-25 08:07:31
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:22:08
                    [post_modified_gmt] => 2023-10-17 13:22:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6279
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [248] => WP_Post Object
                (
                    [ID] => 6278
                    [post_author] => 5
                    [post_date] => 2022-10-25 07:59:13
                    [post_date_gmt] => 2022-10-25 07:59:13
                    [post_content] => 
                    [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:18:28
                    [post_modified_gmt] => 2023-10-17 13:18:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6278
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [249] => WP_Post Object
                (
                    [ID] => 6277
                    [post_author] => 5
                    [post_date] => 2022-10-25 07:51:55
                    [post_date_gmt] => 2022-10-25 07:51:55
                    [post_content] => 
                    [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-14 10:55:31
                    [post_modified_gmt] => 2023-07-14 10:55:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6277
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [250] => WP_Post Object
                (
                    [ID] => 6280
                    [post_author] => 5
                    [post_date] => 2022-10-25 07:42:19
                    [post_date_gmt] => 2022-10-25 07:42:19
                    [post_content] => 
                    [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:26:53
                    [post_modified_gmt] => 2023-10-17 13:26:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6280
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [251] => WP_Post Object
                (
                    [ID] => 6276
                    [post_author] => 5
                    [post_date] => 2022-10-25 07:37:13
                    [post_date_gmt] => 2022-10-25 07:37:13
                    [post_content] => 
                    [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:24:43
                    [post_modified_gmt] => 2023-10-17 13:24:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6276
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [252] => WP_Post Object
                (
                    [ID] => 5829
                    [post_author] => 5
                    [post_date] => 2022-10-11 12:04:17
                    [post_date_gmt] => 2022-10-11 12:04:17
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 09:23:23
                    [post_modified_gmt] => 2024-07-17 09:23:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5829
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [253] => WP_Post Object
                (
                    [ID] => 5828
                    [post_author] => 5
                    [post_date] => 2022-10-11 11:14:22
                    [post_date_gmt] => 2022-10-11 11:14:22
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 09:29:41
                    [post_modified_gmt] => 2024-07-17 09:29:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5828
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [254] => WP_Post Object
                (
                    [ID] => 5827
                    [post_author] => 5
                    [post_date] => 2022-10-11 10:21:39
                    [post_date_gmt] => 2022-10-11 10:21:39
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 09:05:28
                    [post_modified_gmt] => 2024-07-17 09:05:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5827
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [255] => WP_Post Object
                (
                    [ID] => 5814
                    [post_author] => 5
                    [post_date] => 2022-10-05 16:01:43
                    [post_date_gmt] => 2022-10-05 16:01:43
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 09:19:24
                    [post_modified_gmt] => 2024-07-17 09:19:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5814
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [256] => WP_Post Object
                (
                    [ID] => 5813
                    [post_author] => 5
                    [post_date] => 2022-10-05 15:37:35
                    [post_date_gmt] => 2022-10-05 15:37:35
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-16 14:56:45
                    [post_modified_gmt] => 2024-07-16 14:56:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5813
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [257] => WP_Post Object
                (
                    [ID] => 5812
                    [post_author] => 5
                    [post_date] => 2022-10-05 14:34:35
                    [post_date_gmt] => 2022-10-05 14:34:35
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 09:45:00
                    [post_modified_gmt] => 2024-01-11 09:45:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5812
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [258] => WP_Post Object
                (
                    [ID] => 5811
                    [post_author] => 5
                    [post_date] => 2022-10-05 13:31:14
                    [post_date_gmt] => 2022-10-05 13:31:14
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 08:55:31
                    [post_modified_gmt] => 2024-07-17 08:55:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5811
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [259] => WP_Post Object
                (
                    [ID] => 5810
                    [post_author] => 5
                    [post_date] => 2022-10-05 12:10:58
                    [post_date_gmt] => 2022-10-05 12:10:58
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-16 14:48:42
                    [post_modified_gmt] => 2024-07-16 14:48:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5810
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [260] => WP_Post Object
                (
                    [ID] => 5807
                    [post_author] => 5
                    [post_date] => 2022-10-05 10:53:32
                    [post_date_gmt] => 2022-10-05 10:53:32
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 08:52:06
                    [post_modified_gmt] => 2024-07-17 08:52:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5807
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [261] => WP_Post Object
                (
                    [ID] => 5809
                    [post_author] => 5
                    [post_date] => 2022-10-05 07:50:36
                    [post_date_gmt] => 2022-10-05 07:50:36
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:22:58
                    [post_modified_gmt] => 2024-09-23 10:22:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5809
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [262] => WP_Post Object
                (
                    [ID] => 5782
                    [post_author] => 5
                    [post_date] => 2022-09-16 07:28:56
                    [post_date_gmt] => 2022-09-16 07:28:56
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:43:22
                    [post_modified_gmt] => 2023-06-22 13:43:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [263] => WP_Post Object
                (
                    [ID] => 5781
                    [post_author] => 5
                    [post_date] => 2022-09-14 13:33:43
                    [post_date_gmt] => 2022-09-14 13:33:43
                    [post_content] => 
                    [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:39:31
                    [post_modified_gmt] => 2023-06-20 10:39:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5781
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [264] => WP_Post Object
                (
                    [ID] => 5779
                    [post_author] => 5
                    [post_date] => 2022-09-14 13:01:55
                    [post_date_gmt] => 2022-09-14 13:01:55
                    [post_content] => 
                    [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:37:55
                    [post_modified_gmt] => 2023-06-20 10:37:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5779
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [265] => WP_Post Object
                (
                    [ID] => 5778
                    [post_author] => 5
                    [post_date] => 2022-09-14 11:49:49
                    [post_date_gmt] => 2022-09-14 11:49:49
                    [post_content] => 
                    [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:49:46
                    [post_modified_gmt] => 2023-11-10 13:49:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5778
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [266] => WP_Post Object
                (
                    [ID] => 5777
                    [post_author] => 5
                    [post_date] => 2022-09-14 11:30:25
                    [post_date_gmt] => 2022-09-14 11:30:25
                    [post_content] => 
                    [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:32:58
                    [post_modified_gmt] => 2023-06-20 10:32:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5777
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [267] => WP_Post Object
                (
                    [ID] => 5776
                    [post_author] => 5
                    [post_date] => 2022-09-14 11:17:28
                    [post_date_gmt] => 2022-09-14 11:17:28
                    [post_content] => 
                    [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:33:48
                    [post_modified_gmt] => 2024-10-28 12:33:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5776
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [268] => WP_Post Object
                (
                    [ID] => 5775
                    [post_author] => 5
                    [post_date] => 2022-09-13 13:17:53
                    [post_date_gmt] => 2022-09-13 13:17:53
                    [post_content] => 
                    [post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:32:11
                    [post_modified_gmt] => 2023-06-20 10:32:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5775
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [269] => WP_Post Object
                (
                    [ID] => 5653
                    [post_author] => 5
                    [post_date] => 2022-08-25 12:56:30
                    [post_date_gmt] => 2022-08-25 12:56:30
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:00:47
                    [post_modified_gmt] => 2023-06-22 14:00:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [270] => WP_Post Object
                (
                    [ID] => 5652
                    [post_author] => 5
                    [post_date] => 2022-08-25 12:26:53
                    [post_date_gmt] => 2022-08-25 12:26:53
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:48:11
                    [post_modified_gmt] => 2023-06-22 13:48:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [271] => WP_Post Object
                (
                    [ID] => 5634
                    [post_author] => 5
                    [post_date] => 2022-08-22 13:18:41
                    [post_date_gmt] => 2022-08-22 13:18:41
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 07:28:32
                    [post_modified_gmt] => 2024-04-10 07:28:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5634
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [272] => WP_Post Object
                (
                    [ID] => 5633
                    [post_author] => 5
                    [post_date] => 2022-08-22 13:15:31
                    [post_date_gmt] => 2022-08-22 13:15:31
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 07:32:31
                    [post_modified_gmt] => 2024-04-10 07:32:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5633
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [273] => WP_Post Object
                (
                    [ID] => 5632
                    [post_author] => 5
                    [post_date] => 2022-08-22 13:03:54
                    [post_date_gmt] => 2022-08-22 13:03:54
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 08:43:51
                    [post_modified_gmt] => 2024-04-10 08:43:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5632
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [274] => WP_Post Object
                (
                    [ID] => 5631
                    [post_author] => 5
                    [post_date] => 2022-08-22 12:52:49
                    [post_date_gmt] => 2022-08-22 12:52:49
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 08:50:09
                    [post_modified_gmt] => 2024-04-10 08:50:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5631
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [275] => WP_Post Object
                (
                    [ID] => 5629
                    [post_author] => 5
                    [post_date] => 2022-08-22 12:19:52
                    [post_date_gmt] => 2022-08-22 12:19:52
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 09:39:05
                    [post_modified_gmt] => 2024-04-10 09:39:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5629
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [276] => WP_Post Object
                (
                    [ID] => 5627
                    [post_author] => 5
                    [post_date] => 2022-08-22 11:56:36
                    [post_date_gmt] => 2022-08-22 11:56:36
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 10:16:53
                    [post_modified_gmt] => 2024-04-10 10:16:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5627
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [277] => WP_Post Object
                (
                    [ID] => 5626
                    [post_author] => 5
                    [post_date] => 2022-08-22 11:12:04
                    [post_date_gmt] => 2022-08-22 11:12:04
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 11:27:24
                    [post_modified_gmt] => 2024-04-10 11:27:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5626
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [278] => WP_Post Object
                (
                    [ID] => 5624
                    [post_author] => 5
                    [post_date] => 2022-08-17 08:56:52
                    [post_date_gmt] => 2022-08-17 08:56:52
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 13:47:22
                    [post_modified_gmt] => 2024-04-10 13:47:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5624
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [279] => WP_Post Object
                (
                    [ID] => 5623
                    [post_author] => 5
                    [post_date] => 2022-08-16 15:29:11
                    [post_date_gmt] => 2022-08-16 15:29:11
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 12:55:01
                    [post_modified_gmt] => 2024-04-10 12:55:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5623
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [280] => WP_Post Object
                (
                    [ID] => 5622
                    [post_author] => 5
                    [post_date] => 2022-08-16 14:49:36
                    [post_date_gmt] => 2022-08-16 14:49:36
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 12:24:34
                    [post_modified_gmt] => 2024-04-10 12:24:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5622
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [281] => WP_Post Object
                (
                    [ID] => 5620
                    [post_author] => 5
                    [post_date] => 2022-08-12 12:05:12
                    [post_date_gmt] => 2022-08-12 12:05:12
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 12:05:12
                    [post_modified_gmt] => 2022-08-12 12:05:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5620
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [282] => WP_Post Object
                (
                    [ID] => 5619
                    [post_author] => 5
                    [post_date] => 2022-08-12 12:02:21
                    [post_date_gmt] => 2022-08-12 12:02:21
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 12:48:01
                    [post_modified_gmt] => 2022-10-12 12:48:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5619
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [283] => WP_Post Object
                (
                    [ID] => 5618
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:52:17
                    [post_date_gmt] => 2022-08-12 11:52:17
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:52:17
                    [post_modified_gmt] => 2022-08-12 11:52:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5618
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [284] => WP_Post Object
                (
                    [ID] => 5617
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:49:46
                    [post_date_gmt] => 2022-08-12 11:49:46
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:49:46
                    [post_modified_gmt] => 2022-08-12 11:49:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5617
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [285] => WP_Post Object
                (
                    [ID] => 5616
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:45:22
                    [post_date_gmt] => 2022-08-12 11:45:22
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:45:22
                    [post_modified_gmt] => 2022-08-12 11:45:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5616
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [286] => WP_Post Object
                (
                    [ID] => 5615
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:40:08
                    [post_date_gmt] => 2022-08-12 11:40:08
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:40:08
                    [post_modified_gmt] => 2022-08-12 11:40:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5615
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [287] => WP_Post Object
                (
                    [ID] => 5614
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:34:41
                    [post_date_gmt] => 2022-08-12 11:34:41
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-29 11:28:05
                    [post_modified_gmt] => 2022-09-29 11:28:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5614
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [288] => WP_Post Object
                (
                    [ID] => 5612
                    [post_author] => 5
                    [post_date] => 2022-08-12 10:14:31
                    [post_date_gmt] => 2022-08-12 10:14:31
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:07:37
                    [post_modified_gmt] => 2024-08-19 15:07:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5612
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [289] => WP_Post Object
                (
                    [ID] => 5611
                    [post_author] => 5
                    [post_date] => 2022-08-12 10:05:33
                    [post_date_gmt] => 2022-08-12 10:05:33
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 10:05:33
                    [post_modified_gmt] => 2022-08-12 10:05:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5611
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [290] => WP_Post Object
                (
                    [ID] => 5610
                    [post_author] => 5
                    [post_date] => 2022-08-12 09:31:00
                    [post_date_gmt] => 2022-08-12 09:31:00
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:09:01
                    [post_modified_gmt] => 2024-08-19 15:09:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5610
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [291] => WP_Post Object
                (
                    [ID] => 5609
                    [post_author] => 5
                    [post_date] => 2022-08-12 09:24:43
                    [post_date_gmt] => 2022-08-12 09:24:43
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:50:42
                    [post_modified_gmt] => 2024-10-28 12:50:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5609
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [292] => WP_Post Object
                (
                    [ID] => 5608
                    [post_author] => 5
                    [post_date] => 2022-08-12 09:09:54
                    [post_date_gmt] => 2022-08-12 09:09:54
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:05:22
                    [post_modified_gmt] => 2024-08-19 15:05:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5608
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [293] => WP_Post Object
                (
                    [ID] => 5599
                    [post_author] => 5
                    [post_date] => 2022-08-11 14:17:45
                    [post_date_gmt] => 2022-08-11 14:17:45
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:38:13
                    [post_modified_gmt] => 2024-10-28 12:38:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5599
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [294] => WP_Post Object
                (
                    [ID] => 5596
                    [post_author] => 5
                    [post_date] => 2022-08-11 12:52:07
                    [post_date_gmt] => 2022-08-11 12:52:07
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:03:44
                    [post_modified_gmt] => 2024-08-19 15:03:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5596
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [295] => WP_Post Object
                (
                    [ID] => 5595
                    [post_author] => 5
                    [post_date] => 2022-08-11 12:36:15
                    [post_date_gmt] => 2022-08-11 12:36:15
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:01:10
                    [post_modified_gmt] => 2024-08-19 15:01:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5595
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [296] => WP_Post Object
                (
                    [ID] => 5594
                    [post_author] => 5
                    [post_date] => 2022-08-11 12:13:32
                    [post_date_gmt] => 2022-08-11 12:13:32
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:00:34
                    [post_modified_gmt] => 2024-08-19 15:00:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5594
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [297] => WP_Post Object
                (
                    [ID] => 5593
                    [post_author] => 5
                    [post_date] => 2022-08-11 11:48:52
                    [post_date_gmt] => 2022-08-11 11:48:52
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 14:59:00
                    [post_modified_gmt] => 2024-08-19 14:59:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5593
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [298] => WP_Post Object
                (
                    [ID] => 5592
                    [post_author] => 5
                    [post_date] => 2022-08-11 11:16:19
                    [post_date_gmt] => 2022-08-11 11:16:19
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-24 13:15:35
                    [post_modified_gmt] => 2024-07-24 13:15:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5592
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [299] => WP_Post Object
                (
                    [ID] => 5591
                    [post_author] => 5
                    [post_date] => 2022-08-11 10:18:46
                    [post_date_gmt] => 2022-08-11 10:18:46
                    [post_content] => 
                    [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:04:27
                    [post_modified_gmt] => 2024-08-19 15:04:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5591
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [300] => WP_Post Object
                (
                    [ID] => 5427
                    [post_author] => 5
                    [post_date] => 2022-07-22 15:20:29
                    [post_date_gmt] => 2022-07-22 15:20:29
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 09:57:36
                    [post_modified_gmt] => 2023-06-21 09:57:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5427
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [301] => WP_Post Object
                (
                    [ID] => 4857
                    [post_author] => 5
                    [post_date] => 2022-06-02 10:16:52
                    [post_date_gmt] => 2022-06-02 10:16:52
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:09:51
                    [post_modified_gmt] => 2023-11-10 15:09:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4857
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [302] => WP_Post Object
                (
                    [ID] => 4855
                    [post_author] => 5
                    [post_date] => 2022-06-01 11:59:15
                    [post_date_gmt] => 2022-06-01 11:59:15
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-24 13:07:11
                    [post_modified_gmt] => 2024-07-24 13:07:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4855
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [303] => WP_Post Object
                (
                    [ID] => 4853
                    [post_author] => 5
                    [post_date] => 2022-06-01 11:47:22
                    [post_date_gmt] => 2022-06-01 11:47:22
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-24 13:05:57
                    [post_modified_gmt] => 2024-07-24 13:05:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4853
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [304] => WP_Post Object
                (
                    [ID] => 4704
                    [post_author] => 5
                    [post_date] => 2022-04-26 15:08:03
                    [post_date_gmt] => 2022-04-26 15:08:03
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:25:04
                    [post_modified_gmt] => 2024-07-23 14:25:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4704
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [305] => WP_Post Object
                (
                    [ID] => 4703
                    [post_author] => 5
                    [post_date] => 2022-04-26 14:56:55
                    [post_date_gmt] => 2022-04-26 14:56:55
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:29:54
                    [post_modified_gmt] => 2024-07-23 14:29:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4703
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [306] => WP_Post Object
                (
                    [ID] => 4702
                    [post_author] => 5
                    [post_date] => 2022-04-26 14:46:00
                    [post_date_gmt] => 2022-04-26 14:46:00
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:30:58
                    [post_modified_gmt] => 2024-07-23 14:30:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4702
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [307] => WP_Post Object
                (
                    [ID] => 4701
                    [post_author] => 5
                    [post_date] => 2022-04-26 14:30:45
                    [post_date_gmt] => 2022-04-26 14:30:45
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:29:12
                    [post_modified_gmt] => 2024-07-23 14:29:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4701
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [308] => WP_Post Object
                (
                    [ID] => 4700
                    [post_author] => 5
                    [post_date] => 2022-04-26 14:23:46
                    [post_date_gmt] => 2022-04-26 14:23:46
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:28:37
                    [post_modified_gmt] => 2024-07-23 14:28:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4700
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [309] => WP_Post Object
                (
                    [ID] => 4699
                    [post_author] => 5
                    [post_date] => 2022-04-26 14:06:18
                    [post_date_gmt] => 2022-04-26 14:06:18
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:27:46
                    [post_modified_gmt] => 2024-07-23 14:27:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4699
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [310] => WP_Post Object
                (
                    [ID] => 4698
                    [post_author] => 5
                    [post_date] => 2022-04-26 12:27:58
                    [post_date_gmt] => 2022-04-26 12:27:58
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:26:02
                    [post_modified_gmt] => 2024-07-23 14:26:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4698
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [311] => WP_Post Object
                (
                    [ID] => 4697
                    [post_author] => 5
                    [post_date] => 2022-04-26 12:05:54
                    [post_date_gmt] => 2022-04-26 12:05:54
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:51:07
                    [post_modified_gmt] => 2023-11-10 13:51:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4697
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [312] => WP_Post Object
                (
                    [ID] => 4696
                    [post_author] => 5
                    [post_date] => 2022-04-26 11:05:38
                    [post_date_gmt] => 2022-04-26 11:05:38
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-11 12:45:04
                    [post_modified_gmt] => 2024-07-11 12:45:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4696
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [313] => WP_Post Object
                (
                    [ID] => 4695
                    [post_author] => 5
                    [post_date] => 2022-04-26 09:54:07
                    [post_date_gmt] => 2022-04-26 09:54:07
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-24 12:48:56
                    [post_modified_gmt] => 2023-11-24 12:48:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4695
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [314] => WP_Post Object
                (
                    [ID] => 4691
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:59:51
                    [post_date_gmt] => 2022-04-25 12:59:51
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-26 14:37:35
                    [post_modified_gmt] => 2022-09-26 14:37:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4691
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [315] => WP_Post Object
                (
                    [ID] => 4690
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:53:48
                    [post_date_gmt] => 2022-04-25 12:53:48
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 09:46:23
                    [post_modified_gmt] => 2022-08-11 09:46:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4690
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [316] => WP_Post Object
                (
                    [ID] => 4689
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:48:26
                    [post_date_gmt] => 2022-04-25 12:48:26
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 09:46:36
                    [post_modified_gmt] => 2022-08-11 09:46:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4689
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [317] => WP_Post Object
                (
                    [ID] => 4688
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:44:13
                    [post_date_gmt] => 2022-04-25 12:44:13
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 09:46:53
                    [post_modified_gmt] => 2022-08-11 09:46:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4688
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [318] => WP_Post Object
                (
                    [ID] => 4687
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:41:22
                    [post_date_gmt] => 2022-04-25 12:41:22
                    [post_content] => 
                    [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 09:47:22
                    [post_modified_gmt] => 2022-08-11 09:47:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4687
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [319] => WP_Post Object
                (
                    [ID] => 4686
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:37:16
                    [post_date_gmt] => 2022-04-25 12:37:16
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 09:47:39
                    [post_modified_gmt] => 2022-08-11 09:47:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4686
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [320] => WP_Post Object
                (
                    [ID] => 4685
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:29:54
                    [post_date_gmt] => 2022-04-25 12:29:54
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-29 11:26:17
                    [post_modified_gmt] => 2022-09-29 11:26:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4685
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [321] => WP_Post Object
                (
                    [ID] => 4684
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:25:07
                    [post_date_gmt] => 2022-04-25 12:25:07
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:17:01
                    [post_modified_gmt] => 2024-07-23 14:17:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4684
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [322] => WP_Post Object
                (
                    [ID] => 4683
                    [post_author] => 5
                    [post_date] => 2022-04-25 12:03:48
                    [post_date_gmt] => 2022-04-25 12:03:48
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:19:16
                    [post_modified_gmt] => 2024-07-23 14:19:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4683
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [323] => WP_Post Object
                (
                    [ID] => 4682
                    [post_author] => 5
                    [post_date] => 2022-04-25 11:56:46
                    [post_date_gmt] => 2022-04-25 11:56:46
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:18:05
                    [post_modified_gmt] => 2024-07-23 14:18:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4682
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [324] => WP_Post Object
                (
                    [ID] => 4681
                    [post_author] => 5
                    [post_date] => 2022-04-25 11:39:24
                    [post_date_gmt] => 2022-04-25 11:39:24
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:21:29
                    [post_modified_gmt] => 2024-07-23 14:21:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4681
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [325] => WP_Post Object
                (
                    [ID] => 4680
                    [post_author] => 5
                    [post_date] => 2022-04-25 11:17:54
                    [post_date_gmt] => 2022-04-25 11:17:54
                    [post_content] => 
                    [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:34:18
                    [post_modified_gmt] => 2024-10-28 12:34:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4680
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [326] => WP_Post Object
                (
                    [ID] => 4580
                    [post_author] => 5
                    [post_date] => 2022-03-31 14:34:38
                    [post_date_gmt] => 2022-03-31 14:34:38
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:58:04
                    [post_modified_gmt] => 2023-11-10 13:58:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4580
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [327] => WP_Post Object
                (
                    [ID] => 4519
                    [post_author] => 5
                    [post_date] => 2022-03-25 12:48:09
                    [post_date_gmt] => 2022-03-25 12:48:09
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-sample-grant-terms-conditions
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:17:34
                    [post_modified_gmt] => 2024-08-19 15:17:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4519
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [328] => WP_Post Object
                (
                    [ID] => 4516
                    [post_author] => 5
                    [post_date] => 2022-03-23 09:07:57
                    [post_date_gmt] => 2022-03-23 09:07:57
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:38:44
                    [post_modified_gmt] => 2024-10-28 12:38:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4516
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [329] => WP_Post Object
                (
                    [ID] => 4205
                    [post_author] => 5
                    [post_date] => 2022-02-28 15:24:19
                    [post_date_gmt] => 2022-02-28 15:24:19
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:01:27
                    [post_modified_gmt] => 2023-06-22 14:01:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [330] => WP_Post Object
                (
                    [ID] => 4204
                    [post_author] => 5
                    [post_date] => 2022-02-28 14:53:11
                    [post_date_gmt] => 2022-02-28 14:53:11
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:52:02
                    [post_modified_gmt] => 2023-06-22 13:52:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [331] => WP_Post Object
                (
                    [ID] => 4201
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:33:22
                    [post_date_gmt] => 2022-02-28 13:33:22
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:02:58
                    [post_modified_gmt] => 2023-06-22 14:02:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [332] => WP_Post Object
                (
                    [ID] => 4200
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:13:29
                    [post_date_gmt] => 2022-02-28 13:13:29
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:54:49
                    [post_modified_gmt] => 2023-06-22 13:54:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [333] => WP_Post Object
                (
                    [ID] => 4066
                    [post_author] => 5
                    [post_date] => 2022-01-07 11:35:15
                    [post_date_gmt] => 2022-01-07 11:35:15
                    [post_content] => 
                    [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:31:50
                    [post_modified_gmt] => 2024-09-23 10:31:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4066
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [334] => WP_Post Object
                (
                    [ID] => 4065
                    [post_author] => 5
                    [post_date] => 2022-01-07 11:21:06
                    [post_date_gmt] => 2022-01-07 11:21:06
                    [post_content] => 
                    [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:33:48
                    [post_modified_gmt] => 2024-09-23 10:33:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4065
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [335] => WP_Post Object
                (
                    [ID] => 4064
                    [post_author] => 5
                    [post_date] => 2022-01-07 10:57:29
                    [post_date_gmt] => 2022-01-07 10:57:29
                    [post_content] => 
                    [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:34:53
                    [post_modified_gmt] => 2024-09-23 10:34:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4064
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [336] => WP_Post Object
                (
                    [ID] => 4063
                    [post_author] => 5
                    [post_date] => 2022-01-07 10:34:51
                    [post_date_gmt] => 2022-01-07 10:34:51
                    [post_content] => 
                    [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:25:43
                    [post_modified_gmt] => 2024-09-23 10:25:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4063
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [337] => WP_Post Object
                (
                    [ID] => 4062
                    [post_author] => 5
                    [post_date] => 2022-01-07 10:03:12
                    [post_date_gmt] => 2022-01-07 10:03:12
                    [post_content] => 
                    [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:30:50
                    [post_modified_gmt] => 2024-09-23 10:30:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4062
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [338] => WP_Post Object
                (
                    [ID] => 4061
                    [post_author] => 5
                    [post_date] => 2022-01-07 09:46:42
                    [post_date_gmt] => 2022-01-07 09:46:42
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:24:42
                    [post_modified_gmt] => 2024-09-23 10:24:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4061
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [339] => WP_Post Object
                (
                    [ID] => 4060
                    [post_author] => 5
                    [post_date] => 2022-01-07 09:40:49
                    [post_date_gmt] => 2022-01-07 09:40:49
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 10:21:47
                    [post_modified_gmt] => 2023-10-17 10:21:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4060
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [340] => WP_Post Object
                (
                    [ID] => 3792
                    [post_author] => 5
                    [post_date] => 2021-09-09 14:23:13
                    [post_date_gmt] => 2021-09-09 14:23:13
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:07:03
                    [post_modified_gmt] => 2024-10-30 10:07:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3792
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [341] => WP_Post Object
                (
                    [ID] => 3791
                    [post_author] => 5
                    [post_date] => 2021-09-09 14:18:44
                    [post_date_gmt] => 2021-09-09 14:18:44
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:14:00
                    [post_modified_gmt] => 2024-10-30 10:14:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3791
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [342] => WP_Post Object
                (
                    [ID] => 3789
                    [post_author] => 5
                    [post_date] => 2021-09-09 14:07:30
                    [post_date_gmt] => 2021-09-09 14:07:30
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:12:17
                    [post_modified_gmt] => 2024-10-30 10:12:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3789
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [343] => WP_Post Object
                (
                    [ID] => 3788
                    [post_author] => 5
                    [post_date] => 2021-09-09 14:00:40
                    [post_date_gmt] => 2021-09-09 14:00:40
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:12:47
                    [post_modified_gmt] => 2024-10-30 10:12:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3788
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [344] => WP_Post Object
                (
                    [ID] => 3786
                    [post_author] => 5
                    [post_date] => 2021-09-09 13:20:21
                    [post_date_gmt] => 2021-09-09 13:20:21
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:50:25
                    [post_modified_gmt] => 2024-10-30 09:50:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3786
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [345] => WP_Post Object
                (
                    [ID] => 3784
                    [post_author] => 5
                    [post_date] => 2021-09-09 13:03:52
                    [post_date_gmt] => 2021-09-09 13:03:52
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:07:55
                    [post_modified_gmt] => 2024-10-30 10:07:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3784
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [346] => WP_Post Object
                (
                    [ID] => 3783
                    [post_author] => 5
                    [post_date] => 2021-09-09 12:41:47
                    [post_date_gmt] => 2021-09-09 12:41:47
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-11 09:17:03
                    [post_modified_gmt] => 2023-08-11 09:17:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3783
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [347] => WP_Post Object
                (
                    [ID] => 3782
                    [post_author] => 5
                    [post_date] => 2021-09-09 12:36:36
                    [post_date_gmt] => 2021-09-09 12:36:36
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-09 13:49:10
                    [post_modified_gmt] => 2024-01-09 13:49:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3782
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [348] => WP_Post Object
                (
                    [ID] => 3781
                    [post_author] => 5
                    [post_date] => 2021-09-09 12:29:54
                    [post_date_gmt] => 2021-09-09 12:29:54
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:51:56
                    [post_modified_gmt] => 2024-10-30 09:51:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3781
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [349] => WP_Post Object
                (
                    [ID] => 3778
                    [post_author] => 5
                    [post_date] => 2021-09-09 11:52:53
                    [post_date_gmt] => 2021-09-09 11:52:53
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-11 09:16:10
                    [post_modified_gmt] => 2023-08-11 09:16:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3778
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [350] => WP_Post Object
                (
                    [ID] => 3765
                    [post_author] => 5
                    [post_date] => 2021-09-01 14:09:03
                    [post_date_gmt] => 2021-09-01 14:09:03
                    [post_content] => 
                    [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 15:59:35
                    [post_modified_gmt] => 2023-08-02 15:59:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3765
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [351] => WP_Post Object
                (
                    [ID] => 3764
                    [post_author] => 5
                    [post_date] => 2021-09-01 12:17:32
                    [post_date_gmt] => 2021-09-01 12:17:32
                    [post_content] => 
                    [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 14:25:34
                    [post_modified_gmt] => 2023-08-14 14:25:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3764
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [352] => WP_Post Object
                (
                    [ID] => 3758
                    [post_author] => 5
                    [post_date] => 2021-08-26 12:04:03
                    [post_date_gmt] => 2021-08-26 12:04:03
                    [post_content] => 
                    [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-09 13:50:07
                    [post_modified_gmt] => 2024-01-09 13:50:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3758
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [353] => WP_Post Object
                (
                    [ID] => 3757
                    [post_author] => 5
                    [post_date] => 2021-08-25 08:42:34
                    [post_date_gmt] => 2021-08-25 08:42:34
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:48:41
                    [post_modified_gmt] => 2023-06-26 13:48:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3757
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [354] => WP_Post Object
                (
                    [ID] => 3756
                    [post_author] => 5
                    [post_date] => 2021-08-25 08:10:37
                    [post_date_gmt] => 2021-08-25 08:10:37
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:23:27
                    [post_modified_gmt] => 2023-06-26 12:23:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [355] => WP_Post Object
                (
                    [ID] => 3755
                    [post_author] => 5
                    [post_date] => 2021-08-25 07:55:51
                    [post_date_gmt] => 2021-08-25 07:55:51
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:26:18
                    [post_modified_gmt] => 2024-01-10 16:26:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [356] => WP_Post Object
                (
                    [ID] => 3754
                    [post_author] => 5
                    [post_date] => 2021-08-24 13:43:37
                    [post_date_gmt] => 2021-08-24 13:43:37
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-27 11:40:49
                    [post_modified_gmt] => 2023-06-27 11:40:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3754
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [357] => WP_Post Object
                (
                    [ID] => 3753
                    [post_author] => 5
                    [post_date] => 2021-08-24 13:14:41
                    [post_date_gmt] => 2021-08-24 13:14:41
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 14:08:59
                    [post_modified_gmt] => 2023-06-26 14:08:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3753
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [358] => WP_Post Object
                (
                    [ID] => 3751
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:54:56
                    [post_date_gmt] => 2021-08-24 12:54:56
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 14:08:20
                    [post_modified_gmt] => 2023-06-26 14:08:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3751
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [359] => WP_Post Object
                (
                    [ID] => 3749
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:40:53
                    [post_date_gmt] => 2021-08-24 12:40:53
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-27 11:35:25
                    [post_modified_gmt] => 2023-06-27 11:35:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [360] => WP_Post Object
                (
                    [ID] => 3748
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:31:07
                    [post_date_gmt] => 2021-08-24 12:31:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-16 14:19:34
                    [post_modified_gmt] => 2023-10-16 14:19:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [361] => WP_Post Object
                (
                    [ID] => 3747
                    [post_author] => 5
                    [post_date] => 2021-08-24 11:12:07
                    [post_date_gmt] => 2021-08-24 11:12:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:19:26
                    [post_modified_gmt] => 2023-06-26 12:19:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3747
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [362] => WP_Post Object
                (
                    [ID] => 3746
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:45:05
                    [post_date_gmt] => 2021-08-24 10:45:05
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:56:28
                    [post_modified_gmt] => 2023-06-26 13:56:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3746
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [363] => WP_Post Object
                (
                    [ID] => 3744
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:32:54
                    [post_date_gmt] => 2021-08-24 10:32:54
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:23:55
                    [post_modified_gmt] => 2024-01-10 16:23:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [364] => WP_Post Object
                (
                    [ID] => 3743
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:19:00
                    [post_date_gmt] => 2021-08-24 10:19:00
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:25:37
                    [post_modified_gmt] => 2024-01-10 16:25:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [365] => WP_Post Object
                (
                    [ID] => 3736
                    [post_author] => 5
                    [post_date] => 2021-08-24 07:47:09
                    [post_date_gmt] => 2021-08-24 07:47:09
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:32:46
                    [post_modified_gmt] => 2024-01-10 16:32:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3736
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [366] => WP_Post Object
                (
                    [ID] => 3726
                    [post_author] => 5
                    [post_date] => 2021-08-23 16:13:39
                    [post_date_gmt] => 2021-08-23 16:13:39
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:58:56
                    [post_modified_gmt] => 2023-11-10 13:58:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3726
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [367] => WP_Post Object
                (
                    [ID] => 3725
                    [post_author] => 5
                    [post_date] => 2021-08-23 13:56:41
                    [post_date_gmt] => 2021-08-23 13:56:41
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:50:49
                    [post_modified_gmt] => 2023-06-26 13:50:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3725
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [368] => WP_Post Object
                (
                    [ID] => 3724
                    [post_author] => 5
                    [post_date] => 2021-08-23 13:11:07
                    [post_date_gmt] => 2021-08-23 13:11:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 15:11:11
                    [post_modified_gmt] => 2023-08-02 15:11:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3724
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [369] => WP_Post Object
                (
                    [ID] => 3722
                    [post_author] => 5
                    [post_date] => 2021-08-23 12:12:50
                    [post_date_gmt] => 2021-08-23 12:12:50
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:24:33
                    [post_modified_gmt] => 2023-06-26 12:24:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3722
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [370] => WP_Post Object
                (
                    [ID] => 3696
                    [post_author] => 5
                    [post_date] => 2021-08-19 14:23:22
                    [post_date_gmt] => 2021-08-19 14:23:22
                    [post_content] => 
                    [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 16:03:12
                    [post_modified_gmt] => 2023-08-02 16:03:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3696
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [371] => WP_Post Object
                (
                    [ID] => 3493
                    [post_author] => 5
                    [post_date] => 2021-08-10 11:15:39
                    [post_date_gmt] => 2021-08-10 11:15:39
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:58:36
                    [post_modified_gmt] => 2023-06-22 13:58:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [372] => WP_Post Object
                (
                    [ID] => 3379
                    [post_author] => 5
                    [post_date] => 2021-06-30 17:56:54
                    [post_date_gmt] => 2021-06-30 17:56:54
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 13:39:06
                    [post_modified_gmt] => 2022-10-12 13:39:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3379
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [373] => WP_Post Object
                (
                    [ID] => 3378
                    [post_author] => 5
                    [post_date] => 2021-06-30 17:55:17
                    [post_date_gmt] => 2021-06-30 17:55:17
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-24 12:55:37
                    [post_modified_gmt] => 2024-07-24 12:55:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3378
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [374] => WP_Post Object
                (
                    [ID] => 3377
                    [post_author] => 5
                    [post_date] => 2021-06-30 17:20:14
                    [post_date_gmt] => 2021-06-30 17:20:14
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-24 13:03:56
                    [post_modified_gmt] => 2024-07-24 13:03:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3377
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [375] => WP_Post Object
                (
                    [ID] => 3376
                    [post_author] => 5
                    [post_date] => 2021-06-30 16:38:25
                    [post_date_gmt] => 2021-06-30 16:38:25
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-24 13:09:14
                    [post_modified_gmt] => 2024-07-24 13:09:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3376
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [376] => WP_Post Object
                (
                    [ID] => 3375
                    [post_author] => 5
                    [post_date] => 2021-06-30 16:36:27
                    [post_date_gmt] => 2021-06-30 16:36:27
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-24 12:55:34
                    [post_modified_gmt] => 2023-11-24 12:55:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3375
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [377] => WP_Post Object
                (
                    [ID] => 3369
                    [post_author] => 6
                    [post_date] => 2021-06-30 15:09:50
                    [post_date_gmt] => 2021-06-30 15:09:50
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:17:00
                    [post_modified_gmt] => 2023-11-10 15:17:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3369
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [378] => WP_Post Object
                (
                    [ID] => 3367
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:55:06
                    [post_date_gmt] => 2021-06-30 14:55:06
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:14:23
                    [post_modified_gmt] => 2023-11-10 15:14:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3367
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [379] => WP_Post Object
                (
                    [ID] => 3365
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:51:27
                    [post_date_gmt] => 2021-06-30 14:51:27
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:10:53
                    [post_modified_gmt] => 2023-11-10 15:10:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3365
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [380] => WP_Post Object
                (
                    [ID] => 3362
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:47:24
                    [post_date_gmt] => 2021-06-30 14:47:24
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:14:42
                    [post_modified_gmt] => 2023-11-10 15:14:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3362
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [381] => WP_Post Object
                (
                    [ID] => 3359
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:38:46
                    [post_date_gmt] => 2021-06-30 14:38:46
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:16:07
                    [post_modified_gmt] => 2023-11-10 15:16:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3359
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [382] => WP_Post Object
                (
                    [ID] => 3358
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:47:23
                    [post_date_gmt] => 2021-06-30 13:47:23
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:16:29
                    [post_modified_gmt] => 2023-11-10 15:16:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3358
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [383] => WP_Post Object
                (
                    [ID] => 3357
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:41:11
                    [post_date_gmt] => 2021-06-30 13:41:11
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:05:19
                    [post_modified_gmt] => 2023-11-10 15:05:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3357
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [384] => WP_Post Object
                (
                    [ID] => 3355
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:30:36
                    [post_date_gmt] => 2021-06-30 13:30:36
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:09:10
                    [post_modified_gmt] => 2023-11-10 15:09:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3355
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [385] => WP_Post Object
                (
                    [ID] => 3353
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:25:17
                    [post_date_gmt] => 2021-06-30 13:25:17
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:12:34
                    [post_modified_gmt] => 2023-11-10 15:12:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3353
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [386] => WP_Post Object
                (
                    [ID] => 3350
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:18:18
                    [post_date_gmt] => 2021-06-30 13:18:18
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:13:14
                    [post_modified_gmt] => 2023-11-10 15:13:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3350
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [387] => WP_Post Object
                (
                    [ID] => 3347
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:12:31
                    [post_date_gmt] => 2021-06-30 13:12:31
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:13:45
                    [post_modified_gmt] => 2023-11-10 15:13:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3347
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [388] => WP_Post Object
                (
                    [ID] => 3346
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:07:59
                    [post_date_gmt] => 2021-06-30 13:07:59
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:10:13
                    [post_modified_gmt] => 2023-11-10 15:10:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3346
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [389] => WP_Post Object
                (
                    [ID] => 3345
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:04:52
                    [post_date_gmt] => 2021-06-30 13:04:52
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:08:39
                    [post_modified_gmt] => 2023-11-10 15:08:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3345
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [390] => WP_Post Object
                (
                    [ID] => 3344
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:02:36
                    [post_date_gmt] => 2021-06-30 13:02:36
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-22
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:10:07
                    [post_modified_gmt] => 2023-06-21 12:10:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [391] => WP_Post Object
                (
                    [ID] => 3343
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:57:07
                    [post_date_gmt] => 2021-06-30 12:57:07
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-21
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:11:24
                    [post_modified_gmt] => 2023-06-21 12:11:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3343
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [392] => WP_Post Object
                (
                    [ID] => 3342
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:50:17
                    [post_date_gmt] => 2021-06-30 12:50:17
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:07:11
                    [post_modified_gmt] => 2023-06-21 12:07:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3342
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [393] => WP_Post Object
                (
                    [ID] => 3341
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:44:43
                    [post_date_gmt] => 2021-06-30 12:44:43
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:06:00
                    [post_modified_gmt] => 2023-06-21 12:06:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3341
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [394] => WP_Post Object
                (
                    [ID] => 3339
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:37:28
                    [post_date_gmt] => 2021-06-30 12:37:28
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:08:28
                    [post_modified_gmt] => 2023-06-21 12:08:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3339
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [395] => WP_Post Object
                (
                    [ID] => 3338
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:27:08
                    [post_date_gmt] => 2021-06-30 12:27:08
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:08:16
                    [post_modified_gmt] => 2024-01-11 10:08:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3338
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [396] => WP_Post Object
                (
                    [ID] => 3335
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:20:18
                    [post_date_gmt] => 2021-06-30 12:20:18
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:07:38
                    [post_modified_gmt] => 2023-11-10 15:07:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3335
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [397] => WP_Post Object
                (
                    [ID] => 3336
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:18:57
                    [post_date_gmt] => 2021-06-30 12:18:57
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:05:22
                    [post_modified_gmt] => 2023-06-21 12:05:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3336
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [398] => WP_Post Object
                (
                    [ID] => 3331
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:09:31
                    [post_date_gmt] => 2021-06-30 12:09:31
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:04:36
                    [post_modified_gmt] => 2023-06-21 12:04:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3331
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [399] => WP_Post Object
                (
                    [ID] => 3329
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:04:02
                    [post_date_gmt] => 2021-06-30 12:04:02
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:10:20
                    [post_modified_gmt] => 2024-01-11 10:10:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3329
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [400] => WP_Post Object
                (
                    [ID] => 3327
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:47:34
                    [post_date_gmt] => 2021-06-30 11:47:34
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 14:57:10
                    [post_modified_gmt] => 2023-08-02 14:57:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3327
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [401] => WP_Post Object
                (
                    [ID] => 3326
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:35:26
                    [post_date_gmt] => 2021-06-30 11:35:26
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:00:27
                    [post_modified_gmt] => 2023-06-21 12:00:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3326
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [402] => WP_Post Object
                (
                    [ID] => 3323
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:15:16
                    [post_date_gmt] => 2021-06-30 11:15:16
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:10:57
                    [post_modified_gmt] => 2024-01-11 10:10:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [403] => WP_Post Object
                (
                    [ID] => 3321
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:12:36
                    [post_date_gmt] => 2021-06-30 11:12:36
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-13-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 10:02:31
                    [post_modified_gmt] => 2023-06-21 10:02:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3321
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [404] => WP_Post Object
                (
                    [ID] => 3318
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:46:25
                    [post_date_gmt] => 2021-06-30 10:46:25
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:45:02
                    [post_modified_gmt] => 2024-09-04 10:45:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3318
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [405] => WP_Post Object
                (
                    [ID] => 3316
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:25:45
                    [post_date_gmt] => 2021-06-30 10:25:45
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 11:58:34
                    [post_modified_gmt] => 2023-06-21 11:58:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3316
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [406] => WP_Post Object
                (
                    [ID] => 3315
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:19:01
                    [post_date_gmt] => 2021-06-30 10:19:01
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 11:52:22
                    [post_modified_gmt] => 2023-06-21 11:52:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3315
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [407] => WP_Post Object
                (
                    [ID] => 2909
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:13:58
                    [post_date_gmt] => 2021-05-19 15:13:58
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:45:09
                    [post_modified_gmt] => 2023-06-22 14:45:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [408] => WP_Post Object
                (
                    [ID] => 2908
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:08:05
                    [post_date_gmt] => 2021-05-19 15:08:05
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:37:32
                    [post_modified_gmt] => 2023-06-22 14:37:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [409] => WP_Post Object
                (
                    [ID] => 2907
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:46:20
                    [post_date_gmt] => 2021-05-19 14:46:20
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:40:14
                    [post_modified_gmt] => 2023-06-22 14:40:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [410] => WP_Post Object
                (
                    [ID] => 2893
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:40:45
                    [post_date_gmt] => 2021-05-19 14:40:45
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:34:03
                    [post_modified_gmt] => 2023-06-22 14:34:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [411] => WP_Post Object
                (
                    [ID] => 2892
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:30:23
                    [post_date_gmt] => 2021-05-14 19:30:23
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:57:50
                    [post_modified_gmt] => 2024-10-28 12:57:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [412] => WP_Post Object
                (
                    [ID] => 2890
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:14:07
                    [post_date_gmt] => 2021-05-14 19:14:07
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:34:52
                    [post_modified_gmt] => 2023-06-22 14:34:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [413] => WP_Post Object
                (
                    [ID] => 2889
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:09:07
                    [post_date_gmt] => 2021-05-14 19:09:07
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-21 11:28:56
                    [post_modified_gmt] => 2024-10-21 11:28:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [414] => WP_Post Object
                (
                    [ID] => 2885
                    [post_author] => 5
                    [post_date] => 2021-05-14 18:17:37
                    [post_date_gmt] => 2021-05-14 18:17:37
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:36:43
                    [post_modified_gmt] => 2023-06-22 14:36:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [415] => WP_Post Object
                (
                    [ID] => 2824
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:39:49
                    [post_date_gmt] => 2021-04-16 16:39:49
                    [post_content] => 
                    [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 16:04:12
                    [post_modified_gmt] => 2023-08-02 16:04:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [416] => WP_Post Object
                (
                    [ID] => 2822
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:09:31
                    [post_date_gmt] => 2021-04-16 16:09:31
                    [post_content] => 
                    [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 09:04:12
                    [post_modified_gmt] => 2024-09-04 09:04:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [417] => WP_Post Object
                (
                    [ID] => 2820
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:44:14
                    [post_date_gmt] => 2021-04-16 12:44:14
                    [post_content] => 
                    [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 11:09:49
                    [post_modified_gmt] => 2024-10-30 11:09:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [418] => WP_Post Object
                (
                    [ID] => 2744
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:12:35
                    [post_date_gmt] => 2021-03-30 15:12:35
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:25:08
                    [post_modified_gmt] => 2024-10-30 10:25:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [419] => WP_Post Object
                (
                    [ID] => 2749
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:10:16
                    [post_date_gmt] => 2021-03-30 15:10:16
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:27:08
                    [post_modified_gmt] => 2024-10-30 10:27:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [420] => WP_Post Object
                (
                    [ID] => 2748
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:05:46
                    [post_date_gmt] => 2021-03-30 15:05:46
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 2748
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:25:33
                    [post_modified_gmt] => 2024-10-30 10:25:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [421] => WP_Post Object
                (
                    [ID] => 2743
                    [post_author] => 5
                    [post_date] => 2021-03-24 15:11:40
                    [post_date_gmt] => 2021-03-24 15:11:40
                    [post_content] => 
                    [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:23:00
                    [post_modified_gmt] => 2024-10-30 10:23:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [422] => WP_Post Object
                (
                    [ID] => 2742
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:37:07
                    [post_date_gmt] => 2021-03-24 13:37:07
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:23:42
                    [post_modified_gmt] => 2024-10-30 10:23:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [423] => WP_Post Object
                (
                    [ID] => 2741
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:32:55
                    [post_date_gmt] => 2021-03-24 13:32:55
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:27:49
                    [post_modified_gmt] => 2024-10-30 10:27:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [424] => WP_Post Object
                (
                    [ID] => 2739
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:12:14
                    [post_date_gmt] => 2021-03-24 13:12:14
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 10:34:52
                    [post_modified_gmt] => 2023-09-01 10:34:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [425] => WP_Post Object
                (
                    [ID] => 2737
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:00:46
                    [post_date_gmt] => 2021-03-24 13:00:46
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:56:13
                    [post_modified_gmt] => 2024-09-04 10:56:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [426] => WP_Post Object
                (
                    [ID] => 2736
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:15:15
                    [post_date_gmt] => 2021-03-23 18:15:15
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:28:15
                    [post_modified_gmt] => 2024-10-30 10:28:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [427] => WP_Post Object
                (
                    [ID] => 2734
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:01:22
                    [post_date_gmt] => 2021-03-23 18:01:22
                    [post_content] => 
                    [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:22:17
                    [post_modified_gmt] => 2024-10-30 10:22:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [428] => WP_Post Object
                (
                    [ID] => 2457
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:25:57
                    [post_date_gmt] => 2021-02-25 15:25:57
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 11:05:57
                    [post_modified_gmt] => 2024-10-30 11:05:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [429] => WP_Post Object
                (
                    [ID] => 2461
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:35
                    [post_date_gmt] => 2021-02-25 15:23:35
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 08:34:20
                    [post_modified_gmt] => 2023-08-14 08:34:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [430] => WP_Post Object
                (
                    [ID] => 2462
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:19
                    [post_date_gmt] => 2021-02-25 15:23:19
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 08:38:00
                    [post_modified_gmt] => 2023-08-14 08:38:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [431] => WP_Post Object
                (
                    [ID] => 2463
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:22:52
                    [post_date_gmt] => 2021-02-25 15:22:52
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:56:24
                    [post_modified_gmt] => 2024-09-04 10:56:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [432] => WP_Post Object
                (
                    [ID] => 2464
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:51
                    [post_date_gmt] => 2021-02-25 15:21:51
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 08:33:41
                    [post_modified_gmt] => 2023-08-14 08:33:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [433] => WP_Post Object
                (
                    [ID] => 2465
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:32
                    [post_date_gmt] => 2021-02-25 15:21:32
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 08:39:58
                    [post_modified_gmt] => 2023-08-14 08:39:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [434] => WP_Post Object
                (
                    [ID] => 2466
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:40
                    [post_date_gmt] => 2021-02-25 15:20:40
                    [post_content] => 
                    [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-09 13:55:12
                    [post_modified_gmt] => 2024-01-09 13:55:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [435] => WP_Post Object
                (
                    [ID] => 2467
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:15
                    [post_date_gmt] => 2021-02-25 15:20:15
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 08:32:07
                    [post_modified_gmt] => 2023-08-14 08:32:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [436] => WP_Post Object
                (
                    [ID] => 2444
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:27:20
                    [post_date_gmt] => 2021-01-19 09:27:20
                    [post_content] => 
                    [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:42:15
                    [post_modified_gmt] => 2023-06-20 10:42:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [437] => WP_Post Object
                (
                    [ID] => 2443
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:14:03
                    [post_date_gmt] => 2021-01-19 09:14:03
                    [post_content] => 
                    [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:46:42
                    [post_modified_gmt] => 2023-06-20 10:46:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [438] => WP_Post Object
                (
                    [ID] => 2442
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:56:32
                    [post_date_gmt] => 2021-01-19 06:56:32
                    [post_content] => 
                    [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-09 13:56:25
                    [post_modified_gmt] => 2024-01-09 13:56:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [439] => WP_Post Object
                (
                    [ID] => 2441
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:48:04
                    [post_date_gmt] => 2021-01-19 06:48:04
                    [post_content] => 
                    [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:51:31
                    [post_modified_gmt] => 2023-06-20 10:51:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [440] => WP_Post Object
                (
                    [ID] => 1395
                    [post_author] => 7
                    [post_date] => 2020-05-30 21:25:33
                    [post_date_gmt] => 2020-05-30 21:25:33
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:18:12
                    [post_modified_gmt] => 2024-08-19 15:18:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [441] => WP_Post Object
                (
                    [ID] => 1394
                    [post_author] => 7
                    [post_date] => 2020-05-30 21:22:44
                    [post_date_gmt] => 2020-05-30 21:22:44
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-sample-terms-conditions
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:19:03
                    [post_modified_gmt] => 2024-08-19 15:19:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [442] => WP_Post Object
                (
                    [ID] => 1308
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:17:48
                    [post_date_gmt] => 2020-05-23 17:17:48
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 06:58:07
                    [post_modified_gmt] => 2024-09-20 06:58:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [443] => WP_Post Object
                (
                    [ID] => 1283
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:57:44
                    [post_date_gmt] => 2020-05-22 22:57:44
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:36:58
                    [post_modified_gmt] => 2024-09-23 10:36:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [444] => WP_Post Object
                (
                    [ID] => 1275
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:39:41
                    [post_date_gmt] => 2020-05-22 22:39:41
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:33:11
                    [post_modified_gmt] => 2024-09-23 10:33:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [445] => WP_Post Object
                (
                    [ID] => 1274
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:38:47
                    [post_date_gmt] => 2020-05-22 22:38:47
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 09:04:22
                    [post_modified_gmt] => 2024-07-17 09:04:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [446] => WP_Post Object
                (
                    [ID] => 1268
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:27:54
                    [post_date_gmt] => 2020-05-22 22:27:54
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 07:00:28
                    [post_modified_gmt] => 2024-09-20 07:00:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [447] => WP_Post Object
                (
                    [ID] => 1253
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:42:28
                    [post_date_gmt] => 2020-05-22 21:42:28
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 06:51:10
                    [post_modified_gmt] => 2024-09-20 06:51:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [448] => WP_Post Object
                (
                    [ID] => 1240
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:22:47
                    [post_date_gmt] => 2020-05-22 21:22:47
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:26:42
                    [post_modified_gmt] => 2024-09-23 10:26:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [449] => WP_Post Object
                (
                    [ID] => 1221
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:09:53
                    [post_date_gmt] => 2020-05-22 20:09:53
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfpi3-template-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-29 12:09:52
                    [post_modified_gmt] => 2024-08-29 12:09:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [450] => WP_Post Object
                (
                    [ID] => 1218
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:04:53
                    [post_date_gmt] => 2020-05-22 20:04:53
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 12:06:00
                    [post_modified_gmt] => 2024-04-10 12:06:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [451] => WP_Post Object
                (
                    [ID] => 1211
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:50:22
                    [post_date_gmt] => 2020-05-22 19:50:22
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 06:52:24
                    [post_modified_gmt] => 2024-09-20 06:52:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [452] => WP_Post Object
                (
                    [ID] => 1206
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:37:27
                    [post_date_gmt] => 2020-05-22 19:37:27
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-global-access-commitment-and-humanitarian-license
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-19 15:16:57
                    [post_modified_gmt] => 2024-08-19 15:16:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [453] => WP_Post Object
                (
                    [ID] => 1200
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:35:05
                    [post_date_gmt] => 2020-05-22 19:35:05
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-16 14:46:00
                    [post_modified_gmt] => 2024-07-16 14:46:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [454] => WP_Post Object
                (
                    [ID] => 1205
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:33:17
                    [post_date_gmt] => 2020-05-22 19:33:17
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-29 13:09:07
                    [post_modified_gmt] => 2023-06-29 13:09:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [455] => WP_Post Object
                (
                    [ID] => 1204
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:31:46
                    [post_date_gmt] => 2020-05-22 19:31:46
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 14:56:09
                    [post_modified_gmt] => 2023-08-02 14:56:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [456] => WP_Post Object
                (
                    [ID] => 1203
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:30:52
                    [post_date_gmt] => 2020-05-22 19:30:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-29 13:18:43
                    [post_modified_gmt] => 2023-06-29 13:18:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [457] => WP_Post Object
                (
                    [ID] => 1202
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:28:49
                    [post_date_gmt] => 2020-05-22 19:28:49
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-29 13:12:39
                    [post_modified_gmt] => 2023-06-29 13:12:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [458] => WP_Post Object
                (
                    [ID] => 1201
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:26:29
                    [post_date_gmt] => 2020-05-22 19:26:29
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 11:36:46
                    [post_modified_gmt] => 2024-01-11 11:36:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [459] => WP_Post Object
                (
                    [ID] => 1199
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:21:57
                    [post_date_gmt] => 2020-05-22 19:21:57
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:47:24
                    [post_modified_gmt] => 2024-10-28 12:47:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [460] => WP_Post Object
                (
                    [ID] => 1198
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:12:54
                    [post_date_gmt] => 2020-05-22 19:12:54
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-16 14:39:16
                    [post_modified_gmt] => 2024-07-16 14:39:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [461] => WP_Post Object
                (
                    [ID] => 1190
                    [post_author] => 6
                    [post_date] => 2020-05-22 01:59:48
                    [post_date_gmt] => 2020-05-22 01:59:48
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:24:04
                    [post_modified_gmt] => 2024-09-23 10:24:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [462] => WP_Post Object
                (
                    [ID] => 1187
                    [post_author] => 6
                    [post_date] => 2020-05-22 01:56:10
                    [post_date_gmt] => 2020-05-22 01:56:10
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 12:31:21
                    [post_modified_gmt] => 2024-04-10 12:31:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [463] => WP_Post Object
                (
                    [ID] => 1184
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:08:17
                    [post_date_gmt] => 2020-05-22 00:08:17
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:50:58
                    [post_modified_gmt] => 2024-09-04 10:50:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [464] => WP_Post Object
                (
                    [ID] => 1178
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:55:50
                    [post_date_gmt] => 2020-05-21 23:55:50
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 06:50:27
                    [post_modified_gmt] => 2024-09-20 06:50:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [465] => WP_Post Object
                (
                    [ID] => 1176
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:52:12
                    [post_date_gmt] => 2020-05-21 23:52:12
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 10:30:44
                    [post_modified_gmt] => 2023-10-17 10:30:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [466] => WP_Post Object
                (
                    [ID] => 1171
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:33:24
                    [post_date_gmt] => 2020-05-21 23:33:24
                    [post_content] => 
                    [post_title] => IMI 1 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-1-model-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-19 15:52:45
                    [post_modified_gmt] => 2024-09-19 15:52:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [467] => WP_Post Object
                (
                    [ID] => 1165
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:23:57
                    [post_date_gmt] => 2020-05-21 23:23:57
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 06:59:18
                    [post_modified_gmt] => 2024-09-20 06:59:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [468] => WP_Post Object
                (
                    [ID] => 1160
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:18:03
                    [post_date_gmt] => 2020-05-21 23:18:03
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:32:40
                    [post_modified_gmt] => 2024-09-23 10:32:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [469] => WP_Post Object
                (
                    [ID] => 1159
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:14:15
                    [post_date_gmt] => 2020-05-21 23:14:15
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:33:10
                    [post_modified_gmt] => 2024-01-10 16:33:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [470] => WP_Post Object
                (
                    [ID] => 1158
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:12:13
                    [post_date_gmt] => 2020-05-21 23:12:13
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 08:57:40
                    [post_modified_gmt] => 2024-07-17 08:57:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [471] => WP_Post Object
                (
                    [ID] => 1139
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:35:04
                    [post_date_gmt] => 2020-05-21 22:35:04
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-17 09:00:46
                    [post_modified_gmt] => 2024-07-17 09:00:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [472] => WP_Post Object
                (
                    [ID] => 1128
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:50:04
                    [post_date_gmt] => 2020-05-21 21:50:04
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 06:54:46
                    [post_modified_gmt] => 2024-09-20 06:54:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [473] => WP_Post Object
                (
                    [ID] => 1111
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:03:23
                    [post_date_gmt] => 2020-05-21 21:03:23
                    [post_content] => 
                    [post_title] => IMI 1 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-1-model-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-19 15:53:40
                    [post_modified_gmt] => 2024-09-19 15:53:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [474] => WP_Post Object
                (
                    [ID] => 996
                    [post_author] => 7
                    [post_date] => 2020-05-18 19:58:18
                    [post_date_gmt] => 2020-05-18 19:58:18
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-16 14:20:47
                    [post_modified_gmt] => 2023-10-16 14:20:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 
    [has_agreement_filters] => 1
    [has_any_agreement_filter] => Array
        (
            [agreement-type] => 
        )

    [found_agreements] => 1
    [has_provision_filters] => 
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 51
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [371] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 102
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [271] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 84
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [281] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [278] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 99
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 92
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 62
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 96
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 71
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 79
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 13
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 43
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 70
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [290] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 61
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [372] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 36
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 53
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 88
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 41
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 91
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [282] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 58
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 51
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [clinical-trial-conduct] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 102
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [donation] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 84
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [ensuring-continuity] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [roles-responsibilities] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 99
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 92
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 62
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [license-grants] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 96
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [ownership-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 71
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 79
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 13
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 43
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 70
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [publication-of-results] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 61
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [quality-management] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 36
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 53
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 88
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 41
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 91
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [territory-access-commitments] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 58
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
        )

)